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Amyotrophic Lateral Sclerosis is a devastating disease involving progressive
degeneration of motor neurons in the brain, brainstem, and spinal cord. Life expectancy

after diagnosis is between 3-5 years on average, with current treatments only extending
life by several months. Novel therapeutic targets are sorely needed.
We combined RNA-Sequencing, systems biology analyses, and molecular biology
assays to elucidate sALS group-specific differences in postmortem cervical spinal
sections (7 sALS samples and 8 neurologically healthy controls) that may be relevant to
disease pathology. >55 million paired end (2X150) RNA-sequencing reads per sample
were generated, processed, and aligned to an hg19 human reference transcriptome then
genome.
In the work presented in Chapter 2, we used bioinformatics tools to identify
differentially expressed genes (DEGs) between our sALS and control sample groups.
Further, we used Weighted Gene Co-Expression Network Analysis (WGCNA), an
unsupervised analysis, to identify gene co-expression networks associated with sALS
disease status in our sample set. Qiagen’s Ingenuity Pathway Analysis revealed our sALS
group-specific DEGs and a sALS group-specific gene co-expression network were both
associated with inflammatory processes and TNF-α signaling. Further, Tumor Necrosis
Factor Alpha Induced Protein 2 (TNFAIP2) was identified as a sALS group-specific
upregulated DEG and a network hub gene in that gene co-expression network. We
hypothesized its upregulation in our patients’ tissues was a result of increased TNF-α
signaling and that it functionally contributed to motor neuron death via TNF superfamily
apoptotic pathways. Transient overexpression of TNFAIP2 led to decreased cell viability
in both neural stem cells and induced pluripotent stem cell (iPSC)-derived motor neurons.
Further, inhibition of activated caspase 9 (a protein necessary for TNF superfamily
mitochondrial-mediated apoptosis) reversed this effect in neural stem cells.

In the work presented in Chapter 3, we used bioinformatics tools to identify sALS
group-specifc mitochondrial DEGs. We did not identify any in our sample set.
In the work presented in Chapter 4, we used DEXSeq to identify sALS groupspecific differentially used exons (DUEs). Qiagen’s Ingenuity Pathway Analysis revealed
our sALS group-specific DUEs were associated with cholesterol biosynthesis. Cholesterol
biosynthesis defects cause several rare neurodegenerative disorders, and may
functionally contribute to sALS pathology.

CHAPTER 1: Introduction

I.

Perturbations in Amyotrophic Lateral Sclerosis:
Amyotrophic Lateral Sclerosis (ALS) is a devastating disease involving

progressive degeneration of motor neurons in the brain, brainstem, and spinal cord. Life
expectancy after diagnosis is between 3-5 years on average, with current treatments only
extending life by several months. Novel therapeutic targets are sorely needed.
We hypothesize perturbed cellular processes in ALS patients’ tissues promote
motor neuron death, and these perturbations are caused by aberrant gene expression
events. Further, we presume these aberrant gene expression events can be identified
using techniques commonly used in gene expression studies.
We combined RNA-Sequencing, systems biology analyses, and molecular biology
assays to elucidate sALS group-specific gene and exon expression level differences in
postmortem cervical spinal sections (7 sALS samples and 8 neurologically healthy
controls) that may be relevant to disease pathology. For each tested gene or exon, a
sALS group-specific difference was identified when the sALS sample group’s
representative expression value was statistically significantly different from the
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neurologically healthy control sample group’s representative expression value after
multiple corrections. The remainder of this introductory section provides background
information relevant to our gene expression study.

II.

Known RNA species in eukaryotic cells:
A gene’s deoxyribonucleic acid (DNA) sequence is used to generate a

complementary ribonucleic acid (RNA) transcript via transcription. In Eukaryotic cells,
transcription of each RNA molecule requires an RNA polymerase (RNAP) and general
transcription factors (TFs). In eukaryotic cells, known types of RNA can be broadly
separated into three major groups based on their functions. These groups are 1) RNAs
involved in protein synthesis and localization, 2) RNAs involved in post-transcriptional
modification or telomere DNA replication, and 3) regulatory RNAs.
RNAs involved in protein synthesis and localization include pre-messenger RNAs
(pre mRNAs), messenger RNAs (mRNAS), ribosomal RNAs (rRNAs), transfer RNAs
(tRNAs), and signal recognition particle RNAs (7SL RNA). Pre mRNAs undergo splicing
prior to becoming mature mRNAs. mRNAs are then used to encode polypeptides via
ribosomal-mediated translation in the cytosol, with contributions from rRNAs and tRNAs.
7SL RNA comprises part of the signal recognition particle, a protein-RNA complex that
mediates the transport of secretory and membrane proteins to a cell’s plasma membrane
or endoplasmic reticulum (Luirink, Sinning 2004).
RNAs involved in post-transcriptional modification or telomere DNA replication
include small nuclear RNAs (snRNAs), small nucleolar RNAs (snoRNA), Ribonucleases
P and MRP (RNase P and RNase MRP), and telomerase RNA component (TERC).
2

snRNAs comprise part of the spliceosome complex, and functionally contribute to
processing pre mRNAs into mature mRNAs. Additionally, U1 snRNA has been shown to
regulate RNA Polymerase II’s initiation phase (Kwek et al. 2002). snoRNAs are most
widely known for their role in chemically modifying rRNAs during their maturation process.
snoRNAs also modify other non-coding RNAs (ncRNAs), impact protein translation, and
play a role in maintaining genome stability (Matera, Terns, Terns 2007). Ribonucleases
P and MRP are essential for the maturation of tRNAs and rRNAs, respectively (Piccinelli,
Rosenblad, Samuelsson 2005). Finally, TERC is an RNA component of telomerase, a
ribonucleoprotein that extends telomeric DNA repeat sequences at the end of
chromosomes. Telomerase reverse transcribes TERC’s RNA sequence into telomeric
DNA repeat sequences. These are added onto chromosome ends during telomere
elongation, and protect those chromosomes’ ends from degradation (Artandi 2006).
Regulatory ncRNAs include piwi-interacting RNAs (piRNAs), microRNAs
(miRNAs), small interfering RNAs (siRNAs), and long noncoding RNAs (lncRNAs).
piRNAs bind piwi proteins to form RNA-protein complexes, and prevent translation of
RNA transcripts from mobile elements in germ line cells across various species (Weick,
Miska 2014). Mobile elements are DNAs that insert themselves into various parts of the
genome, and their RNA transcripts encode proteins that mediate their movement from
one genomic location to another. Silencing mobile elements’ RNA transcripts in germline
cells is important, as it can prevent the transmission of deleterious mutations (caused by
the insertion of mobile elements into susceptible genomic regions) to offspring.
miRNAs and siRNAs are single stranded RNAs (ssRNA) derived from transcribed
hairpin structures and double-stranded RNAs (dsRNA), respectively. The existence of
3

endogenous siRNAs (or siRNAs encoded by the host’s genome) was only recently
confirmed in vertebrate species (Piatek, Werner 2014). miRNA synthesis involves two
RNA selective endonucleases (Drosha and Dicer), an Argonaute protein, and other
species-specific protein factors. siRNA synthesis involves these same components,
except it does not involve contributions from Drosha (Piatek, Werner 2014). A miRNA or
siRNA binds to an Argonaute protein (forming an RNA-induced silencing complex known
as RISC) prior to hybridizing their target mRNA via complementary basepairing.
Hybridization typically occurs between the RISC’s miRNA (or siRNA) and a portion of the
mRNA’s 3’ untranslated region. After hybridization, the RISC complex reduces translation
of the target mRNA by 1) rendering it vulnerable to degradation after shortening its polyAtail, 2) reducing how efficiently it is translated into a corresponding polypeptide (or
polypeptides), or 3) cleaving it into multiple pieces (Fabian, Sonenberg, Filipowicz 2010).
lncRNAs are defined as non-protein coding RNA transcripts longer than 200
nucleotides (a size that was arbitrarily chosen). While genomic analyses have identified
>10,000 lncRNAs encoded by the human genome, their functions remain largely
unknown. However, a variety of lncRNAs have been shown to 1) regulate transcription
and splicing of pre-mRNAs, 2) alter translation of mRNAs, 3) inhibit protein activities, and
4) yield small ncRNAs after they undergo post-transcriptional processing (Chen 2015,
Wilusz, Sunwoo, Spector 2009). Mutations and dysregulations of lncRNAs have been
linked to cardiovascular diseases, neurological diseases, diabetes, HIV, and various
types of cancers (Chen 2015).

III.

RNA processing and alternative splicing in eukaryotic cells:
4

Most pre mRNAs undergo post-transcriptional processing in the nucleus prior to
becoming mature mRNAs. Various protein complexes mediate the addition of a 7methylguanosine cap and a poly-A tail (comprised of linked adenosine monophosphates)
to nearly all pre-mRNAs’ 5’ and 3’ ends, respectively. The cap protects the pre-mRNA
from degradation, promotes downstream nuclear export of the eventual mRNA, and aids
in downstream translation of the eventual mRNA into a polypeptide (Cowling 2009). The
poly-A tail is also known to protect the pre-mRNA from degradation, and aids in translation
of the eventual mRNA (Subtelny et al. 2014).
The majority of eukaryotic genes’ sequences transcribed into pre-mRNAs contain
stretches of deoxyribonucleotides called introns and exons. As a pre-mRNA is processed
into a mature RNA, introns are generally removed whereas some (or all) exons are
retained. Most mammalian pre-mRNAs contain introns that are a few hundred to several
thousand nucleotides long, whereas the size of exons are typically around 120
nucleotides long (Will, Luhrmann 2011).
The spliceosome is a biological complex comprised of numerous snRNAs and
proteins. It removes intronic (and occasionally exonic) sequences from a pre-mRNA,
followed by ligating retained exonic sequences to each other. I will next describe a typical
two-step process for spliceosome-mediated removal of an intronic sequence in a premRNA that is illustrated in Figure 1.
First, snRNAs in the spliceosome recognize specific nucleotide sequences (called
splice sites and a branch site) in a pre-mRNA’s intron. Next, the spliceosome complex
carries out consecutive transesterification reactions to remove the intron and connect the
exons flanking it. The first reaction involves the 2’ hydroxyl group of an adenosine (located
5

in the intron’s branch site) executing a nucleophilic attack on the intron’s 5’ splice site.
This results in cleavage at that site, followed by ligation of the 5’ end of the intron to the
adenosine in the branch site. Next, the recently liberated 5’ exon’s 3’ hydroxyl group
attacks the intron’s 3’ splice site. This leads to ligation of the two exons that were flanking
the intron and removal of that intron (Will, Luhrmann 2011).
While researchers initially believed the spliceosome removed each pre-mRNA’s
introns and retained its exons to generate a single mature mRNA, we now know this isn’t
the only possibility. Alternative splicing events enable the generation of multiple mature
mRNAs from a given pre-mRNA, despite the fact that each copy of that pre-mRNA
possesses the same introns and exons. Figure 2 shows various alternative splicing
events for a given pre-mRNA molecule, and the variety of resultant mature mRNAs.
Alternative splicing events occur in ~95% of eukaryotic genes (Kornblihtt et al.
2013), and lead to a greater diversity of RNA transcripts and polypeptides (transcribed
from the variety of resultant mRNAs). These events are regulated by many factors
including (but not limited to) pre-mRNA nucleotide sequences, cell signaling cascades,
and protein-mediated modifications of spliceosome components.
Alternative splicing likely played an integral role in increasing biological complexity
amongst vertebrate species and has been implicated in numerous human diseases. A
recent study discovered primates have significantly higher frequencies of alternative
splicing events in various organs compared to other vertebrate species when comparing
orthologous genes (Barbosa-Morais et al. 2012). The authors proposed these differences

6

Figure 1. Spliceosome-mediated removal of an intron from a pre-mRNA. This figure shows
a cartoon schematic of spliceosome-mediated removal of an intron. E1 and E2 are exons 1 and
2 flanking the intron, respectively. 5’SS and 3’SS are the intron’s 5’ and 3’ splice sites,
respectively. A is the adenosine located in the intron’s branch point (BP). Adapted from Will,
Luhrmann 2011.
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likely contribute to primates’ increased biological complexity relative to other vertebrates,
as vertebrates have comparable numbers of protein coding genes. Aberrant alternative
splicing events (and their deleterious impact on biological processes) have been
implicated

in

various human diseases including myotonic dystrophy,

dilated

cardiomyopathy, autism spectrum disorder, and cancer (Cieply, Carstens 2015).

IV.

Transcription, splicing, and translation of mitochondrial genes in
eukaryotic cells:
Mitochondria are energy-transducing organelles in eukaryotic cells responsible for

synthesizing the majority of cellular adenosine triphosphate (ATP). Proteins use ATP to
conduct various essential cellular processes including biosynthetic reactions, cell motility,
and cell divison (Taanman 1999). Cells in eukayotic organisms have different numbers of
mitochondria depending on energy demands of their respective tissues. Each
mitochondria contains multiple copies of maternally derived, ~16 kb circular genomes free
of intronic regions (Ladd, Keeney, Govind, Bennett 2014). The mitochondrial genome’s
two strands (light and heavy) collectively have 37 total genes encoding 2 rRNAS, 22
tRNAs, and 13 polypeptides.
Transcription of mitochondrial genes is less understood than transcription of
nuclear genes, but the two processes are thought to share many commonalities.
Mitochondrial transcription involves initiation, elongation, and termination stages. Further,
mitochondrial transcription requires contributions from a mitochondrial RNAP (POLRMT),
a mitochondrial transcription factor A (TFAM), and mitochondrial transcription factors
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Figure 2. Alternative splicing events for a pre-mRNA molecule. This figure shows various
alternative splicing events for a single pre-mRNA molecule that can be executed by the
spliceosome. Adapted from Carpenter et al. 2014.
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TFB1M or TFB2M (Asin-Cayuela, Gustafsson 2007). Other proteins may also contribute
to during these steps, though there is less definitive evidence to support this.
During the initiation step, a transcription initiation complex comprised of POLRMT,
TFB2M, and TFAM binds to one of three promoter regions (HSP1, HSP2, or LSP) found
on the heavy and light strand of the mitochondrial genome. It is not fully understood how
the mitochondrial transcription initiation complex recognizes DNA sequences in these
promoter regions or begins transcription. However, TFAM is suspected to mediate
structural alterations in mtDNA, unwinding it to expose transcription start sites to the
initiation complex.
Fewer details are known about the elongation step. Recent finding suggest
POLRMT binds a protein called mitochondrial transcription elongation factor to form an
elongation complex (Posse et al. 2015). POLRMT is thought to function in the same way
RNA Polymerases I-III do during their respective elongation processes, generating
complementary ssRNA molecules from deoxyribonucleotide sequences. The initiation
complex begins transcription from one of the heavy strand promoters (HSP1 or HSP2),
or the light strand promoter (LSP). Different RNA products are generated depending on
which promoter is used, as discussed in Figure 3.
When transcription is initiated at the HSP1 site, POLRMT stops transcribing
mtDNA upon encountering a termination site (or specific sequence of nucleotides) at the
end of the 16s rRNA sequence. This may involve contributions from a protein (mTERF1).
It is unclear how POLRMT terminates transcription after beginning at HSP2 or LS, though
other termination sites (and interacting proteins) are suspected (Asin-Cayuela,
Gustafsson 2007). Splicing of mitochondrial transcripts is thought to require four enzymes
10

Figure 3. Mitochondrial transcription. This figure shows the mtDNA genome, and transcription
initiation sites for the heavy (HSP1 and HSP2) and light (LSP) mitochondrial DNA strands. HSP1’s
corresponding RNA transcript terminates at the 3’ end of the 16S rRNA region. HSP2’s
corresponding RNA transcript nearly incorporates the entire heavy strand sequence (including all
of genes depicted in blue). Finally, LSP’s corresponding RNA transcript includes the ND6 gene
(in yellow) and primers for initiation of DNA synthesis at the heavy strand origin of replication
(OH). Adapted from Asin-Cayuela, Gustafsson 2007.
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(including mitochondrial RNase P) that mediate endonucleolytic excision of these premRNA transcripts into smaller pieces (Smits, Smeitink, van den Heuvel 2010). These
pieces are mitochondrial mRNAs (encoding rRNAs, tRNAs, mRNAs), or primers involved
in initiation of DNA synthesis.
Translation of mitochondrial mRNAs involves initiation, elongation, and termination
steps. Further, this process involves contributions from 1) mitochondrial-encoded rRNAs
and tRNAs, 2) initiation, elongation, and termination translation proteins, 3) mitochondrial
ribosomal proteins, and 4) mitochondrial aminoacyl-tRNA synthetases and methionyltRNA transformylases (Smits, Smeitink, van den Heuvel 2010).
During the initiation phase, mitochondrial ribosomes are thought to recognize
unique mitochondrial mRNAs with their unstructured 5’ sequences (as mitochondrial
mRNAs do not have caps). The current model proposes a translation factor (mtIF3)
promotes formation of an initiation complex, and the mitochondrial mRNA’s start codon
(with the nucleotide sequence AUG) is bound to the mitochondrial ribosome’s P site. A
different translation factor (mtIF2) facilitates entry of a tRNA carrying a methionine residue
into the mitochondrial ribosome. This tRNA’s anticodon binds the mitochondrial mRNA’s
start codon in the P site, as the tRNA still carries the methionine residue (Smits, Smeitink,
van den Heuvel 2010).
During the elongation step, translation factor proteins assist the mitochondrial
ribosome, tRNAS, and rRNAs in generating a polypeptide from the mitochondrial mRNA.
At this point, the mitochondrial mRNA’s 2nd codon is situated in the mitochondrial
ribosome’s A site. A tRNA with an anticodon complementary to the mitochondrial mRNA’s

12

2nd codon is recruited into the mitochondrial ribosome’s A site, and the tRNA’s anticodon
binds to the mitochondrial mRNA’s 2nd codon. A peptide bond is formed between the
amino acids carried by the tRNAs in the mitochondrial ribosome’s A and P sites, followed
by the mitochondrial mRNA being shifting three nucleotides to the left. This results in the
tRNA bound to the mitochondrial mRNA’s start codon being ejected from the
mitochondrial ribosome, as it no longer carries an amino acid. During this shift, the
mitochondrial mRNA’s 2nd and 3rd codons were moved into the mitochondrial ribosome’s
P and A sites, respectively.
An iterative process ensues involving 1) recruitment of a tRNA with an anticodon
complementary to the mitochondrial mRNA’s codon located in the mitochondrial
ribosome’s A site, 2) formation of a peptide bond between the amino acids carried by the
tRNAs in the mitochondrial ribosome’s A and P sites, 3) the mitochondrial mRNA being
shifted 3 nucleotides to the left, and 4) ejection of the tRNA hybridized to the mitochondrial
mRNA’s most 5’ codon (as it no longer carries an amino acid). This process is repeated
until a stop codon (with a sequence of UAA, UAG, AGA, or AGG) is shifted into the
mitochondrial ribosome’s A site (Smits, Smeitink, van den Heuvel 2010).
During the termination phase, a mitochondrial release factor (mtRF1a) recognizes
the stop codon in the mitochondrial ribosome’s A site, and triggers the release of the
polypeptide from the mitochondrial ribosome. This involves hydrolysis of the ester bond
linking the polypeptide chain to the tRNA in the P site. The ribosome and its associated
proteins then dissociate, and the mitochondrial mRNA transcript is freed. The
mitochondrial mRNA transcript is either translated into additional polypeptide copies by
other mitochondrial ribosomes or degraded (Smits, Smeitink, van den Heuvel 2010).
13

V.

Gene expression levels:
Gene expression is the process by which a gene’s deoxyribonucleotide sequence

is used to generate structural or functional gene products. These include RNAs and/or
proteins. A given gene’s expression level in a biological sample can be estimated by
measuring the amount of its RNA transcripts in that sample. Gene expression levels can
change in response to factors inherent to an organism (such as age, gender, and
hormones), environmental factors (such as drugs, temperature, and light) the organism
encounters (Arslan-Ergul, Adams 2014, Che, Gingerich, Lall, Howell 2002, Rhodes,
Crabbe 2005, Podrabsky, Somero 2004, Rossel, Wilson, Pogson 2002), or an interaction
between the internal and external factors. The temporal, developmental, topographical,
histological, and physiological patterns in which a gene is expressed can provide clues to
its biological role (Shena, Salon, Davis, Brown 1995).
Researchers have long hypothesized multiple genes’ expression patterns
contribute to phenotypic diversity (Romero, Ruvinsky, Gilad 2012). However,
simultaneous measurement of multiple genes’ expression levels was not common
practice (due its technical infeasibility) until DNA microarrays were created for this
purpose in the 1990s (Schena, Salon, Davis, Brown 1995). Next generation RNASequencing has since been created in the late 2000’s (Wang, Gerstein, Snyder 2009),
and both techniques are now commonly used to measure gene expression levels.

VI.

DNA microarrays and next generation RNA-Sequencing:
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DNA microarrays are glass slides with covalently bound single stranded
oligonucleotide probes (typically 60-mers in length) (Mantione et al. 2014). On a
microarray designed to measure gene expression, each probe is complementary in
sequence to part (or all) of an annotated gene’s known or predicted RNA transcripts
(Mantione et al. 2014). There are typically multiple probes assigned to each gene’s RNA
transcripts. The synthesis of these probes relies on known genomic sequence, and/or
known or predicted open reading frames (Malone, Oliver 2011).
When using a DNA microarray to estimate a given sample’s gene expression
levels, researchers will typically 1) isolate that sample’s total RNA or polyA+ RNA, 2)
convert it into double stranded complementary DNA (dscDNA) via reverse transcription,
3) label the dscDNA with a fluorescent dye, 4) denature the labeled dscDNA, 5) hybridize
the denatured cDNA strands to the DNA microarray’s probes via complementary
basepairing, 6) shine a laser on the DNA microarray’s probes to excite the fluorescent
dyes attached to hybridized cDNA strands, 7) record each probe’s fluorescence intensity,
8) process and normalize all probes’ fluorescence intensities, and 9) use all resultant
fluorescence intensity values to estimate each gene’s expression level. The presumption
is each gene’s expression level is positively correlated with its corresponding probes’
fluorescence intensities. When a researcher wants to compare two samples’ gene
expression levels to each other on the same DNA microarray, they follow the steps above
with the exception of labeling each sample’s dscDNAs with a different colored fluorescent
dye in step 3.
DNA sequencing involves determining the identity (and order) of nucleotides in
part (or all) of a DNA molecule. Each sequenced read acquired from a DNA molecule
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reports this information. Current RNA-Sequencing workflows involve isolating a given
sample’s RNAs, converting them into dscDNAs, and generating sequenced reads from
those dscDNAs’ denatured strands. These sequenced reads undergo an alignment step,
where their nucleotide sequences are compared to known genes’ nucleotide sequences.
Each sequenced read is aligned (or assigned) to the genomic location with the highest
level of similarity to it in that comparison. Each gene’s expression level is estimated based
on the total number of sequenced reads that aligned to its transcribed regions.
When using RNA-Sequencing to estimate a given sample’s gene expression
levels, researchers will typically 1) isolate that sample’s total RNA or polyA+ RNA, 1a)
remove rRNAs from total RNA (in cases where polyA+ RNA is not used), 2) fragment
isolated RNA transcripts into a distribution of smaller fragments, 3) convert RNA
fragments into dscDNA molecules, 4) ligate sequencing adaptors to those dscDNA
molecules, 5) amplify dscDNA molecules that were properly ligated with sequencing
adaptors (by targeting sequences in the adaptors) using PCR, 6) denature all residual
dscDNA molecules, 7) hybridize a portion of those dscDNA molecules’ strands to a
sequencing chip (via complementary basepairing between their sequencing adaptors
and oligonucleotides on the chip), 8) generate sequenced reads of those dscDNA
molecule’s bound strands via a sequencer-specific protocol, 9) align sequenced reads
to an organism’s reference transcriptome and/or genome, and 10) use bioinformatic
tools to estimate each gene’s expression level using the aligned sequenced reads.

VII.

Next generation RNA-Sequencing over DNA microarrays:
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Next generation RNA-Sequencing has several advantages over DNA
microarrays when measuring gene expression. First, RNA-Sequencing does not rely on
probes generated using known (or predicted) RNA transcripts from an organism’s
annotated reference transcriptome and/or genome. RNA-Sequencing thereby enables
simultaneous detection of both annotated and novel RNA transcripts (including novel
alternatively spliced RNA transcripts). Second, RNA-Sequencing can detect a much
larger range of gene expression levels compared to a standard whole genome
microarray (Mantione et al. 2014). Intriguingly, RNA-Sequencing doesn’t have known
upper or lower limits for detecting gene expression levels (though detection of lowly
expressed transcripts is intricately related to the number of sequenced reads generated
as discussed later in this dissertation). Third, a given sample’s RNA-sequencing reads
can be used to: estimate each annotated gene’s expression levels, estimate annotated
exons’ expression levels, identify novel RNA transcripts (and novel alternatively spliced
RNA transcripts), detect coding and non-coding RNA transcripts, identify single
nucleotide variants (SNVs), detect insertions and deletions (indels), and identify gene
fusion events (Mantione et al. 2014). Separate DNA microarrays must be custom-made
to separately estimate each annotated exon’s expression level, identify SNVs, detect
non-coding RNA transcripts, or reveal gene fusion events. Finally, a given sample’s
RNA-Sequencing data can be re-analyzed as an organism’s annotated transcriptome
and genome files are updated (Mantione et al. 2014).
There are several disadvantages to using next generation RNA-Sequencing over
DNA microarrays. First, most current RNA-Sequencing platforms preferentially generate
sequenced reads from longer RNA transcripts relative to shorter RNA transcripts
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(Mantione et al. 2014). This can occur even when a longer and shorter RNA transcript
have equal expression levels in the studied biological sample. As gene expression
estimates rely on the number of sequenced reads that align to each gene’s transcribed
regions, this technical bias reduces the accuracy of those estimates. Mathematical
corrections are often applied to account for this bias, but are unlikely to completely
remove its effects. Second, the cost per sample is typically higher for an RNASequencing experiment compared to a DNA microarray experiment, especially when
considering laboratory reagents and data storage. For a given sample, a typical RNASequencing data file is generally larger than 5 gigabytes (GB), whereas a typical DNA
microarray file is usually <1 megabyte (MB) (Mantione et al. 2014). Third, analysis of
RNA-Sequencing data generally requires more training and computer skills compared to
analysis of microarray data (Mantione et al. 2014). All of these disadvantages will likely
change as RNA-Sequencing technologies improve, much like what has been seen as
microarray technologies were refined over the last 15 years.

VIII.

Gene expression studies and hypothesis testing:
Gene expression studies compare measured gene expression levels between two

or more groups, allowing identification of differentially expressed genes (DEG). DEGs are
genes with statistically significantly different expression levels between groups. Overrepresentation analyses can be used to infer a set of DEGs’ likely biological relevance.
These analyses detect statistically significant associations between an input set of genes
compared to predefined groups of genes known to influence various cellular processes.
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Gene expression studies comparing disease and control sample groups can
identify DEGs specific to the disease group (or groups), and reveal cellular processes
associated with those DEGs using over-representation analyses. This approach can
uncover perturbed cellular processes that may reflect disease pathology, and enables
researchers to form novel hypotheses about which genes in a list of DEGs may
functionally impact those cellular processes.
Selecting a candidate gene for hypothesis testing in downstream molecular biology
experiments is rarely trivial, as gene expression studies often yield considerable options.
Typically, researchers select a candidate gene that 1) was identified as a DEG, 2) was in
a group of DEGs associated with cellular processes relevant to disease pathology, and
3) has known structural or functional properties that could plausibly influence one of these
cellular processes.
Systems-level gene co-expression network analyses comparing disease and
control sample groups provide separate criteria for candidate gene selection that can be
used in conjunction with DEG analysis results. These analyses identify gene coexpression networks, or sets of genes clustered together based on similarities in their
measured gene expression levels across samples, associated with disease status. Coexpressed genes are often functionally related, members of the same pathway or
protein complex, or modulated by important regulatory transcriptional programs
(Weirauch 2011). Genes comprising gene-co expression networks associated with
disease status can be input to over-representation analyses, revealing cellular
processes associated with those networks that may be relevant to disease pathology.
Gene co-expression network analyses provide more than a list of genes
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(comprising each identified network) associated with disease status. They also predict
highly connected network hub genes most likely to functionally regulate their network’s
activities and associated cellular processes (Jeong, Mason, Barabasi, Oltvai 2001,
Carter, Brechbuhler, Griffin, Bond 2004). Studies using gene co-expression network
analyses have revealed networks associated with a polygenic trait and plausibly related
cellular processes. Further, several of these networks’ hub genes were previously linked
to the polygenic trait using separate molecular biology techniques (Kogelman et al. 2014,
Maschietto et al. 2015). Arguably more compelling, Horvath et al. showed siRNAmediated reduction of Abnormal Spindle Microtubule Assembly (ASPM), a hub gene in a
gene co-expression network associated with glioblastoma and mitosis, significantly
reduced proliferation rates in glioblastoma tumor cells in vitro (Horvath et al. 2006).
Hub genes in a gene co-expression network associated with both disease status
and cellular processes plausibly related to disease pathology are strong candidates for
hypothesis testing. Hypotheses about a given hub gene’s functional impact on these
cellular processes can be tested using appropriate molecular biology assays in an in vitro
or in vivo model system. Specifically, a researcher can test whether imitating a hub gene’s
expression level as it was observed in their disease sample group perturbs a cellular
process in a manner consistent with what is known about disease pathology.

IX.

Amyotrophic Lateral Sclerosis and its genetic epidemiology:
Amyotrophic Lateral Sclerosis (ALS) is a devastating neurodegenerative disease

caused by the death of upper and lower motor neurons in the brain stem and spinal
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cord. The incidence of ALS in European populations is 2-3 people per year per 100,000
of the general population over the age of 15 years, with men at a slightly higher risk
than women (Al-Chalabi, Hardiman 2013). Clinical features vary considerably across
ALS patients, but always involve progressive muscle weakness and paralysis. Muscles
in the hands and feet (as well as those involved in speaking and swallowing) often
atrophy early in disease progression. The average life expectancy after diagnosis is
between 2-5 years, with patients dying of respiratory failure (as the neurons innervating
their diaphrams and other respiratory muscles die) (Al-Chalabi, Hardiman 2013).
Unfortunately, current drug treatments cannot stop ALS disease progression and only
extend life by a few months.
10% of patients report a first degree relative with ALS and receive a familial ALS
(fALS) diagnosis, whereas the remaining 90% of patients report no family history
(receiving a diagnosis of sporadic ALS [sALS]). Early familial aggregation studies, twin
studies, and epidemiological studies suggested genetic factors contribute to both forms
of ALS (Al-Chalabi et al. 2010, Chio et al. 2013, Fang et al. 2009, Wingo et al. 2011).
While discerning fALS from sALS is extremely challenging using the traditional El
Escorial clinical guidelines (Al-Chalabi 2013), genetic studies have revealed important
differences between their molecular etiologies.
fALS is transmitted in a Mendelian fashion. Bonafide causal mutations have been
identified within 9 genes using classic linkage and/or next generation DNA sequencing
techniques, and there is preliminary evidence for causal mutations in an additional 15
genes to date (Renton, Chio, Traynor 2014). As sequencing costs decrease and more
fALS pedigrees are studied, the number of identified causal mutations (and implicated
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genes) is expected to grow. As of 2014, causal mutations in the 9 thoroughly
substantiated ALS genes account for ~67% of fALS in Caucasian patients as of 2014
(Renton, Chio, Traynor 2014).
Interestingly, causal mutations in those same 9 genes only account for ~11% of
sALS in Caucasian patients (Renton, Chio, Traynor 2014). While it is likely causal
mutations residing in other genes account for some portion of the remaining sALS
cases, the majority of sALS is suspected to have polygenic and environmental
contributions (Al-Chalabi, Hardiman 2013, Hardiman, Greenway 2007). Various
exploratory approaches have been (and continue to be) adopted to elucidate sALS’
polygenic contributions.
14 Genomewide association studies (GWAS) comparing allele frequencies at
millions of single nucleotide polymorphisms (SNPs) in sALS cases vs. neurologically
healthy controls have implicated numerous chromosomal regions, though only one
association signal on chromosome 9 has been replicated across studies. That signal
was instrumental in cloning Chromosome 9 Open Reading Frame 72 (C9ORF72), a gene that
carries variable amounts of intronic repeat sequences across individuals. An excess number of
repeats has been shown to cause ALS, and accounts for 7% of sALS in Caucasians as of
2014 (Renton, Chio, Traynor 2014). Larger sample sizes in ALS GWAS will likely increase the
number of identified and replicated signals moving forward, as has been observed in other
neurodegenerative diseases (Hollingworth et al. 2011, Nalls et al. 2011).
A recent study (Cirulli et al. 2015) compared whole exome sequencing data from
2,874 ALS patients and 6,405 healthy controls in search of rare (likely deleterious)
coding variants (SNVs and indels) that may contribute to ALS pathology. 105 of these
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patients had fALS, whereas the rest of the patients had sALS. An excess of rare coding
SNVs were discovered in 1) genes known to harbor fALS causal mutations and 2)
genes associated with autophagy and neuroinflammation.
Other studies focused on identifying de novo mutations in affected sALS patients
that were absent in his/her parents. Early studies using this approach found de novo
mutations known to cause fALS in sALS-affected offspring via sequencing individual
genes of interest (Alexander et al. 2002, Chio et al. 2011). A more recent study (Chesi
et al. 2013) surveyed sALS-affected offsprings’ protein coding regions for de novo
mutations using whole exome sequencing. These researchers discovered sALSaffected offspring had a statistically significant excess of de novo mutations in chromatin
regulator genes. While replication and functional validation is needed, this is an
interesting finding and represents a promising approach for identifying rare genetic
variants in sALS patients that may be relevant to disease pathology.

X.

Scope of this dissertation project:

In the subsequent chapters of this dissertation project, I will detail our lab’s ALS
gene expression study comparing tissues from sALS patients and neurologically healthy
controls. Our overarching goal was to identify sALS group-specific differences and their
associated cellular processes that may be relevant to disease pathology.
Broadly, we used RNA-Sequencing and selected bioinformatics analyses to
compare gene (and exon) expression levels in postmortem cervical spinal sections from
human sALS patients and neurologically healthy controls. This enabled identification of
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sALS group-specific differences. We relied on systems biology analyses to identify
cellular processes associated with these sALS group-specific differences. We presumed
sALS group-specific differences in select genes’ (or exons’) expression levels
holistically induced changes in their associated cellular processes, and some of these
changes may have functionally contributed to disease pathology. Finally, we used
molecular biology techniques to assess whether overexpression of an identified hub
gene’s expression level (as observed in our sALS sample group) perturbed an
associated cellular process in a manner consistent with what is known about ALS
pathology. Findings from this study have been used as rationale in the development of
an ALS drug screening assay and the design of an ALS clinical trial.

24

CHAPTER 2: Tumor Necrosis Factor-mediated Inflammation is identified as a
major abnormality in Postmortem sALS patients’ cervical spinal sections

I.

Introduction:
A comprehensive review of ALS gene expression studies dating back to 2001 was

recently published (Heath, Kirby, Shaw 2006). Tissue types compared between ALS and
control samples included: human bicep muscle, human lymphocytes, human and rodent
spinal tissue containing disease-vulnerable motor neurons, rodent gastrocnemius, and
isolated human and rodent spinal motor neurons.
There was a broad range in the number (14 to 1,182) and identity of ALS groupspecific DEGs discovered in each study. Interestingly, a recurrent set of associated
cellular processes emerged across over-representation analyses using these sets of
DEGs. These included oxidative stress, mitochondrial dysfunction, apoptosis,
cytoskeletal architecture, inflammation, RNA processing, and protein aggregation.
Separate molecular biology assays revealed various ALS tissues from human patients
and rodents carrying fALS causal mutations showed increased oxidative damage
(Ferrante et al. 1997, Andrus, Fleck, Gurney, Hall 1998, Hall et al. 1998, Liu, Wen, Liu, Li
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1999, Chang et al. 2008), abnormal mitochondrial morphology (Sasaki and Iwata 2007,
Sasaki and Iwata 1996, Hirano, Donnenfeld, Sasaki, Nakano 1984, Higgins, Jung, Xu
2003, Kong and Xu 1998, Damiano et al. 2006, Mattiazzi et al. 2002), and elevated
inflammation (Schiffer, Cordera, Cavalla, Migheli 1996, Nagy, Kato, Kushner 1994, Zhao,
Beers, Appel 2013, Turner et al. 2004, Corcia et al. 2012, Henkel et al. 2004, Lewis et al.
2014, Alexianu, Kozovska, Appel 2001, Henkel, Beers, Siklos, Appel 2006, Poloni et al.
2000, Babu et al. 2008, Cereda et al. 2008, Elliott 2001, Hensley et al. 2002, Yoshihara
et al. 2002). Increased inflammatory tumor necrosis factor (TNF-α) signaling (Poloni et al.
2000, Babu et al. 2008, Cereda et al. 2008, Elliott 2001, Hensley et al. 2002, Yoshihara
et al. 2002) in ALS tissues may have therapeutic relevance, as it is known to carry out
cell fate decisions that may contribute to motor neuron death (Probert 2015). Further,
elevated TNF-α signaling been previously shown to induce motor neuron death (He, Wen,
Strong 2002, Robertson et al. 2001, Terrado et al. 2000). Taken together, it is likely
aberrations in these cellular processes contribute to ALS onset, progression, and
symptoms.
Previous studies identified ALS group-specific gene co-expression networks
associated with immune response, stress response, post-translational modifications, and
neuroprotective processes (Holtman et al. 2015, Saris et al. 2009). Further, several of
these networks’ predicted hub genes were shown to functionally impact a cellular process
associated with their respective network. Glutathione synthetase (GSS) and Aconitase2
(ACO2) both play important roles in stress response. GSS encodes a protein important
for generation of glutathione, an antioxidant that prevents DNA damage from reactive
oxygen species. ACO2 encodes an enzyme important for detecting oxidative stress,
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preserving mitochondrial DNA integrity, and preventing mitochondrial-mediated apoptosis
(Kim et al. 2014). AXL receptor tyrosine kinase (AXL) plays an important role in
neuroprotective processes, and was recently implicated in microglial phagocytosis of
apoptotic cells and myelin (Holtman et al. 2015).
In this chapter, we used a combination of RNA-sequencing, bioinformatics tools,
systems biology analyses, and in vitro molecular biology experiments to elucidate sALS
group-specific nuclear gene expression level differences and assess their biological
significance. Specifically, we set out to 1) identify cellular processes associated with sALS
group-specific nuclear gene expression level differences that may be relevant to disease
pathology, and 2) test hypotheses generated from those results assessing whether a
network hub gene’s expression level was functionally related to apoptosis in relevant cell
types in vitro.

II.

Methods:

Biological samples used: Human cervical spinal section tissues from 7 ALS patients
and 8 neurologically healthy controls were procured from the National Disease Research
Interchange (Philadelphia, PA). We defined neurologically healthy controls as individuals
that were not diagnosed with ALS or any other neurodegenerative disorder. In addition to
ALS disease status, we received information about each individual’s age (at time of
death), ethnicity, and gender. Unfortunately, we did receive information about any
individual’s history of medication use or postmortem interval, which may have influenced
our measured gene expression levels. We chose to study isolated RNA from postmortem
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human cervical spinal sections, as they included disease-vulnerable motor neurons (as
well as astrocytes and microglia).
Each sample’s frozen tissue embedded in OCT was shipped to us on dry ice. NDRI
provided age, ethnicity, gender, and disease status data for each sample. On average,
ALS patients were 67.71 years old at death (standard deviation of 7.99 years), whereas
neurologically healthy controls were 69.75 years old at death (standard deviation of 11.29
years). There was no statistically significant difference in age between the two groups as
assessed by a Student’s T test (p=0.697). All 7 ALS patients were Caucasian, with 4
Males and 3 Females. 6 of the neurologically healthy controls were Caucasian, and 2
were African American. There were 4 males and 4 females in the neurologically healthy
control sample group. Each sample’s age, ethnicity, and gender information can be found
in Table 1.
Total RNA isolation: For each sample, twenty 20-micron cross sections of cervical spinal
tissue embedded in OCT were iteratively cut using a Cryostat. The cross sections were
placed in a tube of Qiazol within the Cryostat, and then repeatedly passed through a 19G
hypodermic needle attached to a 1 mL sterile syringe to lyse cell membranes. Total RNA
was extracted following the miRNeasy Mini (Qiagen) kit workflow, including the optional
on-column DNase treatment step to prevent downstream DNA-derived sequencing reads.
Eluted total RNA was further purified using the RNeasy Micro kit (Qiagen) to remove
organic contaminants. We elected to use total RNA (instead of polyA+ RNAs only) for
generating RNA-sequencing libraries. This allowed us to measure pre-mRNAs, mRNAs,
lncRNAs, tRNAs, and mitochondrial RNAs (mtRNAs). We selected the Qiagen miRNeasy
Mini kit over similar kits, as Qiagen RNA isolation products
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Table 1: Sample demographics
Age

Ethnicity

Gender

ALS1

70

Caucasian

Male

ALS2

67

Caucasian

Male

ALS3

80

Caucasian

Female

ALS4

57

Caucasian

Male

ALS9

75

Caucasian

Female

ALS10

64

Caucasian

Female

ALS14

61

Caucasian

Male

CTL6

80

African-American

Male

CTL8

67

Caucasian

Female

CTL16

66

Caucasian

Female

CTL22

54

Caucasian

Male

CTL23

65

African-American

Female

CTL24

83

Caucasian

Male

CTL25

59

Caucasian

Male

CTL27

84

Caucasian

Female

Patients

Controls
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performed well at preserving RNA quality in a recent comparative analysis with other RNA
isolation products (Sellin, Kiss, Smith, Oris 2014).
For each sample, smaller RNA transcripts (<100 nucleotides) were lost in a
purification step using the RNeasy Micro kit columns. This included miRNAs, piRNAs,
siRNAs, snRNAs, and snoRNAs. We used this purification step as 1) organic
contaminants may interfere with downstream rRNA removal, and 2) sequencing smaller
RNA transcripts requires Illumina sequencing parameters (shorter single end reads)
incompatible with those that best suited for our scientific questions.
RNA quantification and quality assessments: Each sample’s isolated total RNA was
next quantified using a Nanodrop 2000c spectrophotometer (Thermo Scientific), and its
quality was assessed using the Experion automated electrophoresis system (Bio-Rad).
Bio-Rad’s Experion calculated an RNA Quality Index (RQI) score for each sample via
comparing three portions of the sample’s electrophoretic profile to a manufactured
standard of degraded RNAs. RNA Quality Index (RQI) values ranged between 1-10, with
increasing values representing higher quality RNA with less degradation.
Sample inclusion criteria: We used 500 ng of high quality total RNA (RQI score ≥7) to
construct each sample’s RNA-sequencing library. The Illumina Truseq® Stranded Total
RNA HT kit required between 100-1,000 ng of total RNA per sample, and was designed
to accept RNA with any level of degradation (RQI score 1-10).
Using a larger amount of input total RNA buffers the inevitable loss of isolated RNA
transcripts across the RNA-sequencing library preparation kit’s reaction and purification
steps. Using high quality RNA (characterized by less degraded RNA transcripts)
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increases the chance of generating sequencing reads that preserve longer stretches
(more nucleotides) of their originating RNA molecules. In general, these sequencing
reads have a higher probability of aligning to the human genome in a downstream step
compared to sequencing reads containing shorter stretches of their originating RNA
molecules.
Taken together, using a larger amount of high quality RNA for each sample likely
increased 1) the number and variety of isolated RNA transcripts represented in their final
RNA-Sequencing library, and 2) the proportion of their sequencing reads that aligned to
the reference genome. Concurrently, this likely increased our downstream gene
expression level estimates.
RNA-Sequencing library preparation kit overview: We used the Illumina Truseq®
Stranded Total RNA HT kit to generate each sample’s final RNA-sequencing library. This
kit converted fragmented pieces of each sample’s isolated RNA transcripts into dscDNAs
with Illumina sequencing adaptors ligated to their 5’ and 3’ ends, hereby referred to as
sequenceable dscDNA molecules.
Denatured strands from these sequenceable dscDNA molecules were bound to
the Illumina NextSeq 500 flowcell and underwent amplification prior to sequencing. All
details related to these processes are provided in a subsequent section. Ultimately, the
Illumina NextSeq 500 workflow produced two sequencing reads from each bound strand
that was amplified and sequenced, hereby referred to as Read 1 and Read 2. Each of
these reads reported the identity of 150 nucleotides beginning at opposite ends of the
cDNA fragment contained in each sequenced strand. Figure 4 shows where these
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sequenced reads were generated from in each sequenced strand.
RNA-Sequencing library preparation kit workflow: The Illumina Truseq® Stranded
Total RNA HT kit converted fragmented pieces of each sample’s isolated RNA
transcripts into sequenceable dscDNA molecules. This multi-step process involved 1)
removal of rRNAs from total RNA, 2) RNA fragmentation using divalent cations and
heat, 3) dscDNA generation, 4) addition of a single A nucleotide to the 3’ end of both
cDNA strands in each dscDNA molecule, 5) ligation of Illumina i5 and i7 sequencing
adaptors with single T nucleotide overhangs to both ends of each dscDNA molecule,
and 6) enrichment PCR amplification to increase the ratio of sequenceable dscDNA
molecules to dscDNA molecules ligated with one or zero sequencing adaptors. DNA
purification steps were performed after steps 3, 5, and 6.
rRNA comprises 80-90% of total RNA in human cell types surveyed (O’Neil, Glowatz,
Schlumpberger 2013; Wilhelm, Landry 2009). The Illumina Truseq® Stranded Total
RNA HT kit removed rRNAs from each of our sample’s total RNA via Ribo-Zero
technology shown in Figure 5. This rRNA removal step ensured 80-90% of our
downstream RNA-sequencing reads didn’t correspond to rRNA transcripts. This
involved 1) denaturing each sample’s total RNA, 2) hybridizing rRNA molecules to
oligonucleotides (attached to magnetic probes) with complementary sequences, 3)
placing all sample tubes on a magnet, and 4) allowing time for the magnetized beads
(with attached rRNA-probe complexes) to be pulled to the side of each tube. Each
sample’s supernatant containing unbound RNAs was then collected for proceeding
steps.
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Figure 4. Sequenceable dscDNA molecule and sequencing reads. This figure shows what
part of the sequenceable dscDNA molecule strand is read to generate Read 1 and Read 2
sequences. Part A shows a sequenceable dscDNA molecule generated by converting a fragment
of a single stranded RNA transcript into a dscDNA molecule (blue dots) flanked by double
stranded Illumina i5 (green dots) and i7 (yellow dots) sequencing adaptors. The sequenceable
dscDNA molecule was denatured, enabling one or both of its denatured strands to bind to the
Illumina NextSeq 500 flowcell. A PCR bridge amplification was performed, followed by NextSeq
500 sequencing. Part B shows where Illumina NextSeq 500 sequencing reads 1 and 2 come from
in a sequenced strand. Each sequencing read was 150 nucleotides in length.
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RNA transcripts were next fragmented to a size range between 120-220
nucleotides (with a median fragment size of 150 nucleotides) using divalent cations and
heat. Based on annotated (known) RNA transcripts in the hg19 human genome, the
average length of a mature mRNA transcript is 2,227 nucleotides long (Kim et al. 2013).
RNA fragmentation ensured sequenceable dscDNA molecules generated from isolated
RNA transcripts were amenable to Illumina Nextseq 500 sequencing parameters using
150 nucleotide reads. Fragmented RNAs were subsequently primed with random
hexamers for first strand cDNA synthesis.
First strand synthesis was performed using standard components (reverse
transcriptase, reaction buffer, nucleotides) and Actinomycin D to prevent DNAdependent DNA synthesis. This increased the likelihood resultant sequencing data had
a minimal number of reads derived from DNA molecules.
Second strand synthesis using standard reagents (DNA polymerase, RNase H,
reaction buffer, dATPs, dCTPs, dGTPs) and dUTPs in place of dTTPs was next. The
DNA polymerase incorporated dUTPs instead of dTTPs into the second strand, thereby
marking that strand. During a downstream enrichment PCR amplification step, that DNA
polymerase didn’t incorporate nucleotides past the first dUTP it encountered in the
second strand. This ensured only the first strand of cDNAs (antisense to the original
RNA transcript it was reverse transcribed from) were ultimately sequenced. This
allowed us to align each sequenced read to the DNA strand its corresponding RNA
molecule was transcribed from. This was especially important for identifying antisense
transcripts, determining which strand of lncRNAs was transcribed, and identifying
overlapping genes’ boundaries when they resided on the same strand.
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Figure 5. Ribo-Zero technology. This figure shows a cartoon schematic of how ribosomal RNAs
(rRNAs) are removed from each sample’s total RNA. DNase-treated total RNA is mixed together
with rRNA removal solution. This solution contains magnetic rRNA removal probes carrying
oligonucleotide sequences complementary to rRNA species. After these probes’ oligonucleotides
hybridize to their complementary rRNAs in the total RNA mixture, magnetic beads are added into
the entire solution. These magnetic beads bound the magnetic rRNA removal probes regardless
of whether their oligonucleotides were hybridized to rRNAs or not. Tubes were then placed on a
magnet, and RNAs unbound to these rRNA removal probes were collected for proceeding
steps. Illumina; [accessed 2016 Feb 26]. Adapted from http://www.illumina.com/products/ribozero-rrna-removal-human-mouse-rat.html.
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dscDNAs next underwent consecutive ligation-based reactions to add i5 and i7
Illumina sequencing adaptors to their 5’ and 3’ ends. In the first reaction, a single dATP
nucleotide was ligated to the 3’ end of both cDNA strands in each dscDNA molecule.
Next, both ends of each dscDNA molecule were ligated to a double stranded i5 or i7
Illumina sequencing adaptor via complementary dATP-dTTP hybridization. This was
successful as these adaptors had single dTTP overhangs that complemented the
dscDNA molecule’s single dATP overhangs. Each sample was assigned a different
Illumina i5 sequencing containing a unique 8-nucleotide index sequence, and one
identical i7 Illumina sequencing adaptor.
As each sample’s sequenceable dscDNA molecules possessed a different 8nucleotide index sequence in their respective i5 adapters, we were able to mix multiple
sample’s sequenceable dscDNA molecules together prior to Illumina NextSeq500
sequencing. We could then denature and sequence denatured dscDNA strands from
these multi-sample pools. Most importantly, resultant Read 1 and 2 sequencing reads
generated from each sequenced strand could be assigned to their correct sample using
that strand’s index sequence.
The final step in this kit’s workflow involved an enrichment PCR amplification.
This amplification used standard reagents (DNA polymerase, buffer, dNTPs), and
served to increase the number of sequenceable dscDNA molecules relative to dscDNA
molecules improperly ligated with one or zero sequencing adaptors. This ensured a
negligible amount of unsequenceable denatured strands (from improperly ligated
dscDNA molecules) bound the NextSeq 500 flowcell.
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DNA purification steps were performed after steps 3, 5, and 6. These relied on
Agencourt AMPure XP beads. Agencourt Ampure XP beads are paramagnetic
polystyrene beads coated in carboxyl molecules. They are suspended in a solution
containing polyethylene glycol and salt, as these components cause DNA to bind to the
AMPure XP beads’ carboxyl groups provided proper stoichiometry. Specified amounts
of the Ampure XP bead solution were added to each sample after the steps listed
above. DNA molecules were given time to bind the paramagnetic beads. Sample tubes
were next placed on a magnet, allowing the DNA-paramagnetic bead complexes to be
pulled to the side of the tube. The supernatant was discarded, and the beads
(complexed to DNA molecules) were washed twice with 70% ethanol. DNA molecules
were finally eluted from the paramagnetic beads using 1X TE and gathered for the next
step.
Quality control: We next ran several quality control steps to ensure we generated high
quality RNA-Sequencing libraries, as this increased the likelihood our downstream gene
expression estimates were accurate. We assessed whether each sample had 1) the
expected size distribution of sequenceable dscDNA molecules (mean fragment size
around 260 basepairs) generated by the Illumina Truseq® Stranded Total RNA HT kit,
and 2) comparable molar amounts of sequenceable dscDNA molecules across
samples.
We determined the size distribution of each sample's sequenceable dscDNA
molecules using the BioRad Experion (Bio-Rad). We measured each library’s molar
amount of sequenceable dscDNA molecules using a CFX96 Touch Real-Time PCR
Detection System (Bio-Rad) and a KAPA Library Quantification Kit (Kapa Biosystems).
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This kit provided qPCR amplification reagents for absolute quantitation, including 6
standards containing different molar amounts of a 452-basepair DNA fragment ligated
with Illumina sequencing adaptors to generate a standard curve.
NextSeq 500 pre-sequencing steps: We employed Cofactor Genomics (St. Louis,
MO) to perform two Illumina NextSeq 500 sequencing runs to generate all samples'
sequencing data. Prior to the first run, we created a composite RNA-Sequencing pool
by combining an equimolar amount of sequenceable dscDNA molecules from 6 of our
samples. This same approach was used for the remaining 9 samples prior to the
second run several months later.
An aliquot of each pooled RNA-Sequencing library containing sequenceable
dscDNA molecules was first denatured before being washed over the surface of a
NextSeq 500 flowcell. The flowcell had two types of covalently bound oligonucleotides.
The first type was complementary to each strand's Illumina i5 sequencing adapter, and
the second type was complementary to each strand's Illumina i7 sequencing adapter.
Approximately 400 million denatured strands attached to the flowcell via their i5 or i7
Illumina sequencing adaptor hybridizing to a complementary oligonucleotide covalently
bound to the flowcell surface. Figure 6A shows a denatured strand's i5 Illumina
sequencing adaptor hybridizing to a complementary oligonucleotide covalently bound to
the flowcell surface.
DNA polymerase and unlabeled dNTPs (dATP, dCTP, dGTP, and dTTP) were next
added to the flowcell. The polymerase extended each covalently bound oligonucleotide
hybridized to a denatured strand, iteratively incorporating nucleotides complementary to
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those in the denatured strand. This created a complementary copy of each denatured
strand that hybridized an oligonucleotide bound to the flowcell. Further, each
complementary copy was attached to the flowcell via the covalently bound oligonucleotide
at its base. Each resultant double stranded molecule was then denatured, and the original
denatured strand was washed away. These events can be seen in Figure 6B and 6C.
Each covalently bound strand next underwent a three-step PCR bridge
amplification process that can be seen in Figure 7. First, the free end of each strand
physically bent over, allowing its Illumina i5 or i7 sequencing adaptor to hybridize to its
complementary oligonucleotide covalently bound to the flowcell. Second, DNA
polymerase and unlabeled dNTPs (dATP, dCTP, dGTP, dTTP) were added. The
polymerase extended each recently hybridized covalently bound oligonucleotide,
iteratively incorporating complementary nucleotides to the strand that just attached to it.
Finally, resultant double stranded molecules were cleaved, causing the ends of each
strand that were not covalently bound to the flowcell to be released. Both strands took on
a vertical position.
These three steps were iteratively repeated to generate each strand's cluster. A
cluster is a clonal population of a single bound strand, comprised of up to one thousand
covalently bound copies of it. After the final bridge PCR amplification cycle was complete,
the reverse strand from every double stranded molecule in each cluster was cleaved and
washed away. The remaining forward strands were used for Read 1 generation.
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Figure 6. Creation of a complementary copy of each denatured strand. This figure shows a
cartoon schematic of how a denatured strand from a sequenceable dscDNA molecule hybridized
to the flowcell (A), was copied (B), and was washed away (C). Its complementary copy remained
attached to the flowcell via a covalently bound oligonucleotide at its base. Illumina; [accessed
2016 Feb 26]. Adapted from video on http://www.illumina.com/technology/next-generationsequencing/paired-end-sequencing_assay.html.
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Figure 7. PCR Bridge amplification of each covalently bound strand. This figure shows a
cartoon schematic of (A) hybridization between a bound strand’s sequencing adaptor and a
complementary flowcell oligonucleotide after the strand bent over, (B) a double stranded
molecule after a complementary copy of that strand was generated, and (C) two covalently
bound strands after their free (non-bound ends) were released from the flowcell. This three-step
process was repeated to generate up to one thousand copies of the original bound strand.
Illumina; [accessed 2016 Feb 26]. Adapted from video on
http://www.illumina.com/technology/next-generation-sequencing/paired-endsequencing_assay.html.

41

NextSeq 500 sequencing overview and Read 1 preparatory steps: The remaining
steps of Illumina NextSeq 500 sequencing ultimately produced two sequencing reads for
each bound strand that was clonally amplified to generate each cluster. These two
sequencing reads, Read 1 and Read 2, each reported 150 nucleotides beginning at
opposite ends of each bound strand's cDNA fragment. A visual depiction of these reads
can be seen in Figure 4.
Prior to beginning Read 1's "sequencing by synthesis" process, two types of
sequencing primers were added to the flowcell. The first type was complementary to a
portion of each strand's Illumina i5 sequencing adapter, and the second type was
complementary to a portion of each strand's Illumina i7 sequencing adapter. A
sequencing primer hybridized to a portion of the sequencing adapter (i5 or i7) in every
strand's unbound end via complementary basepairing. An example of the first type of
sequencing primer hybridizing to its complementary i5 sequencing adaptor in a strand's
unbound end can be seen in Figure 8A.
Read 1 "Sequencing by Synthesis": Read 1 acquisition involved 150 iterative
"sequencing by synthesis" cycles following the same four steps. First, DNA polymerase
and 4 unique reversible terminator nucleotides complementary to each covalently bound
strand’s dNTPs (dATP, dCTP, dGTP, dTTP) were added to the flowcell. Each reversible
terminator nucleotide was unique in that it emitted a different wavelength when excited
by a laser in a downstream step. Second, each of the four fluorescently labeled reversible
terminator nucleotides competed to extend the chain of nucleotides (beginning adjacent
to the recently hybridized sequencing adaptor) towards the flowcell. Only the reversible
terminator nucleotide complementary to the covalently bound strand's dNTP at each
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Figure 8. Read 1 “Sequencing by Synthesis”. This figure shows a cartoon schematic of (A)
hybridization between a bound strand’s sequencing adaptor and a complementary sequencing
primer (purple circles), and (B) a close-up of that strand’s growing Read 1 oligonucleotide chain
comprised of complementary reversible terminator nucleotides after the first 7 cycles. These
reversible terminator nucleotides are color coded by their unique emission wavelengths when
shone with a laser. Illumina; [accessed 2016 Feb 26]. Adapted from video on
http://www.illumina.com/technology/next-generation-sequencing/paired-endsequencing_assay.html.
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position was incorporated (with the exception of rare errors). Third, a laser was shone at
every cluster on the flowcell. A detector recorded the emission wavelength (and signal
intensity) from incorporated reversible terminator nucleotides at that position in every
strand in every cluster. The signal-to-noise ratio for detection of reversible terminator
nucleotides’ emitted wavelengths was improved in each cluster as a result of the strand’s
clonal amplification.

Lastly, the inhibitor on each incorporated reversible terminator

nucleotide was removed, allowing this iterative process to repeat until the 150th cycle
was completed. A cartoon depiction of a Read 1 molecule after the first 7 cycles can be
seen in Figure 8B.
Index Read acquisition: Index read acquisition involved 8 iterative “sequencing by
synthesis” cycles, enabling us to retrieve the 8-nucleotide index sequence in the i5
sequencing adapter of every strand in every cluster. As mentioned in a previous section,
each of our samples was assigned a different Illumina i5 sequencing adapter containing
a unique 8-nucleotide index sequence (and an identical Illumina i7 sequencing adapter)
following generation of dscDNAs. Retrieving the index sequence in each strand's i5
sequencing adapter allowed us to determine which sample that sequenced strand came
from. More importantly, it enabled us to determine which sample Read 1 and Read 2
sequencing reads (generated from that same strand) belonged to.
Prior to the 8 “sequencing by synthesis” cycles, the recently generated chain of
150 nucleotides (corresponding to Read 1) hybridized to each covalently bound strand in
each cluster was washed away. An index sequencing primer complementary to a portion
of each strand's i5 sequencing adaptor was added to the flowcell, and allowed time to
hybridize to its corresponding sequence.
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Eight iterative “sequencing by synthesis” cycles were carried out following the
same four steps. First, DNA polymerase and 4 unique reversible terminator nucleotides
complementary to each covalently bound strand’s dNTPs (dATP, dCTP, dGTP, dTTP)
were added to the flowcell. Each reversible terminator nucleotide was unique in that it
emitted a different wavelength when excited by a laser in a downstream step. Second,
each of the four fluorescently labeled reversible terminator nucleotides competed to
extend the chain of nucleotides (beginning adjacent to the recently hybridized index
primer) towards the flowcell. Only the reversible terminator nucleotide complementary to
the covalently bound strand's dNTP at each position was incorporated (with the exception
of rare errors). Third, a laser was shone at every cluster in the flowcell. A detector
recorded the emission wavelength (and signal intensity) from incorporated reversible
terminator nucleotides at that position in every strand in each cluster. The signal-to-noise
ratio for detection of reversible terminator nucleotides’ emitted wavelengths was improved
in each cluster as a result of the strand’s clonal amplification. Lastly, the inhibitor on each
incorporated reversible terminator nucleotide was removed, allowing this iterative process
to repeat until the 8th cycle was completed.
Read 2 preparation and acquisition: Prior to beginning Read 2’s “sequencing by
synthesis” process, the recently generated chain of 8 nucleotides (corresponding to the
index read) hybridized to each covalently bound strand in each cluster was washed away.
The remaining steps prior to Read 2 acquisition can be seen in Figure 9.
First, the free end of each strand then physically bent over, allowing its Illumina i5
or i7 sequencing adaptor to hybridize to its complementary oligonucleotide covalently
bound to the flowcell. Next, DNA polymerase and unlabeled dNTPs (dATP, dCTP, dGTP,
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dTTP) were added. The polymerase extended each recently hybridized covalently bound
oligonucleotide, incorporating nucleotides complementary to the strand that just attached
to it. Finally, resultant double stranded molecules were cleaved, causing the ends of each
strand that were not covalently bound to the flowcell to be released. Both strands took on
a vertical position.
Each resultant forward strand was cleaved and washed away. The remaining
reverse strand remained unaltered. Two types of sequencing primers were added to the
flowcell. The first type was complementary to a portion of each strand's Illumina i5
sequencing adapter, and the second type was complementary to a portion of each
strand's Illumina i7 sequencing adapter. A sequencing primer hybridized to a portion of
the sequencing adapter (i5 or i7) in every reverse strand's unbound end via
complementary basepairing.
Read 2 acquisition involved 150 iterative “sequencing by synthesis” cycles
following the same four steps as Read 1 acquisition. Each covalently bound reverse
strand used for Read 2 acquisition was an inverted complementary copy of the strand
used for Read 1 acquisition. Read 2 thereby began at the opposite end of each bound
strand’s cDNA fragment (directly adjacent to the Illumina i5 or i7 adaptor) relative to where
Read 1 began.
Data processing, FastQ files, and phred scores: Proprietary Illumina software
algorithms were used to process the emission wavelength and signal intensity from
incorporated reversible terminator nucleotides at every position in every strand in every
cluster during the acquisition of Read 1, Index Read, and Read 2. For each strand that
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Figure 9. Steps prior to Read 2 “Sequencing by Synthesis”. This figure shows a cartoon
schematic of (A) the covalently bound strand used for Read 1 generation after its index read was
washed away, (B) hybridization between this strand’s sequencing adaptor and a complementary
flowcell oligonucleotide after the strand bent over, (C) a double stranded molecule after a
complementary copy was generated, (D) two covalently bound complementary strands after their
free (non-bound ends) were cleaved from the flowcell, (E) removal of the forward strand, and (F)
hybridization of a Read 2 sequencing primer to the bound strand’s sequencing adaptor prior to
Read 2 Sequencing by Synthesis. Illumina; [accessed 2016 Feb 26]. Adapted from video on
http://www.illumina.com/technology/next-generation-sequencing/paired-endsequencing_assay.html.
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was clonally amplified to generate each cluster, corresponding Read 1 and Read 2 150
nucleotide sequences (hereby referred to as a paired end read) were reported. Each
paired end read was assigned to the correct sample using their sequenced strand’s index
read.
For each sample, all paired end reads’ Read 1 and Read 2 sequences were sent
in separate FastQ text files. Each Read 1 and Read 2 sequence reported the identity of
all 150 sequenced nucleotides and each nucleotide’s associated PHRED quality score.
This PHRED quality score signified the probability that nucleotide’s reported identity was
the result of a sequencing error. Table 2 details several possible PHRED scores and their
corresponding error probabilities.
FastQC for initial quality check: Each sample’s FastQ files were separately input into
FastQC (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/) to identify data
quality issues pertaining to the sequencer and/or the RNA-Sequencing library itself.
Quality was assessed across a range of metrics including average PHRED quality score
per position across reads, overall GC content, sequence length distribution,
overrepresented sequences, and duplicate read frequency.
Processing of sequencing reads prior to alignment: For each sample, we processed
all paired end reads to increase their probability of aligning to the hg19 human reference
genome in a proceeding step. A small portion of each sample’s paired end reads were
generated from sequenced strands containing a cDNA fragment <150 nucleotides in
length. 150 nucleotide Read 1 and Read 2 sequencing reads generated from these
strands necessarily contained nucleotides from an illumina i5 or i7 adaptor as a result.
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Table 2: PHRED quality scores
PHRED Quality
Score

Probability of
Sequencing Error

Probability Reported
Nucleotide is Accurate

10

1 in 10

90%

20

1 in 100

99%

30

1 in 1000

99.9%

40

1 in 10,000

99.99%

50

1 in 100,000

99.999%
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Further, nucleotides towards the 3’ end of Read 2 sequencing reads are known to have
lower PHRED scores as a result of Illumina sequencing chemistry degradation towards
the end of a run.
For each paired end read, we used Trimmomatic (Bolger, Lohse, and Usadel
2014) to remove nucleotides 1) belonging to Illumina i5 or i7 sequencing adaptors
and/or 2) with a PHRED score <20 found in the 3’ end of their Read 1 or Read 2
sequences. This ensured paired end reads didn’t fail downstream alignment to the hg19
human reference genome because they contained 1) Illumina sequencing adaptor
nucleotides that didn’t match any sequence in the hg19 human reference genome or 2)
an excess of incorrectly identified nucleotides (as a result of sequencing errors) that
didn’t match the hg19 human reference genome. We only retained reads that were ≥ 50
nucleotides in length after removing these select nucleotides. Each sample’s processed
Read 1 and Read 2 sequences were output into new Read 1 and Read 2 fastQ text files
for downstream analyses.
FastQC for pre-alignment quality check: Each sample’s Read 1 and Read 2 fastQ text
files

output

by

Trimmomatic

were

separately

(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/)

input
to

into

FastQC

ensure

Illumina

sequencing adaptor sequences were successfully removed, and the average PHRED
score for nucleotides towards the 3’ end of Read 2 sequencing reads increased.
Alignment of paired end reads: We selected Tophat2 (Kim et al. 2013), an open
source program specially designed for RNA-Sequencing data, to attempt alignment of
each sample’s paired end reads to the hg19 human reference transcriptome then hg19
human reference genome. We first downloaded hg19 human reference transcriptome
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(known RNA transcripts) and genome (known primary sequence) text files from the
Illumina iGenomes UCSC hg19 directory on the Tophat2 webpage
(https://ccb.jhu.edu/software/tophat/igenomes.shtml).
In the context of this RNA-Sequencing experiment, alignment involved comparing
the nucleotide sequences of each paired end read (Read 1 and 2) to the nucleotide
sequences of all known RNA transcripts, 22 autosomes, X chromosome, Y chromosome,
and mitochondrial genome. Each paired end read’s alignment reflected what part of the
genome that paired end read’s corresponding RNA molecule was transcribed from.
A paired end read qualified for alignment if it did not exceed Tophat2’s default
quality thresholds for the number of nucleotides that 1) didn’t match the reference genome
(as a result of biological variation and/or sequencing errors), or 2) were not present in the
reference genome.
Prior to Tophat2’s first step, we used the Burrows-Wheeler Aligner (Li and Durbin
2010), an open source software program, to align 5 million of each sample’s paired end
reads to the hg19 human reference transcriptome. This allowed us to estimate the
average size (and standard deviation) of cDNA fragments in each sample’s sequenced
strands. Tophat2 creators reported their software aligns a larger number of each sample’s
paired end reads to the hg19 human reference transcriptome and genome when these
calculated metrics are provided relative to when they are not.
For each sample, Tophat2 attempted to align each paired end read (Read 1 and
Read 2 from each sequenced strand) to the hg19 human reference transcriptome then
hg19 human reference genome using a 5-step process shown in Figure 10. First, Tophat2
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attempted to align (or map) each paired end read to all known transcripts in the hg19
human reference transcriptome. If the complete sequences of both reads in a paired end
read mapped within the boundaries of a known transcript, that paired end read was
aligned to that transcript. Second, Tophat2 attempted to map each unaligned paired end
read to all known exons in the reference genome. If the complete sequences of both reads
in a paired end read mapped within the boundaries of a known exon, that paired end read
was aligned to that exon.
Prior to the next step, Tophat2 generated a list of putative spliceosome splice sites
(GT and AG) across introns in the hg19 human reference genome. Third, Read 1 and
Read 2 in each unaligned paired end read were broken into smaller segments no greater
than 25 nucleotides in length. Tophat2 attempted to align these segments to all known
exons in the hg19 human reference genome. If multiple segments from a given paired
end read mapped to exons separated by one or more introns flanked with putative splice
sites, those segments were aligned to those exons. Fourth, Tophat2 concatenated
sequences flanking putative splice sites in the hg19 human reference genome, and then
attempted to map all unaligned segments to them. These concatenated sequences did
not belong to known exons in the genome. Aligned segments in steps 3 and/or 4 were rejoined to make full-length reads. Fifth, TopHat2 attempted to re-map any portion of an
aligned paired end read mapped to an intron to exonic sequence. For each sample,
Tophat2 output an accepted_hits.bam file reporting where each aligned paired end read
mapped in the genome.
Calculation

of

sequencing

alignment

metrics:

We

used

Picard

Tools

(http://picard.sourceforge.net), an open source software package, to calculate select
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Figure 10. Tophat2 alignment of each sequenced read. This figure shows a cartoon schematic
of Tophat2’s method for aligning a RNA-Sequencing read to a reference transcriptome then
genome. This illustration depicts alignment of a single end read (equivalent to a Read 1 in our
study), but the alignment process is the same for paired end reads. Adapted from Kim et al 2013.
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alignment metrics for each sample’s aligned paired end reads. For each sample, Picard
Tools reported: the total number of sequenced nucleotides (contained in their paired end
reads) that Tophat2 attempted to align to the hg19 human reference genome, the % of
sequenced nucleotides that were successfully aligned to the hg19 human reference
genome, the % of sequenced nucleotides that aligned to mRNA species, the % of
sequenced nucleotides that aligned to rRNA, tRNA, or mtRNA species, and the % of
sequenced nucleotides that aligned to intronic or intergenic regions.
For each sample, Picard Tools calculated these metrics via comparing aligned
paired end reads to 1) the Illumina iGenomes refFlat text file that contained all known
RNA transcripts, introns, and intergenic regions in the hg19 human reference genome,
and 2) an interval file I created containing known rRNA, tRNA, and mtRNA transcripts in
the hg19 human reference genome.
fALS causal point mutation analysis: We assessed whether any of our sALS samples
carried any of 471 known pathogenic coding variants (contained across 21 different
genes) mutually reported to cause fALS in three separate databanks (Abel, Powell,
Andersen, Al-Chalabi 2013, Landrum et al. 2014, Stenson et al. 2014). All of these genes
have been reported to carry mutations that cause ALS in a recent publication (Renton,
Chio, Traynor 2014). This involved using a variety of open source bioinformatic software
programs including the Genome Analysis Tool Kit (GATK) (McKenna et al. 2010, DePristo
et al. 2011, Van der Auwera et al. 2013), STAR (Dobin et al. 2013), and Picard Tools
(http://picard.sourceforge.net). For each sALS sample, GATK identified qualifying
sequence variants, or alleles that don’t match the reference genome, following a 4-step
pipeline (https://www.broadinstitute.org/gatk/guide/article?id=3891).
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This pipeline involved 1) attempting to align each sALS sample’s paired end reads
to the hg19 human reference genome using STAR, 2) removing each sALS sample’s
paired end reads that aligned to an identical genomic location, 3) re-assigning PHRED
scores to all nucleotides in each sALS sample’s remaining aligned paired end reads, and
4) identifying each sALS sample’s sequence variants that passed GATK’s default quality
filters.
We used STAR, an open source program specially designed for RNA-Sequencing
data, to attempt to align each sALS sample’s paired end reads to the hg19 human
reference genome. STAR used each sALS sample’s Read 1 and Read 2 FastQ files from
Trimmomatic as input, and output a file containing their aligned paired end reads for
downstream analysis. The GATK developers recommended STAR over Tophat, as it
yielded a higher proportion of validated sequence variants within their pipeline in an
unpublished comparative analysis.
We used Picard Tools to remove each sALS sample’s paired end reads that
aligned to an identical genomic location (aka duplicate reads). For each qualifying
genomic location, one aligned paired end read was retained for downstream analysis.
This step was taken as duplicate reads can result from PCR amplification reactions during
RNA-Sequencing library preparation as opposed to transcriptional events that occurred
in that sample’s tissues. Further, sequencing variants identified in such duplicate reads
may reflect a PCR artifact (i.e. a DNA polymerase erred and that nucleotide was
propagated into multiple PCR copies) as opposed to a biological feature in that sample’s
tissues.
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GATK next re-assigned a PHRED score to every nucleotide in each sALS sample’s
remaining aligned paired end sequencing reads. GATK reported Illumina sequencing
workflows assign biased PHRED scores to select nucleotides depending on what cycle
that nucleotide was sequenced and what nucleotides preceded it. GATK re-assigned new
PHRED scores to nucleotides that were likely affected by these biases, and did not alter
other nucleotides’ PHRED scores.
Finally, GATK identified each sALS sample’s qualifying sequence variants using
all remaining aligned paired end reads. A sequence variant qualified for identification if it
1) had a GATK GQ score of ≥20 (indicating a 99% or better chance the identity of that
reported sequence variant was correct at that genomic position), and 2) passed all
GATK’s default quality filters designed to prevent false positives from technical artifacts.
These default quality filters disqualified sequence variants if there was evidence for
technical bias related to 1) sequencing depth, 2) where the sequence variant was located
in aligned paired end reads containing it, and 3) the quality of alignment for all aligned
paired end reads containing that sequence variant. GATK output a text file for each
sample listing all their identified sequence variants. We used these lists to determine
whether any sALS sample contained a sequence variant that represented any of the 471
pathogenic fALS mutations.
Gene expression estimate overview: For each sample in this study, a given gene’s
expression level reflected the quantitative amount of its RNA transcripts in that sample’s
postmortem cervical spinal sections. For a given sample, we presumed each gene’s
expression level was preserved by a proportionate number of paired end reads that
aligned to its transcribed regions in that sample’s sequencing data. This concept is
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illustrated in Figure 11. Our downstream gene expression estimates relied on this
presumption. For each sample, we estimated gene expression levels for all annotated
genes in the hg19 human reference genome using several bioinformatics workflows
described in later sections of this document.
Illumina NextSeq 500 sequencing parameters and accuracy of gene expression
estimates: Relative to single end sequencing, paired end sequencing has been shown
to increase both the accuracy of downstream gene expression estimates (Salzman,
Jiang, Wong 2011) and the number of detected splice sites (Chhangawala, Rudy, Mason,
Rosenfeld 2015). Relative to shorter read options, longer reads (≥100 nucleotides) have
been shown to increase both the number of aligned sequenced reads (Cho et al. 2014)
and detected splice sites (Chhangawala, Rudy, Mason, Rosenfeld 2015). These findings
support our decision to use Illumina NextSeq500 paired end 150 nucleotide reads as
opposed to single end (or shorter paired end) reads, and likely increased the accuracy of
our downstream gene expression estimates.
In an RNA-Sequencing study, the total number of sequenced reads obtained for a
given sample is positively correlated with 1) the likelihood genes with lower expression
levels are represented in their sequencing data, and 2) how accurate their gene
expression estimates are likely to be. These relationships reflect Illumina’s (and many
other sequencing platform’s) sampling procedure, where denatured strands from only a
portion of each sample’s sequenceable dscDNA molecules are sequenced. These
concepts are illustrated in Figure 12.
According to a recent study, 45-65 million RNA-sequencing reads generated from
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Figure 11. Presumption underlying our gene expression estimates. This figure shows a
cartoon schematic of the presumption underlying our gene expression estimates. On the left are
a biological sample’s RNA transcripts from three different genes (color-coded red, blue, and
yellow). Each gene’s RNA transcripts were converted into a proportional amount of sequenceable
dscDNA molecules. In the middle, these molecules’ denatured strands hybridized to all the
available spots (or covalently bound complementary oligonucleotides) on the NextSeq500
flowcell. Those spots are color-coded by what gene’s denatured strands bound to them. On the
right is the sample’s paired end reads color-coded by which gene they aligned to, with read 1 and
read 2 sequences on the left and right of the black dash marks, respectively. For this sample,
each gene’s expression level was preserved in their sequencing data. 50%, 40%, and 10% of the
total RNA transcripts and aligned paired end reads corresponded to the blue, red, and yellow
genes, respectively.
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Figure 12. Read count and detection of lowly expressed genes. This figure illustrates how
increasing the number of paired end reads obtained for a given sample is positively correlated
with 1) the likelihood a gene with a low expression level is represented in their sequencing data,
and 2) how accurate gene expression estimates are likely to be. The top and bottom half of the
figure shows what happens when a smaller or larger amount of sequencing reads are generated
for a given sample, respectively. On the left are a biological sample’s RNA transcripts from three
different genes (color-coded red, blue, and yellow). Each gene’s RNA transcripts were converted
into a proportional amount of sequenceable dscDNA molecules. In the middle top half of the
figure, denatured strands from the sample’s more highly expressed genes (red and blue)
hybridized to the smaller number of flowcell spots allotted to this sample. This occurred as a result
of their being more prevalent relative to denatured strands from the yellow gene, and thereby
being more likely to bind the flowcell. In the middle bottom half of the figure, denatured strands
from all three genes hybridized to the larger number of flowcell spots allotted to this sample. On
the right are paired end reads from each scenario. Each paired end read is color-coded by the
gene it aligned to, and Read 1 and Read 2 sequences are on the left and right of the dash mark,
respectively. In the top half of the figure, the lowly expressed yellow gene didn’t have any
corresponding aligned paired end reads in the dataset. Further, the blue and red genes’ aligned
paired end reads made up 65% and 35% of their sequencing data, while their RNA transcripts
made up 55% and 45% of this sample’s total RNA. In the bottom scenario, each gene’s expression
level was accurately preserved in their sequencing data. 55%, 45%, and 5% of the total RNA
transcripts and aligned paired end reads corresponded to the blue, red, and yellow genes,
respectively.
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input total RNA (after rRNA-depletion) offers a comparable detection level for protein
coding genes relative to a standard Agilent DNA microarray (Zhao et al. 2014). There is
not a consensus number of RNA-sequencing reads one should appropriate to each
sample to achieve highly accurate gene expression estimates for very lowly expressed
genes. An early study proposed 200 million reads per sample was necessary to detect
the full range of expressed human RNA transcripts, including those from very lowly
expressed genes (Tarazona et al. 2011). The ENCODE (Encyclopedia of DNA elements)
consortium more recently generated 214 million 100 nucleotide paired end reads per
sample from H1 human embryonic stem cells and performed a saturation analysis
(Djebali et al 2012). They reported 36 and ~80 million paired end reads per sample were
necessary to accurately estimate genes with expression levels corresponding to FPKM
values of >10 and <10, respectively. A recent study (Marinov et al. 2014) related the
number of RNA transcript copies in single GM12878 cells to reported FPKM values, and
found one transcript copy per cell corresponds to an FPKM value of approximately 10.
Annotated genes with FPKM values <10 thereby average less than one transcript copy
per cell, but are expressed in enough of our spinal cells for detection.
Sequencing depth, biological replicates, and DEG identification: Provided a study
goal of identifying DEGs between groups and a limited budget, researchers will often
decrease the number of sequenced reads per sample while increasing the number of
biological replicates per group. DEG identification analyses model intra-group variability
in each gene’s aligned sequenced read counts across samples prior to inter-group
comparisons to identify DEGs. Including more biological replicates per group enables
more accurate intra-group variability estimates, and has been shown to increase the
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number of DEGs identified between groups. A recent analysis revealed ~72% more DEGs
(6,000 vs. 3,500) were identified when comparing MCF7 breast cancer cell groups
(treated or untreated with 17β-estradiol) comprised of 7 samples vs. 3 samples (Liu, Zhou,
White 2014). Every MCF7 breast cancer cell line sample had 30 million total sequenced
reads in that study. Another study (Zhang et al. 2014) reported a similar increase (~59%)
in the number of DEGs identified when comparing lymphoblastoid cell line groups
comprised of 8 samples vs. 3 samples. This study showed further expanding each
lymphoblastoid cell line groups’ size from 8 to 14 biological replicates increased the
number of identified DEGs by only ~12.5% (2000 vs. 2250). This suggests diminishing
returns in how many additional DEGs are identified when including more than 8 biological
replicates per group. Taken together, these findings supported our decision to acquire
>55 million paired end reads per sample, and compare 7 sALS samples to 8
neurologically healthy control samples for DEG identification.
HTSeq-Count: We used HTSeq-Count (Anders, Pyl, Huber 2015), an open source
program specially designed for RNA-Sequencing data, to report the total number of paired
end reads that aligned to each annotated gene’s transcribed regions. A paired end read
was counted for an annotated gene if the majority (or all) of its Read 1 and Read 2
sequences aligned to that gene’s transcribed regions. Figure 13 shows various
hypothetical alignments of a sequenced read to a fictitious gene_A, and whether HTSeqCount would count that sequenced read. For each sample, HTSeq-Count produced a
matrix with all annotated genes and their corresponding paired end read count values.
EdgeR and DEG identification: We used EdgeR (Robinson, McCarthy, Smyth 2010),
an open source program specially designed for RNA-Sequencing data, to detect sALS61

group specific DEGs. EdgeR first normalized each sample’s paired end read counts (from
HTSeq-Count) for each annotated gene, producing pseudo counts. Annotated genes’
pseudo counts in our sALS and neurologically healthy control sample groups were then
directly compared to identify sALS group-specific DEGs.
EdgeR followed a multi-step process to normalize each annotated genes’ paired
end read counts across samples. This process involved mathematical normalizations
accounting for 1) differences in the total number of paired end read counts between
samples, 2) differences in RNA species represented in each samples’ sequencing data,
and 3) overdispersion in annotated genes’ paired end read counts across samples.
Differences in the total number of paired end read counts between samples could
reflect each sample’s total number of RNA-Sequencing reads as opposed to differences
in annotated genes’ expression levels. Assume two of our samples’ RNA-Sequencing
libraries had an equal number of sequenceable dscDNA molecules corresponding to a
given annotated gene (suggesting that gene had an equal expression level in both
samples’ postmortem cervical spinal sections).
If more total sequencing reads were generated for one of those samples, that
sample’s sequencing data would likely have more total paired end read counts align to
that annotated gene’s transcribed regions relative to the other sample. This is because
denatured strands from that annotated gene’s sequenceable dscDNA molecules were
appropriated

more

Illumina

NextSeq500

binding

spots

(covalently

bound

oligonucleotides) to potentially hybridize to for sequencing. For each sample, we used
500 ngs of input total RNA to generate their RNA- Sequencing library. However, the RNA
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Figure 13. HT-Seq count scenarios. This figure shows a visual schematic of various
hypothetical alignments of a sequenced read (in teal) to a fictitious gene_A’s transcribed regions.
HT-Seq Count would count that sequenced read for gene_A in scenarios A-E. It would not count
the sequenced read for gene_A in scenarios F-G, as it is unclear whether that read’s
corresponding cDNA fragment was generated from gene_A or gene_B. While these scenarios
depict a single end sequenced read (equivalent to a Read 1 in our study), the counting process
is the same for each paired end read. The program considers the same criteria (the proportion of
a sequenced read aligning to a given gene’s transcribed regions) for counting. Counting reads
in features with htseq-count. Simon Anders; [accessed 2016 Feb 26]. http://wwwhuber.embl.de/users/anders/HTSeq/doc/count.html.
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transcripts comprising each sample’s input total RNA varied. Differences in a given
annotated gene’s aligned paired end read counts across samples could reflect varying
RNA compositions in each sample’s total input RNA (and Illumina’s sampling procedure)
as opposed to gene expression differences. This concept is illustrated in Figure 14.
RNA-Sequencing data is often overdispersed. This means the variance of
sequenced read counts aligned to each gene across each group’s samples often exceeds
what is expected using a Poisson distribution. Use of the Poisson distribution to model
sequenced read counts across each group’s samples could lead to a large number of
false positives in downstream DEG analyses. EdgeR used a negative binomial
distribution to model each annotated gene’s paired end read counts across each group’s
samples to better account for this variance.
EdgeR then estimated the level of dispersion (using conditional maximum
likelihood modeling) for each annotated gene and all annotated genes together. An
empirical Bayes’ theorem was used to moderate overdispersion via shrinking each gene’s
level of dispersion towards the consensus dispersion calculated from all annotated genes
together.
EdgeR replaced each annotated genes’ original paired end read counts across
samples with pseudo counts that incorporated all of the above normalizations. An exact
test (analogous to a Fisher’s Exact test with modifications to suit data modeled using a
negative binomial distribution) was used to directly compare each annotated gene’s
pseudo counts in our sALS and neurologically healthy control sample groups.
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Figure 14. RNA composition differences and gene expression estimates. This figure shows
the effects of RNA composition differences between samples on a given gene’s expression
estimates. On the left are two biological samples’ RNA transcripts from three different genes (red,
blue, and yellow). Each gene’s RNA transcripts were converted into a proportional amount of
sequenceable dscDNA molecules. In the middle, these molecules’ denatured strands hybridized
to all the available spots (or covalently bound complementary oligonucleotides) on the
NextSeq500 flowcell. Those spots are color-coded by what gene’s denatured strands bound to
them. On the right are each sample’s paired end reads color-coded by which gene they aligned
to. Read 1 and read 2 sequences are on the left and right of the black dash marks, respectively.
While both samples had an equal number of RNA transcripts from the yellow gene, sample A
would have a higher yellow gene expression estimate as a result of having more paired end reads
aligned to it. The blue and red genes were expressed at a higher level in sample B relative to
sample A, and the blue gene’s corresponding denatured strands bound more spots on the
flowcell. This led to the yellow gene’s denatured strands being under sampled in sample B, and
a falsely reported difference in the yellow gene’s expression level estimates between the two
samples.
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EdgeR reported an associated p-value for each annotated gene tested. We calculated
each annotated gene’s Benjamini-Hochberg corrected p-value from their EdgeR reported
p-value via the R function p.adjust. Each annotated gene with a Benjamini-Hochberg
corrected p-value < 0.10 was identified as a sALS group-specific DEG.
We used EdgeR’s default workflow for our DEG analysis. We decided to filter out
genes with a cpm (counts per million aligned paired end reads) value <1 in 7 samples.
We chose a cpm value of 1 as smaller values likely reflected noise. We chose 7 samples
as our threshold, as genes that were only expressed in our disease or control group could
play an important role in disease pathology.
DESeq2 and DEG identification: We used DESeq2 (Love, Huber, Anders 2014), an
open source program specially designed for RNA-Sequencing data, to detect sALS
group-specific DEGs. DESeq2 first normalized each sample’s paired end read counts
(from HTSeq-Count) for each annotated gene. Normalized paired end read counts in our
sALS and neurologically healthy control samples were then directly compared to identify
sALS group-specific DEGs.
DESeq2 followed a multi-step process to normalize each sample’s paired end read
counts for each annotated gene. This process involved mathematical normalizations
accounting for 1) differences in the total number of paired end read counts between
samples, 2) overdispersion in annotated genes’ paired end read counts across samples,
and 3) high variance in gene expression fold change values for annotated genes with low
paired end read counts across samples.
Like EdgeR, DESeq2 used a negative binomial distribution to best account for
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variance in each annotated genes’ paired end read counts across each group’s samples.
Unlike EdgeR, DESeq2 calculated the level of dispersion for each annotated gene and
annotated genes with similar expression levels across samples. DESeq2 applied an
empirical Bayes’ theorem to moderate overdispersion via shrinking each gene’s level of
dispersion towards the level of dispersion estimated for genes with a similar expression
level.
Each annotated gene’s normalized paired end read counts across each group’s
samples were used to calculate a log transformed fold change value between groups via
a maximum likelihood model. Log fold change values for annotated genes with a small
number of paired end read counts across both groups’ samples are often artificially high,
owing to a low signal-to-noise ratio. To mediate this, DESeq2 applied an empirical Bayes
procedure to shrink all annotated genes’ log fold change estimates towards zero, applying
more shrinkage to genes with low paired end read counts across samples. This reduced
the chance of false positives in downstream DEG analyses.
To identify sALS group-specific DEGs, DESeq2 applied a Wald test where each
annotated gene’s shrunken log fold change value was divided by its standard error.
Resultant Z-scores were compared to a normal distribution, and a corresponding p-value
was generated. We took all annotated genes’ corresponding p-values, and calculated
corresponding Benjamini-Hochberg corrected p-values using the R function p.adjust.
Each annotated gene with a Benjamini-Hochberg corrected p-value < 0.10 was identified
as a sALS group-specific DEG.
Cufflinks for gene expression estimates: We separately used Cufflinks (Trapnell et al.
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2010), an open source program specially designed for RNA-Sequencing data, to estimate
each sample’s gene expression levels for all annotated genes in the hg19 human
reference genome. Prior to estimating each annotated gene’s expression level for each
sample, Cufflinks calculated each sample’s size distribution of cDNA fragments (in their
sequenced strands) using their aligned paired end reads. This data was used in a
downstream step. Cufflinks then followed a 5-step process to estimate each annotated
gene’s expression level for each sample.
For a given annotated gene, Cufflinks first identified a given sample’s aligned
paired end reads whose corresponding cDNA fragments (in their sequenced strands)
were necessarily generated from different RNA transcripts. This step used maximum
likelihood statistical modeling. Second, Cufflinks used probabilistic modeling (relying on
a proof of Dilworth’s theorem) to identify the minimum number of RNA transcripts that
accounted for that annotated gene’s aligned paired end reads. RNA transcripts identified
in this step included annotated transcripts in hg19 human reference transcriptome and/or
novel transcripts. Third, Cufflinks used an algorithm to probabilistically assign each
aligned paired end read to the RNA transcript its corresponding cDNA fragment was
generated from. The algorithm used the sample’s calculated distribution of cDNA
fragment sizes (in their sequenced strands) as well as the annotated genes’ RNA
transcript splicing structures to accomplish this. Any aligned paired end read whose
corresponding cDNA fragment could have been generated from more than one RNA
transcript was assigned to each of those RNA transcripts. This process is illustrated in
Figure 15.
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Four, Cufflinks estimated that annotated gene’s RNA transcript expression levels.
This involved using a statistical model where the probability of observing each transcript’s
assigned paired end reads from the previous step was linearly related to each transcript’s
expression level. Maximum likelihood equations calculated the most probable quantitative
expression levels for that annotated gene’s RNA transcripts. Each transcript’s expression
level was reported in normalized gene expression units called FPKMs (Fragments Per
Kilobase of exon per Million fragments mapped) whose calculation is explained in a
proceeding section. Finally, Cufflinks estimated that annotated gene’s expression level
by summing all of its RNA transcripts’ FPKM values together.
We did not include each sample’s paired end reads that aligned to rRNA, tRNA,
mtRNA, or unannotated transcripts in our transcript expression estimates. This prevented
RNA composition differences between samples leading to false positives or negatives in
our downstream Cuffdiff2 DEG analysis. The effects of RNA composition differences
between samples on gene expression can be seen in Figure 14.
Cufflinks’ FPKM gene expression units: The Illumina Truseq® Stranded Total RNA HT
kit broke each sample’s isolated RNA transcripts into 120-220 nucleotide fragments (with
a median size of 155 nucleotides) prior to generating sequenceable dscDNA molecules.
For each sample, the length of a given isolated RNA transcript was positively correlated
with both 1) the number of fragments generated from it, and 2) the number of
corresponding sequenceable dscDNA molecules generated from its fragments. Relative
to shorter RNA transcripts, longer RNA transcripts were generally more likely to have a
greater number of corresponding paired end reads (and paired end read counts). This
was because they had more denatured strands that could hybridize to the limited number
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Figure 15. Cufflinks assignment of individual paired end reads to a given annotated gene’s
RNA transcripts. On the left, this figure shows a visual schematic of Cufflinks assignment of
individual paired end reads (dumbbell shaped objects of various sizes) to a given annotated
gene’s three RNA transcripts (colored yellow, purple, and pink and located just above the words
“Transcript coverage and compatibility”). Paired end reads are color-coded by the transcript they
aligned to. Black paired end reads could not be exclusively assigned to one RNA transcript. The
violet paired end read was originally assigned to either the purple or pink transcript. As that sample
did not have many sequenced strands with large cDNA fragments (as indicated by the cDNA
fragment length histogram on the right side of this figure), the violet paired end read was ultimately
assigned to the purple transcript as opposed to the pink transcript. Adapted from Trapnell et al
2010.
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of Illumina NextSeq 500 binding spots (covalently bound oligonucleotides) for
sequencing. Estimating each sample’s gene expression levels using aligned paired end
reads counts alone could thereby lead one to falsely conclude genes with longer RNA
transcripts were expressed at a higher level relative to genes with shorter RNA
transcripts.
To address this issue, Cufflinks reported all transcript (and gene) expression levels
in normalized expression units called FPKM’s as opposed to paired end read counts. Any
given FPKM value was calculated using the equation FPKM = C/LN. C is the number of
paired end reads that aligned to that gene’s transcribed regions (or to that transcript). L
is the length of that gene’s transcribed regions (or the transcript itself) in kilobases. N is
the number (in millions) of sequenced reads acquired for that sample. The FPKM
measurement accounted for differences in the length of each gene’s transcribed regions
(or the length of a given transcript), as well as the total number of sequenced reads for
each sample. The importance of normalizing for differences in the total number of
sequenced paired end reads and its influences on gene expression estimates are
described in the EdgeR section. Figure 16 illustrates the advantage of FPKM
measurements over paired end read counts for accurate expression estimates.
Cuffdiff2 for DEG identification: We used Cuffdiff2 (Trapnell et al. 2013), an open
source program specially designed for RNA-Sequencing data, to detect sALS groupspecific DEGs. For each annotated gene, Cuffdiff2 first performed normalizations of its
transcripts’ FPKM values (from Cufflinks) across samples in our sALS and neurologically
healthy control groups. Representative FPKM values were calculated for our sALS and
neurologically healthy control sample groups, and then directly compared to identify sALS
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Figure 16. Transcript length, raw read count, and FPKM values. This figure shows paired end
read counts vs. FPKM values for four different genes (numbered 1-4) from a hypothetical sample.
Above each gene are the sample’s aligned sequenced reads. Gene 1 and 2 have equally sized
transcribed regions, yet gene 2 was more highly expressed in that sample as evidenced by more
aligned sequenced reads. Both paired end read counts and FPKM values accurately reflected the
expression difference between genes 1 and 2. Genes 3 and 4 have different sized transcribed
regions, but were equally expressed in that sample. However, gene 4 has many more aligned
paired end reads as a result of generating many more denatured strands (from sequenceable
dscDNA molecules) that bound to the flowcell for sequencing. FPKM values accurately reflected
genes 3 and 4 as equally expressed by normalizing for their different sized transcribed regions. If
one were to use the raw read count measurements for genes 3 and 4, they would falsely report a
difference in their expression levels. Adapted from Garber, Grabherr, Guttman, Trapnell 2011.
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group-specific DEGs.
Cuffdiff2 applied mathematical normalizations to RNA transcripts’ FPKM values
that accounted for 1) differences in the total number of assigned paired end reads to RNA
transcripts across samples in each group, 2) uncertainty associated with Cufflinks’
assignment of each paired end read to an RNA transcript, and 3) overdispersion in RNA
transcripts’ FPKM values across each group’s samples.
Cuffdiff2 used a mathematical normalization that accounted for differences in the
total number of paired end reads assigned to RNA transcripts between samples in each
group. This was the same normalization EdgeR used to account for differences in the
total number of paired end reads aligned to annotated genes across samples. Rationale
for this normalization step and its influences on expression level estimates are the same
for transcripts as they are for genes, and can be seen in the EdgeR section.
It has been observed that up to 50% of a given sample’s aligned sequenced reads
can be assigned to more than one RNA transcript in an annotated gene (Trapnell et al.
2013). This makes sense as human genes’ RNA transcripts often share large amounts of
sequence, and many genes have paralogs with highly similar sequences. For every
sample, Cuffdiff2 used a beta distribution to statistically model the level of uncertainty
associated with each paired end read’s assignment to an RNA transcript.
Like paired end read counts, FPKM values for each RNA transcript across each
group’s samples are often overdispersed. This means the variance of each transcript’s
FPKM values across each group’s samples generally exceeds what is expected using a
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Poisson distribution. Cuffdiff2 used a negative binomial distribution to model each RNA
transcript’s FPKM values across each group’s samples to better account for this variance.
Cuffdiff2 applied an algorithm mixing results from the beta and negative binomial
distributions for each RNA transcript’s FPKM values across each group’s samples.
Resultant beta negative binomial distributions accounted for variability in each RNA
transcript’s FPKM values owing to 1) uncertainty associated with Cufflinks’ assignment of
each paired end read to an RNA transcript, and 2) overdispersion in RNA transcripts’
FPKM values across each group’s samples.
For each annotated gene, Cuffdiff2 calculated representative FPKM values for our
sALS and neurologically healthy control sample groups. For each sample group, this
involved statistically accounting for the mean, variance, and covariance of all of its
transcripts’ normalized FPKM values across samples. Cuffdiff2 then calculated an
expression ratio (fold change) by dividing the sALS sample group’s representative FPKM
value by the neurologically healthy control sample group’s representative FPKM value.
Log-transforming this expression ratio generated a test statistic that followed a standard
normal distribution when divided by its variance. Cuffdiff2 then conducted a two-sided t
test to assess the significance of the test statistic, and reported an associated p-value for
that annotated gene. When an annotated gene had a representative FPKM value of zero
in one of our groups, a one-sided t test was conducted. We took all annotated genes’
corresponding p-values, and calculated their Benjamini-Hochberg corrected p-values
using the R function p.adjust. Each annotated gene with a Benjamini-Hochberg corrected
p-value < 0.10 was identified as a sALS group-specific DEG.

74

Weighted Gene Co-Expression Network Analysis (WGCNA): We used WGCNA
(Langfelder, Horvath 2008) to identify gene co-expression networks statistically
associated with our sALS sample group. WGCNA followed a 6-step process to predict
which genes were co-expressed, cluster them into gene networks, test which gene
networks were associated with disease status, and aid our selection of hub genes. The
mathematical formulas used in each step are not included in this description, but can be
found in an earlier publication (Zhang, Horvath 2005).
First, WGCNA calculated an adjacency matrix (a gene network) that reported a
correlation value between every pair of genes’ expression values across all 15 samples.
This analysis presumes the higher the correlation value between a pair of genes, the
more likely they are functionally connected. Once the adjacency matrix was constructed,
summation of any individual gene’s correlation values to all other genes reflected its level
of overall connectedness.
Second, the adjacency matrix was raised to a software-determined exponential
power determined by the input dataset. This served to reduce noise by pushing lower
pairwise gene correlation values closer to zero relative to higher values. The exponential
power used was the lowest value needed to ensure the network approximated scale-free
topology. In this context, scale-free topology was satisfied when a small number of genes
(hub genes) were highly connected to other genes, whereas the majority of genes were
weakly connected to other genes. Many biological (including gene co-expression)
networks have demonstrated scale-free topology (Zhang, Horvath 2005), and specifically
manipulating these networks’ highly connected members modulated cellular processes
associated with these networks (Jeong, Mason, Barabasi, Oltvai 2001, Carter,
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Brechbuhler, Griffin, Bond 2004). This step laid the foundation for identification of hub
genes within smaller modules (networks) of interest later in this analysis.
Third, the adjacency matrix was transformed into a topological overlap matrix by
calculating topological overlap (TOM) scores for each gene. This score accounted for
each pair of genes’ connection strength (adjacency value) to each other as well as their
connection strengths (adjacency values) to every other gene in the adjacency matrix.
Higher TOM scores indicated a pair of genes was more likely connected to each other
and a shared set of other genes.
Fourth, WGCNA identified gene co-expression networks (or modules) via average
linkage hierarchical clustering using a dissimilarity score (1-TOM score for every gene)
as a measure of distance. The resultant dendrogram of clustered genes was segregated
into individual modules with at least 30 genes using WGCNA’s dynamic tree-cutting
algorithm (Langfelder, Horvath 2008).
Fifth, WGCNA calculated each module’s eigengene, or first principle component,
using all samples’ gene expression values for all genes in each module. A module
eigengene was considered a summarized expression profile representative of that
module. Each module’s eigengene was then correlated against every other module’s
eigengene. If two or more modules’ eigengenes had a correlation value >.75, those
modules were merged together to form a larger module. Module eigengenes were recalculated at this stage and the process was repeated until no two modules’ eigengenes
had a correlation value >.75.
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Finally, each module eigengene was tested for statistical association to our
provided phenotypic traits. We assessed whether each module’s eigenegene was
associated with disease status, gender, or age. P-values based on the Student’s t-test
were reported, and are equivalent to a Wald test in a univariable linear regression model.
For all samples, we input a filtered list of 13,301 genes and their Cufflinks FPKM
values. All of these genes had an FPKM value >2 in at least 7 samples. We chose an
FPKM of 2 as smaller values more likely reflected noise. We chose 7 for our sample
threshold as genes that were only expressed in our sALS or neurologically healthy control
sample group could play an important role in disease pathology. We log-transformed
these FPKM values using log2 (FPKM value +1) as recommended on the WGCNA FAQ’s
page
(http://labs.genetics.ucla.edu/horvath/CoexpressionNetwork/Rpackages/WGCNA/faq.ht
ml) prior to analysis.
Our analysis was guided by steps 1, 2b, and 3 in the R Tutorial listed under I.
Network analysis of liver expression data from female mice: finding modules related to
body weight from the WGCNA website
(http://labs.genetics.ucla.edu/horvath/CoexpressionNetwork/Rpackages/WGCNA/Tutori
als/).
We deviated from the tutorial several times. We generated a signed weighted
adjacency matrix as opposed to the default unsigned weighted network. We chose this
option to preserve the directions of every pair of genes’ correlation, as a positive
correlation may indicate biological activation whereas a negative correlation may indicate

77

biological repression. Unsigned networks did not preserve the direction of correlation. We
used the bicor (biweight midcorrelation) correlation in place of the Pearson correlation to
construct our adjacency matrix and determine the exponential value necessary to
approximate scale-free topology. We chose this option as we had a small sample size,
and biweight midcorrelations are more robust to outliers compared to Pearson
correlations

(Langfelder,

Horvath

2012).

We

added

the

flag

corOptions=list(maxPOutliers=0.1)) to further reduce outlier effects.
WGCNA hub gene identification: We identified module hub genes using WGCNA’s
intramodular connectivity and modular membership scores calculated for every gene in
each prioritized module. The intramodular connectivity score reflected the cumulative
connection strength a given module gene had with all other module genes. The modular
membership score reflected how representative that gene’s expression values were of
the module as a whole.
Hub genes typically have large values for both of these metrics. We considered
each gene’s gene significance score to further prioritize one hub gene over another. This
score reflected how strongly a given gene’s expression values correlated with disease
status in our set of samples.
Ingenuity Pathway Analysis: We used QIAGEN’s Ingenuity Pathway Analysis to assess
what canonical signaling pathways, diseases/disorders, and upstream regulators
(molecules known to influence various genes’ expression levels) were statistically
significantly associated with each of our prioritized gene sets. For each prioritized gene
set, IPA used a right-tailed Fisher Exact test to assess the number of genes in that gene
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set that were separately associated with each canonical signaling pathway,
disease/disorder, and upstream regulator in the IPA Knowledge base. Association pvalues relating each prioritized gene set to each tested canonical signaling pathway,
disease/disorder, and upstream regulator were reported.
In Vitro models for hypothesis testing: For hypothesis testing, we relied on in vitro
models using neural stem cells and iPSC-derived motor neurons. Neural stem cells are
precursors of the cervical spinal cell populations (astrocytes, microglia, and motor
neurons) that we isolated RNA from for each sample. We opted for in vitro cell models
over transgenic animals carrying a fALS causal point mutation. We suspect findings in
these cells models would more accurately reflect what occurs in sALS patients’ diseasevulnerable cervical spinal cells in vivo, as recent studies show the majority of sALS is not
caused by a monogenic mutations (Renton, Chio, Traynor 2014).
Neural stem cell derivation and maintenance: Donor blood mononuclear cells were
reprogrammed to a pluripotent state and neuralized as previously described (O’Brien,
2015). The resulting neural stem cells (NSC) were maintained in a dividing state on
Geltrex (Life Technologies, Grand Island, NY) coated tissue culture ware in NSC Growth
Medium [KnockOut DMEM/F-12 containing 2 mM GlutaMAX-I supplement, 20 ng/mL
human recombinant basic fibroblast growth factor (bFGF), epidermal growth factor (EGF),
2% StemPro neural supplement, 100 ug/mL pyruvate and 50 ug/ml uridine]. NSC were
grown at 37C in a 5% CO2 incubator with the oxygen concentration held at 5%, and
media was changed every 2 to 3 days. Cultures were passaged when 90% confluent.
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NSC treatment groups and transfection: 24 hours before the MTT assay, media was
exchanged for five groups of NSC cultures with Optimem Media (Thermo-Scientific)
containing 1) Fugene HD reagent alone, 2) Fugene HD reagent + GFP plasmid, 3)
Fugene HD reagent + 100 ngs TNFAIP2-IRES-GFP plasmid, 4) Fugene HD reagent +
100 ngs TNFAIP2-IRES-GFP plasmid + 75 uM caspase 8 inhibitor, or 5) Fugene HD
reagent + 100 ngs TNFAIP2-IRES-GFP plasmid + 75 uM caspase 9 inhibitor. They were
then incubated as described in the above section.
The TNFAIP2-IRES-GFP plasmid can be seen in Figure 17. The GFP plasmid only
differed in not possessing the TNFAIP2 and internally ribosome entry site (IRES)
cassettes. Both plasmids were complexed with FuGENE HD Transfection Reagent
(Promega) according to manufacturer instructions prior to transfection. The cell
permeable caspase inhibitors used (Sigma Aldrich) were peptides that irreversibly bound
to the catalytic sites of their respective activated caspases. Each of the 5 NSC treatment
groups consisted of eight independent cell cultures. Experiment done in collaboration with
Jim Bennett and Paula Keeney.
Exposing NSCs to TNF-, Isolating RNA, and qPCR

48 hours before harvest, medium was exchanged on 80% confluent NSC cultures
with 1% DMSO (Sigma, St. Louis) in NSC growth medium and incubated as above. 24
hours before harvest, medium was exchanged with 1% DMSO or 100 ng/mL HumanKine
Tumor Necrosis Factor- (Sigma) in growth medium and incubated. After 24 hours, cells
were lifted using TrypLE (Life Technologies), washed, and each pellet sonicated in 350
ul Buffer RLT Plus (Qiagen, Valencia, CA). RNA was isolated using an AllPrep DNA/RNA
Mini Kit (Qiagen) with an on-column DNase digestion. RNA quality and quantity were
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Figure 17. TNFAIP2-IRES-GFP plasmid. This figure shows the TNFAIP2-IRES-GFP plasmid.
The internal ribosome entry site (IRES) cannot be seen, but is located between the TNFAIP2 and
GFP cassettes. CMV promoter driven transcription encoded the full length TNFAIP2 and GFP
proteins.
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assessed using a BioRad Experion Electrophoresis Station and a Standard Sensitivity
Chip. All samples had a RQI value of 9.5 or higher. 1300 ng of RNA from each sample
were reverse transcribed to dscDNA using an iScript kit (Bio-Rad, Hercules, CA)
according to directions. Forward (FP) and reverse primers (RP) for SybrGreen detection
were designed by Beacon Designer v 8.12 (Premier Biosoft, www.PremierBiosoft.com)
using human gene cDNA sequences downloaded from PubMed, and were synthesized
by Operon. qPCR reactions (including forward and reverse primers at 250 nM and
standard qPCR reagents) were run on the BioRad CFX96. The BioRad CFX96
automatically detected cycle threshold (Ct) values for each of our 9 DEGs in each tested
sample.
Gene normalization was carried out using Qiagen RT2 Profiler Human
Housekeeping gene plates, with each cDNA tested in duplicate for expression of the 12
housekeeping genes. qbasePLUS software (BioGazelle, www.Biogazelle.com) was
used to determine the most stable genes (GAPDH, RPL13A, RPL3O) across all
experiments. The geometric means of these three genes’ expression levels in each cDNA
sample were used to normalize expression of the nine DEGs examined by qPCR. 8
independent NSC cultures were run. Experiment done in collaboration with Jim Bennett
and Paula Keeney.
iPSC generation and neural Induction: Integration-free iPSCs were generated from
peripheral blood mononuclear cells (MNC) from a neurologically healthy, Caucasian male
donor (aged 62) using a previously described protocol (Dowey et al. 2012) with
modifications (O’Brien, Keeney, Bennett 2015). Briefly, the pEB-C5 and pEB-Tg plasmids
(Addgene) were electroporated into cells using an Amaxa Nucleofector 4D system
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(Lonza, Allendale, NJ). After three weeks, viable colonies were expanded in mTeSR
medium on Geltrex (Life Technologies) coated plates. Neuralization of iPSCs was
accomplished using PSC Neural Induction Medium (Life Technologies) according to the
protocol with modifications (Amoroso et al. 2013). All cultures were maintained at 37°C in
a humidified CO2 incubator with the oxygen level held at 5%.
Motor neuron differentiation and transfection: Neuralized iPSCs were grown in neural
induction media containing DMEM/F12 with 0.2 μM LDN-193189 (LDN; Stemgent), 10
μM SB431542 (SB; Stemgent), 10 ng/mL BDNF (R&D systems), 0.4 ug/mL L-ascorbic
acid (Sigma), 2 mM GlutaMAX-I supplement, 1% N-2 supplement, and 1% nonessential
amino acids (NEAA). Two days later, 1 μM retinoic acid was added. On day four, LDN/SB
was stopped and 1 μM smoothened agonist (SAG; Calbiochem) and 0.5 μM PM were
added. On day 14, cells were switched to neurobasal media containing 2 mM GlutaMAXI, 2% B-27, 1% NEAA, 0.4 ug/mL AA, 10 ng/mL GDNF (R&D), 10 ng/mL CNTF (R&D).
Media was replaced every 2-3 days. All cell culture materials were purchased from Life
Technologies. All cultures were grown at 37°C in 5% oxygen and 5% CO2 conditions. We
found motor neurons had a ~15-22 fold increase in expression of motor neuron specific
markers HB9 and ISL1 at day 21, suggesting successful differentiation (O’Brien, Keeney,
Bennett 2015).
On day 21 of differentiation, iPSC-derived motor neuron cultures were transfected
with 100 ngs of TNFAIP2-GFP plasmid or GFP plasmid. The TNFAIP2-GFP plasmid was
different from the TNFAIP2-IRES-GFP plasmid mentioned above, in that it did not contain
and IRES. It therefore produced a TNFAIP2 protein with a GFP fused to its N terminus.
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Both of these plasmids were complexed with FuGENE HD Transfection Reagent
(Promega) according to manufacturer instructions prior to transfection.
Real-time quantitative PCR (qPCR): We used qPCR to measure TNFAIP2 expression
in our iPSC-derived motor neuron groups transfected with either TNFAIP2-GFP plasmid
or the GFP plasmid. RNA was extracted from iPSC-derived motor neuron cultures with
the RNeasy Plus Micro Kit (Qiagen) according to manufacturer instructions. Quantification
of isolated RNA was performed using a Nanodrop 2000c spectrophotometer (Thermo
Scientific). RNA was reverse transcribed into dscDNA using the iScript cDNA synthesis
kit (BioRad). For qPCR, 50 ngs of dscDNA per well was loaded into a 96-well plate and
analyzed with the CFX96 Real Time PCR Detection System (BioRad). All samples were
analyzed in triplicate. Data was normalized to the geometric mean of two reference genes
determined to have the greatest stability using the software qbasePLUS-GeNorm
(BioGazelle; 14.3.3.Z and CYC1). Statistics were calculated using an unpaired twosample Welch’s t-test in Prism software (GraphPad, Prism).
MTT assay: After 24 hours, cell viability was measured in our transfected NSC and iPSCderived motor neuron cultures using the In Vitro Toxicology Assay Kit, MTT based
(Sigma, TOX1) according to manufacturer instructions. For each tested culture, this
colorimetric assay measured the amount of yellow water-soluble substrate 3-(4,5dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) that was converted to
formazen. This served as a proxy for cell viability, as this conversion process is carried
out by living cells’ mitochondrial dehydrogenases. Experiments done in collaboration with
Jim Bennett, Paula Keeney, and Laura O’ Brien.
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FLICA® 660 Activated Caspase 3/7 Assay: After 24 hours, activated Caspase 3/7
levels, markers of apoptosis, were measured in iPSC-derived motor neuron cultures using
the FLICA® 660 Caspase 3/7 Assay Kit (ImmunoChemistry Technologies) according to
manufacturer instructions. This involved measuring each culture’s amount of fluorescent
antibodies specific to activated Caspases 3 and 7 that bound to their respective proteins.
For quantification, cells were fixed and 10 representative fields were taken with an
Olympus FV1000 confocal microscope. Images were analyzed using MetaMorph image
analysis software (Molecular Devices) and pixel intensity was normalized to the number
of cells per image. Cells were identified by DAPI nuclear staining.
III.

Results

Sequencing metrics: We collected >55 million paired end reads per sample using the
Illumina NextSeq500. Picard’s CollectRNASeqMetrics (http://picard.sourceforge.net)
reported the following averaged metrics across samples: 68,613,940 paired end reads,
65.62% of sequenced nucleotides that passed Tophat2’s filters and aligned to the hg19
reference genome, 33.23% of nucleotides that aligned to mRNA species, 29.01% of
sequenced nucleotides that aligned to rRNA, tRNA, or mtRNA species, and 37.76% of
nucleotides that aligned to intronic/intergenic regions. Individual samples metrics can be
found in Table 3.
Our samples’ averaged % of sequenced nucleotides aligning to mRNA and
intronic/intergenic regions was highly similar to what has been observed in other RNASequencing studies using total RNA to construct RNA-Sequencing libraries (Ameur et al.
2011, Shanker et al. 2015).
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Sequencing data quality: For each sample, we used FastQC to assess the quality of
all paired end reads’ Read 1 and Read 2 sequences prior to and after Trimmomatic
processing. All samples’ paired end reads passed FastQC’s quality assessments before
and after Trimmomatic processing. Trimmomatic processing successfully increased
each sample’s average PHRED quality scores for nucleotides towards the 3’ end of
their Read 2 sequences, and removed all Illumina sequencing adaptor sequences from
Read 1 and Read 2 sequences. Figure 18 shows ALS1’s analyzed Read 2 sequences
before and after Trimmomatic processing. These results are representative of what we
observed for all samples.
Presence of known fALS mutations in our sALS samples’ sequenced reads: As of
2014, 11% of sALS in Caucasian patients was accounted for by causal mutations in 9
different loci (Renton, Chio, Traynor 2014). Causal fALS mutations have been identified
in at least 13 other genes, and may account for a larger proportion of sALS in Caucasian
patients (Renton, Chio, Traynor 2014, Abel, Powell, Andersen, Al-Chalabi 2013). We
assessed whether any of our sALS samples carried any of 471 known pathogenic coding
variants contained in 21 different genes shown in Table 4. ELP3 was not included, as it
did not have any qualifying pathogenic variants in any of the three databanks surveyed.
We discovered an sALS sample (ALS4) carried a pathogenic variant from this list.
This variant is a missense mutation (A4V) in the Superoxide Dismutase 1 (SOD1) gene,
and was found in nearly half of ALS4’s paired end reads (754/1576) that aligned to that
portion of SOD1. This suggests there was no transcriptional preference for the wildtype
or mutant DNA sequence. No other fALS pathogenic variants were found in ALS4 or the
other ALS samples. None of these 21 genes were differentially expressed between our
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Table 3: Sequencing metrics
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patient and control samples. We did not remove ALS4 from our sALS sample group in
downstream analyses despite this finding. A recent review (Heath, Kirby, Shaw 2013) of
ALS gene expression studies dating back to 2001 revealed various sALS and fALS tissuespecific DEGs were associated with a recurrent set of cellular processes including
oxidative stress, mitochondrial dysfunction, apoptosis, cytoskeletal architecture,
inflammation, RNA processing, and protein aggregation. Despite varying genetic
etiologies, it appears fALS and sALS share a convergent set of perturbed cellular
processes, which could explain why distinguishing fALS from sALS using traditional
clinical guidelines is extremely challenging (Al-Chalabi, Hardiman 2013). Inclusion of
ALS4 is thereby unlikely to hinder our ability to identify cellular processes that may be
perturbed in sALS and relevant to disease pathology.
DEG Testing and associated cellular processes: We elected to identify sALS groupspecific DEGs using Cufflinks/Cuffdiff2, DESeq2, and EdgeR. In a direct comparison, all
three analyses showed different limitations in DEG identification after analyzing the same
benchmark datasets (Zhang et al. 2014). EdgeR identified the most DEGs, but also
reported the most false positive DEGs. DESeq2 identified the fewest DEGs when input
samples had different numbers of total sequencing reads. Cuffdiff2 identified the fewest
DEGs when each sample had less than 20 million total sequencing reads. The authors
recommended a conservative approach of using at least two (if not all three) analyses to
identify DEGs, and proceeding with DEGs mutually reported by multiple analyses to avoid
pursuing false positives DEGs. We will likely learn more about which of these DEG tests
is most accurate via future comparative analyses using larger benchmark datasets with
varying properties. Further, DEG tests that are superior to these three will likely emerge
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Figure 18. FastQC analyses of ALS1’s Read 2 sequences before and after Trimmomatic
processing. This figure shows FastQC plots of the average PHRED quality score per position
across all of ALS1’s Read 2s before (A) and after (B) Trimmomatic processing, and the presence
of Illumina sequencing adaptor nucleotides per position across all of ALS1’s Read 2s before (C)
and after (D) Trimmomatic processing. The x axes in all plots report the nucleotide position in
analyzed Read 2s. The Y axes in A and B are PHRED quality scores. The blue lines that extend
from left to right in A and B represent the average PHRED quality score across nucleotide
positions in analyzed Read 2s. The Y axes in C and D are percentages of nucleotides that
correspond to Illumina sequencing adaptors per position in across all analyzed Read 2s.
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Table 4: Genes with known fALS mutations
# of Known
Pathogenic

Gene

Chromosomal
Position

Coding Mutations

ALS2

2q33

15

ANG

14q11

36

ATXN2

12q24

3

C9orf72

9p21

1

CHMP2B

3p11

5

DCTN1

2p13

6

FIG4

6q21

5

FUS

16p11

66

HNRNPA1

12q13

2

HNRNPA2B1

7p15

1

NEFH

22q12

9

OPTN

10p13

19

PFN1

17p13

8

SETX

9q34

10

SOD1

21q22

199

SPG11

15q14

1

SQSTM1

5q35

16

TARDBP

1p36

44

UBQLN2

Xp11

12

VAPB

20q13

3

VCP

9p13

10
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as RNA-Sequencing technologies and analytics mature.
At an FDR of .10, 74 sALS group-specific DEGs (56 upregulated and 18
downregulated) were mutually identified using Cuffdiff2, DESeq2, and EdgeR. Figure 19
shows a Venn diagram comparing the numbers of DEGs identified across and between
analyses at an FDR of .10. Cuffdiff2 identified significantly more DEGs at an FDR of <.10
compared to the other two analyses. We suspect this is largely a result of
Cufflinks/Cuffdiff2 employing a considerably different approach to estimating and
comparing gene expression levels compared to the other two analyses.
These 74 DEGs, their Cuffdiff2 fold change values (sALS group relative to our
neurologically healthy control group), representative FPKM values for the ALS and
neurologically healthy control sample groups, and FDR corrected p-values are listed in
Table 5. QIAGEN’s Ingenuity Pathway Analysis revealed our 74 DEGs were associated
with multiple canonical signaling pathways, disease/disorders, and upstream regulators
related to inflammatory cellular processes. TNF-α was identified as an upstream
regulator. These IPA results are shown in Table 7.
To avoid false negatives, we identified all DEGs reported at an FDR of <.01 by any
of the three analyses. QIAGEN’s Ingenuity Pathway Analysis revealed those 200 DEGs
were also associated with multiple canonical signaling pathways and upstream regulators
related to inflammatory cellular processes. TNF-α was identified as an upstream
regulator. Those IPA results are shown in Table 8.

WGCNA and the black module: We used WGCNA to identify gene modules, or
networks, from our dataset. This unsupervised technique identified 37 interconnected
gene modules (arbitrarily assigned to different colors) from a filtered list of 13,301 genes
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without using 1) information about what genes have been shown to interact in previous
literature, or 2) information about which samples were from our sALS or neurologically
healthy control groups. These modules can be seen in Figure 20. Two of these modules
(MEblack and MEsienna4) were associated with sALS disease status at an uncorrected
p-value <.01. These modules were not significantly associated with age or gender. They
can be seen in Table 6.
Interestingly, QIAGEN’s Ingenuity Pathway Analysis revealed the 495 genes
comprising the module most strongly correlated to sALS disease status (MEblack,
R=0.68, p=0.006) were associated with multiple canonical signaling pathways,
disease/disorders, and upstream regulators related to inflammatory cellular processes.
TNF-α was identified as an upstream regulator. These results can be seen in Table 7.
As these IPA results were highly similar to those for our sALS group-specific
DEGs, we next assessed whether any of those 74 DEGs were found in this module.
Intriguingly, we found approximately 57% (42/74) of our DEGs were contained in this
module. We decided to prioritize hub genes in this module for candidate gene selection.
We found it compelling our sALS group-specific DEGs and a gene co-expression network
associated with sALS disease status were both associated with various inflammatory
cellular processes and TNF-α signaling. We obtained these results despite discovering
both gene sets using independent exploratory approaches. Further, these findings are
consistent with previous studies implicating inflammatory processes and TNF-α signaling
in ALS pathology (as referenced in the introduction of this chapter).
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Figure 19. DEG Identification using different algorithms. This figure shows a Venn diagram
comparing the number of DEGs identified at an FDR of .10 across and between the DEG
analyses.
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Table 5: sALS group-specific DEGs identified at an FDR <.10
DEG

Fold
Change

ALS
FPKM

CTL
FPKM

FDR
pvalue

DEG

Fold
Change

ALS
FPKM

CTL
FPKM

FDR
pvalue

1.66

0.30

0.007

CPM

2.32

15.14

6.52

0.007

0.007

HLA-DOA

2.32

15.64

6.74

0.007

2.29

HTRA4

5.63

PLA2G7

5.59

GPNMB

5.39

237.50

44.03

0.007

TNFAIP2

12.54

5.47

0.007

OTOA

4.78

0.79

0.16

0.074

ABCG1

2.18

12.55

5.75

0.007

APOC1

4.61

348.98

75.64

0.007

TBXAS1

2.12

17.90

8.43

0.007

LILRA4

4.61

6.40

1.39

0.007

HAVCR2

2.07

30.06

14.47

0.007

SIGLEC8

4.40

0.007

CD86

2.01

12.74

6.33

0.007

CHAC1

4.30

4.05

0.94

0.007

OSBPL11

1.98

30.02

15.10

0.007

HLA-DRB1

4.10

80.55

19.64

0.007

CD84

1.98

9.86

4.96

0.007

KLHL6

3.99

9.14

2.29

0.007

IL18

1.97

21.02

10.63

0.041

DPEP2

3.96

3.39

0.86

0.007

PIK3IP1

1.94

38.02

19.57

0.007

LILRA2

3.59

0.007

DNASE2

1.89

15.81

8.33

0.007

CPVL

3.40

44.56

13.10

0.007

ASAH1

1.85

305.78

164.90

0.052

CEBPA

3.29

26.50

8.06

0.007

GPRIN3

1.84

10.27

5.57

0.007

SLC37A2

3.28

7.81

2.38

0.007

OTUD1

1.79

9.10

5.08

0.070

APOE

3.25

1785.64

549.01

0.007

CECR1

1.72

15.26

8.83

0.038

SLC7A7

3.01

0.007

WDR91

1.72

7.03

4.08

0.070

CAPG

2.99

69.99

23.35

0.007

LTA4H

1.65

42.38

25.67

0.062

LILRB4

2.97

9.59

3.22

0.007

GNB4

1.61

31.09

19.26

0.068

FCGR2B

2.97

13.68

4.60

0.007

CXCL8

-5.90

4.78

28.23

0.007

HPSE

2.96

6.28

2.12

0.007

WNT16

-4.83

0.44

2.15

0.007

SELPLG

2.81

0.007

FGF10

-3.40

1.84

6.26

0.023

HLA-DMB

2.76

49.50

17.91

0.007

DCN

-3.17

144.38

458.54

0.007

BMF

2.73

3.64

1.33

0.007

PTGS2

-3.05

3.08

9.42

0.007

KCNA5

2.71

8.08

2.97

0.007

LIPG

-2.72

1.02

2.78

0.018

THEMIS2

2.71

29.82

10.99

0.007

CFH

-2.58

25.78

66.62

0.007

ITGAX

2.68

0.007

FHL2

-2.44

3.93

9.61

0.007

CD37

2.66

30.05

11.28

0.007

COL12A1

-2.42

4.01

9.73

0.007

GK

2.64

15.01

5.68

0.007

KDR

-2.26

5.16

11.68

0.007

FPR3

2.59

10.56

4.07

0.007

MSMO1

-2.23

42.05

93.95

0.007

ZMYND15

2.56

1.79

0.70

0.083

EPHA3

-2.05

2.93

6.02

0.007

CD226

2.51

0.007

NRP1

-2.04

6.36

12.99

0.007

ADAMTS1
4
KCNJ5

2.49

0.71

0.28

0.090

HMGCS1

-2.02

17.63

35.74

0.007

2.42

4.68

1.93

0.030

PPP1R3C

-1.99

20.54

40.97

0.007

CXCL16

2.39

35.65

14.87

0.007

SQLE

-1.92

22.61

43.53

0.007

CTSS

2.36

38.81

16.42

0.007

ITGA8

-1.90

2.14

4.08

0.007

CTSD

2.35

0.007

ABCA8

-1.74

35.29

61.64

0.018

22.32

17.79

6.87

14.67

15.91

13.65

4.16

333.56

3.99

4.04

1.91

4.88

5.64

5.09

1.66

141.72
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WGCNA hub gene identification: 12 genes in the black module had scores in the top
quartile for intramodular connectivity, modular membership, and gene significance
metrics. 9 of these genes were separately identified as upregulated sALS group-specific
DEGs. TNFAIP2, a gene encoding a TNF-α superfamily protein, was one of these nine.
Figure 21 lists all 12 black module hub genes, and contains a graph plotting each black
module gene’s module membership vs. gene significance score.
Selection of TNFAIP2 as our candidate gene for hypothesis testing: We selected
TNFAIP2 as our candidate gene for hypothesis testing for many data-driven reasons.
First, TNFAIP2 belonged to the black module associated with sALS disease status,
inflammatory cellular processes, and TNF signaling. Second, TNFAIP2 was identified as
one of twelve black module hub genes with a score in the top quartile for intramodular
connectivity, modular membership, and gene significance metrics. Third, TNFAIP2 was
mutually identified as an upregulated sALS group-specific DEG using all three DEG
analyses.
Elevated TNF-α signaling plays a known role in cell fate decisions, and induces
apoptosis under certain biological circumstances (Probert 2015). Elevated TNF-α
signaling has been shown to kill motor neurons in previous literature (He, Wen, Strong
2002, Robertson et al. 2001, Terrado et al. 2000). Elevated TNF-α signaling is also
known to increase TNFAIP2 expression in a variety of cell types (Saito et al. 2013,
Zhou, Scoggin, Gaynor, Williams 2003, Tian et al 2005), and elevated TNFAIP2
expression has previously been associated with increased apoptosis (Park et al. 2003,
Rusiniak et al. 2000, Ma et al. 2003). Studies linking elevated TNFAIP2 expression to
increased apoptosis did not assess TNFAIP2’s cellular function or whether TNFAIP2
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Figure 20. WGCNA module identification. This figure shows all 13,301 genes (individual
black lines at top) clustered into different modules based on their topological overlap
dissimilarity scores. The multi-colored panel next to “Dynamic Tree Cut” shows 122 identified
modules using the Dynamic Tree Cut algorithm. The second multi-colored panel shows 37
larger modules identified after merging smaller modules with highly correlated eigengenes
together.
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Disease Status
Pvalue

Gender
Correlation

Gender Pvalue

Age Correlation

Age Pvalue

Module
MEblack
MEsienna4
MEfirebrick3
MEhoneydew1
MEhoneydew
MElightcoral
MEmidnightblue
MEdarkviolet
MEdarkred
MEfirebrick4
MEpaleturquoise
MElavenderblush1
MEbrown
MEantiquewhite2
MEantiquewhite1
MEturquoise
MEbisque4
MEdarkolivegreen2
MEcoral2
MEindianred3
MEdarkmagenta
MEnavajowhite1
MEdarkseagreen3
MElightcyan
MElightyellow
MEmagenta3
MEtan4
MElavenderblush3
MElightpink3
MEblue
MEdarkseagreen2
MEgreen4
MElightslateblue
MEantiquewhite4
MEpink4
MEbrown4
MEcoral4

Disease Status
Correlation

Table 6: Module to phenotype correlation values

0.676
0.662
0.609
0.561
0.544
0.478
0.402
0.391
0.330
0.325
0.305
0.269
0.223
0.214
0.110
0.026
0.023
0.009
0.007
0.001
-0.011
-0.033
-0.033
-0.046
-0.046
-0.110
-0.169
-0.220
-0.273
-0.348
-0.436
-0.510
-0.510
-0.513
-0.569
-0.625
-0.796

0.006
0.007
0.016
0.030
0.036
0.072
0.137
0.149
0.230
0.238
0.269
0.333
0.425
0.444
0.696
0.927
0.935
0.975
0.982
0.999
0.970
0.907
0.906
0.872
0.869
0.697
0.547
0.432
0.325
0.204
0.104
0.052
0.052
0.050
0.027
0.013
0.000

-0.370
-0.023
-0.177
0.236
0.096
-0.638
-0.305
0.039
0.115
0.307
-0.001
-0.003
-0.152
-0.061
0.009
-0.113
0.201
0.073
-0.208
-0.209
0.042
-0.217
0.031
0.154
-0.394
0.392
-0.128
-0.062
-0.304
-0.211
-0.127
-0.138
-0.017
0.044
0.388
0.100
0.090

0.175
0.934
0.527
0.398
0.732
0.010
0.269
0.891
0.684
0.265
0.997
0.993
0.588
0.828
0.973
0.688
0.472
0.797
0.458
0.454
0.883
0.437
0.914
0.584
0.146
0.149
0.649
0.825
0.270
0.451
0.651
0.625
0.953
0.877
0.153
0.724
0.749

-0.014
0.260
0.027
-0.028
-0.045
-0.237
-0.135
-0.043
0.184
0.147
0.145
0.308
0.064
-0.158
0.394
0.175
0.048
0.425
-0.281
-0.076
-0.156
0.108
0.102
0.108
0.114
0.462
0.410
0.077
-0.043
-0.118
0.163
0.013
-0.128
0.354
0.293
0.040
0.169

0.960
0.349
0.923
0.920
0.872
0.396
0.631
0.879
0.513
0.602
0.606
0.264
0.821
0.574
0.146
0.534
0.866
0.115
0.311
0.788
0.579
0.701
0.718
0.702
0.685
0.083
0.129
0.786
0.878
0.677
0.562
0.963
0.650
0.196
0.289
0.888
0.548
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functionally promoted apoptotic processes directly. We hypothesize elevated TNF-α
signaling 1) increased TNFAIP2 expression in our sALS patients’ cervical spinal cells,
and 2) TNFAIP2 functionally contributed to spinal motor neuron death in our sALS
patients via the TNF non-mitochondrial or mitochondrial apoptotic pathway.
TNF-α signaling, TNFAIP2, and other black module hub genes’ expression levels:
IPA identified TNF-α as an upstream regulator of genes comprising the black module
(Table 7). Elevated TNF-α signaling may have induced changes in black module genes’
expression levels, plausibly promoting the black module’s associated inflammatory
processes (and potentially motor neuron death) in our sALS patients’ cervical spinal cells.
If this occurred, we suspect TNF-α signaling accomplished this via altering black module
hub genes’ expression levels. That would be consistent with the theory hub genes
functionally regulate their gene co-expression network’s activities and associated cellular
processes.
Previous literature has already shown elevated TNF-α signaling increases the
expression level of TNFAIP2 (a black module hub gene) in a variety of cell types (Saito
et al. 2013, Zhou, Scoggin, Gaynor, Williams 2003, Tian et al 2005). For these reasons,
we tested whether exposing neural stem cells to TNF-α increased the expression levels
of TNFAIP2 and/or the other 8 black module hub genes identified as sALS group-specific
upregulated DEGs. qPCR data revealed exposing neural stem cells to TNF-α increased
the expression levels of three black module hub genes. These included TNFAIP2,
Apoliprotein E (APOE), and Chemokine Ligand 16 (CXCL16). These results can be seen
in Figure 22.
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Table 7: Comparing IPA results
74 sALS group-specific DEGs
Top Canonical
Pathways

Overlapping
Genes

p-Value

Graft-versus-Host
Disease Signaling

5/48

8.10E-07

Eicosanoid
Signaling

5/64

3.45E-06

Atherosclerosis
Signaling

6/124

495 Black Module Genes
Top Canonical
Pathways

Overlapping
Genes

p-Value

Antigen Presentation
Pathway

11/37

3.31E-10

TREM1 Signaling

14/75

1.11E-09

14/88

9.72E-09

5.73E-06

Altered T and B Cell
Signaling in
Rheumatoid Arthritis

18/171

6.30E-08

15/118

6.54E-08

T Helper Cell
Differentiation

5/71

5.77E-06

Role of NFAT in
Regulation of the
Immune Response

B Cell
Development

4/33

5.91E-06

CD28 Signaling in T
Helper Cells

Top Diseases and
Disorders

p-Value

Top Diseases and
Disorders

p-Value

Endocrine System
Disorders

1.54E-031.12E-13

Inflammatory
Response

1.13E-049.32E-25

Gastrointestinal
Disease

1.49E-031.12E-13

Immunological
Disease

1.35E-042.33E-19

Immunological
Disease

1.53E-031.12E-13

Connective Tissue
Disorders

7.33E-052.79E-19

Metabolic Disease

3.57E-041.12E-13

Inflammatory
Disease

7.80E-052.79E-19

Inflammatory
Response

1.68E-033.16E-09

Skeletal and
Muscular Disorders

7.33E-052.79E-19

Upstream
Regulators

Overlapping
Genes

p-Value

Upstream
Regulators

Overlapping
Genes

p-Value

IFNG

24/610

4.78E-13

lipopolysaccharide

95/763

1.98E-20

IL13

14/192

1.43E-11

IFNG

79/610

2.98E-19

cholesterol

10/109

5.41E-10

genistein

42/212

2.82E-18

lipopolysaccharide

23/763

7.68E-10

TNF-α

75/773

4.85E-12

CAMP

7/43

3.59E-09

fluticasone

22/133

1.41E-11

TNF-α

19/773

3.16E-07

IL13

31/192

6.27E-11
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Table 8: DEGs identified at an FDR <.01 across analyses
200 sALS group-specific DEGs
Top Canonical Pathways

Overlapping Genes

p-Value

Dendritic Cell Maturation

17/177

3.31E-10

Atherosclerosis Signaling

14/124

1.11E-09

T Helper Cell Differentiation

11/71

9.72E-09

Complement System

8/37

6.30E-08

Graft-versus-Host Disease
Signaling

8/48

6.54E-08

Top Diseases and Disorders

p-Value

Metabolic Disease

1.13E-04-9.32E-25

Endocrine System Disorders

1.35E-04-2.33E-19

Gastrointestinal Disease

7.33E-05-2.79E-19

Cardiovascular Disease

7.80E-05-2.79E-19

Connective Tissue Disorders

7.33E-05-2.79E-19

Upstream Regulators

p-Value

IFNG

61/610

1.98E-20

TGFB1

63/813

2.98E-19

lipopolysaccharide

61/763

2.82E-18

beta-estradiol

61/844

4.85E-12

IL13

30/192

1.41E-11

TNF-α

57/773

6.27E-11
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Figure 21. Black module hub genes and TNFAIP2. This figure lists the 12 black module hub
genes and reports whether each was separately identified as an sALS group-specific DEG (A),
and shows a graph plotting each black module gene’s module membership vs. gene significance
score (B). DPP7, MICAL1, and PSAP were not identified as sALS group-specific DEGs. TNFAIP2
is highlighted in green (MM=0.79, GS=0.81) in the plot on the right.
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These findings support IPA’s prediction of TNF-α as an upstream regulator of genes
comprising the black module, and may account for the inflammatory processes
associated with those genes. Elevated TNF-α signaling may account for these hub genes’
increased expression levels as observed in our sALS patients’ RNA-Sequencing data.
These findings are also consistent with our hypothesis that elevated TNF-α signaling
increased TNFAIP2 expression in our sALS patients’ cervical spinal cells.
TNFAIP2 overexpression and apoptosis: If TNFAIP2 functionally contributed to spinal
motor neuron death in our sALS patients, we suspect this occurred via a TNF superfamily
apoptotic pathway. TNF-α signaling can promote cell survival or cell death depending on
cellular and microenvironmental conditions that remain poorly understood (Probert 2015),
and elevated TNF-α signaling has been shown to kill motor neurons in previous literature
(He, Wen, Strong 2002, Robertson et al. 2001, Terrado et al. 2000). Figure 23 shows a
visual of these protein-signaling cascades.
To provide context for the proceeding experiments, I will only describe the TNF
superfamily non-mitochondrial and mitochondrial apoptotic pathways. After TNF-α binds
Tumor Necrosis Factor Receptor 1 (TNFR1), TNFRSF1A-Associated via Death Domain
(TRADD) is recruited. TRADD recruits Fas-Associated Protein With Death Domain
(FADD) and pro-forms of Caspases 8 and 10 (Al-Lamki, Mayadas 2015). The pro-form of
Caspase 8 undergoes auto-proteolytic activation, and activated Caspase 8 is released
into the cytoplasm. The TNF superfamily non-mitochondrial or mitochondrial pathway is
then used to induce apoptosis depending on the cell type (Al-Lamki, Mayadas 2015). The
non-mitochondrial route involves activated Caspase 8 proteolytically activating Caspases
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Figure 22. Hub gene expression levels in NSCs after TNF-α exposure. This figure shows
each of the 9 hub gene’s expression levels in NSCs (n = 8 per group) after treatment with DMSO
or TNF-α for 24 hours. Multiple t-tests were run using Prism, which included corrections for
multiple comparisons using the Holm-Sidak method. * P < 0.01; ** P < 0.001. Experiment done in
collaboration with Jim Bennett and Paula Keeney.
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Figure 23. TNF signaling cascades. This figure shows proteins involved in TNF-α signaling
pathways that promote apoptosis (left) and cell survival (right). TNF signaling. eBioscience;
[accessed 2016 Feb 26].Adapted from http://www.ebioscience.com/resources/pathways/tnfsignaling-pathway.htm.
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3 and 7, which then enter the nucleus and initiate heterochromatic formations and DNA
fragmentation leading to cell death (Al-Lamki, Mayadas 2015, Falschlehner, Emmerich,
Gerlach, Walczak 2007, Matthews, Newbold, Johnstone 2012).The mitochondrial route
involves activated Caspase 8 truncating a pro-apoptotic BCL-2 family member, BH3
interacting-domain death agonist (BID). Truncated BID activates BCL-2-Associated X
Protein (BAX) and/or BCL-2 Homologous Antagonist Killer (BAK), which move to the
mitochondrial membrane and form

homo-oligomers. These protein oligomers

permeabilize the outer mitochondrial membrane by inserting themselves into it, leading
to the release of Cytochrome C. Cytochrome C binds the pro-form of Caspase-9 and
Apoptotic Peptidase Activating Factor 1 (APAF1) to form the apoptosome, and the
apoptosome

proteolytically

activates

Caspase-9.

Activated

Caspase-9

then

proteolytically activates Caspases 3 and 7, which enter the nucleus and initiate
heterochromatic formations and DNA fragmentation leading to cell death (Al-Lamki,
Mayadas 2015, Falschlehner, Emmerich, Gerlach, Walczak 2007, Matthews, Newbold,
Johnstone 2012).
We conducted two experiments that assessed 1) whether overexpression of
TNFAIP2 (observed as a significantly upregulated sALS group-specific DEG) promoted
cell death within in vitro models of disease-vulnerable cells, and 2) whether TNFAIP2mediated cell death relied on activated caspases 8 and/or 9. Specifically, our first
experiment investigated whether NSCs that transiently overexpressed TNFAIP2 and GFP
were significantly less viable than neural stem cells that transiently overexpressed GFP
alone. This experiment also investigated whether inhibiting activated caspase 8 or
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activated caspase 9 reversed any potential TNFAIP2-mediated reduction in NSC viability.
Our second experiment investigated whether iPSC-derived motor neuron cultures that
transiently overexpressed TNFAIP2-GFP (TNFAIP2 protein with a GFP tag fused to its
N-terminus) were significantly less viable and had increased activated caspase 3 and 7
levels relative to iPSC-derived motor neuron cultures that transiently overexpressed GFP
alone.
For our first experiment, we compared cell viability in NSCs that 1) were treated
with DMSO alone (DMSO), 2) were transfected with Fugene reagent alone (FG), 3) were
transfected with Fugene reagent and GFP plasmid to overexpress GFP protein
(GFP/FG), 4) were transfected with Fugene reagent and TNFAIP2-IRES-GFP plasmid to
overexpress TNFAIP2 and GFP proteins (TIG/FG), 5) were given Caspase 8 inhibitor and
were transfected with Fugene reagent and TNFAIP2-IRES-GFP plasmid to overexpress
TNFAIP2 and GFP proteins (C8i/TIG/FG), and 6) were given Caspase 9 inhibitor and
were transfected with Fugene reagent and TNFAIP2-IRES-GFP plasmid to overexpress
TNFAIP2 and GFP proteins (C9i/TIG/FG).
A one way-between subjects ANOVA revealed there was a significant effect of
treatment conditions on cell viability at the p<.05 level for the six treatments (F5, 42) =
106.6, p<0.0001). Post hoc comparisons using the Dunnett’s test for multiple corrections
indicated the mean score for the TIG/FG group (M = 0.207, SD = 0.011) was significantly
different than the DMSO group (M = 0.442, SD = 0.030, p=<0.0001), the FG group (M =
0.324, SD = 0.024, p=<0.0001), the GFP/FG group (M = 0.255, SD = 0.023, p=0.0019),
and the C9i/TIG/FG group (M = 0.264, SD = 0.031, p=0.0002). Taken together, these
results revealed NSCs that transiently overexpressed TNFAIP2 and GFP were
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significantly less viable than NSCs that overexpressed GFP alone. Further, inhibition of
activated caspase 9 reversed this TNFAIP2-mediated reduction in NSC viability, whereas
inhibition of activated caspase 8 did not. These results can be seen in Figure 24.
Compared to iPSC-derived motor neurons transfected with GFP alone, iPSCderived motor neuron cultures that transiently overexpressed TNFAIP2-GFP were 1)
significantly less viable and 2) had significantly elevated levels of activated caspases 3
and 7. These results can be seen in Figure 25. qPCR data revealed TNFAIP2 expression
increased >300-fold in iPSC-derived motor neuron cultures transfected with TNFAIP2GFP relative to GFP alone.
These proof of concept experiments demonstrated transient overexpression of
TNFAIP2 (an upregulated sALS group-specific DEG) promoted cell death within in vitro
models of sALS disease-vulnerable cell types. Further, the TNFAIP2-mediated reduction
in NSC viability relied on activated Caspase 9, a protein necessary for TNF-α superfamily
mitochondrial-mediated apoptosis. Taken together, these results are consistent with our
hypothesis that TNFAIP2 functionally contributed to spinal motor neuron death in our
sALS patients via the TNF superfamily mitochondrial apoptotic pathway.
IV.

Discussion:
In this chapter, we combined deep RNA-Sequencing, systems biology analyses,

and molecular biology assays to elucidate sALS group-specific differences in postmortem
spinal tissues that may be relevant to disease pathology. To our knowledge, our
investigation is the only one that exploits the benefits of next generation RNA-Sequencing
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Figure 24. Cell viability measurements for NSC transfection groups. This figure shows
absorbance readings reflecting MTT metabolism (a function viable cells perform) for our NSC
transfection groups (n = 8 per group). DMSO = DMSO only, FG = Fugene Only, GFP/FG = GFP
plasmid with Fugene, TIG/FG = TNFAIP2-IRES-GFP and Fugene, C8i/TIG/FG = Caspase 8
inhibitor, TFNAIP2-IRES-GFP, and Fugene, and C9i/TIG/FG = Caspase 9 inhibitor, TFNAIP2-IRESGFP, and Fugene. A one-way ANOVA was run using Prism, which included corrections for
multiple comparisons using Dunnett’s Test. ** P< 0.01, *** P < 0.001; **** P < 0.0001. Experiment
done in collaboration with Jim Bennett and Paula Keeney.
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Figure 25. Apoptosis assays in iPSC-derived motor neuron transfection groups. This figure
shows absorbance readings reflecting MTT metabolism (a function viable cells perform) on the
left, and activated Caspase 3/7 levels measured using fluorescently labeled antibodies on the
right for our iPSC-derived motor neuron groups (n = 10 per group). EV = GFP plasmid and
Fugene, TNFAIP2 = TNFAIP2-GFP plasmid and Fugene. Unpaired t-tests were run using Prism.
* P < 0.05, ** P < 0.01. Experiment done in collaboration with Laura O’ Brien.
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(Kratz, Carninci 2014, Wang, Gerstein, Snyder 2009) to measure gene expression
differences in sALS patients’ postmortem cervical spinal tissues containing diseasevulnerable motor neurons. We chose to study gene expression differences in human
sALS patients’ postmortem tissues over fALS rodent tissues, as recent findings suggest
the majority of sALS is not accounted for by known monogenic ALS causal mutations
(Renton, Chio, Traynor 2014). Further, these cervical spinal tissues are inaccessible prior
to these patients’ deaths. The only other RNA-Sequencing study in human postmortem
sALS tissues we are aware of used cerebellar and prefrontal cortex tissues (Pavlou,
Dimitromanolakis, Diamandis 2013), and they also found sALS-group specific DEGs
associated with inflammatory processes.
Previous studies have used gene network analyses to reveal cellular processes
associated with ALS group-specific networks that may be relevant to disease pathology.
Studies using gene co-expression network analyses identified ALS group-specific
networks associated with immune response, stress response, post-translational
modifications, and neuroprotective processes (Holtman et al. 2015, Saris et al. 2009).
Several ALS studies modeled gene networks by only connecting genes with known
interactions in previous literature. They identified ALS group-specific networks associated
with organismal injury, immune response, post-translational modification, regulation of
the cytoskeleton, and extracellular matrix repair (Satoh et al. 2014, Figueroa-Romero et
al. 2012).
Another group (Izik et al. 2015) used a 2-step approach to identify ALS groupspecific gene networks. First, they connected genes based on their co-expression values.
Second, they used an information theoretic algorithm to eliminate indirect connections
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between genes inferred to be connected based on the strength of their co-expression
value alone. They then utilized a MARINa algorithm to identify major regulators (such as
transcription factors) within an ALS group-specific gene network. The MARINa algorithm
predicted 8 network genes were responsible for the elevated rate of apoptosis observed
in their in vitro motor neuron model of ALS. One of those genes, Nuclear Factor of Kappa
Light Polypeptide Gene Enhancer in B-Cells 1 (NFKB1), is a TF with important functions
in innate immune responses. Taken together, these findings support the use of systemslevel gene network analyses to identify cellular processes that may be perturbed in ALS
tissues. Further, they hold potential to unveil therapeutic target genes.
In this study, QIAGEN’s IPA revealed inflammatory processes and TNF-α signaling
were statistically significantly associated with sALS group-specific gene expression
differences identified using independent exploratory DEG analyses (Cuffdiff2, DESeq2,
and EdgeR) and an unsupervised gene co-expression network analysis (WGCNA). This
is consistent with previous ALS studies’ findings, as referenced in the introduction.
qPCR data revealed exposing NSCs to TNF-α increased the expression levels of
TNFAIP2, Apoliprotein E (APOE), and Chemokine Ligand 16 (CXCL16). All three of these
genes were identified as 1) upregulated sALS group-specific DEGs, and 2) hub genes in
a gene co-expression network associated with sALS disease status, inflammatory
processes, and TNF-α signaling. These findings support IPA’s prediction of TNF-α as an
upstream regulator of black module genes, and may account for the inflammatory
processes associated with these genes. The observed increase in TNFAIP2 expression
after NSCs were exposed to TNF-α corroborates previous findings (Saito et al. 2013,
Zhou, Scoggin, Gaynor, Williams 2003, Tian et al 2005), and is consistent with our
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hypothesis that elevated TNF-α signaling increased TNFAIP2 expression in our sALS
patients’ cervical spinal cells.
MTT assay results revealed NSCs that transiently overexpressed TNFAIP2 and
GFP were significantly less viable than NSCs that overexpressed GFP alone. Further,
inhibition of activated Caspase 9 reversed this TNFAIP2-mediated reduction in NSC
viability. Relative to iPSC-derived motor neuron cultures that transiently overexpressed
GFP, iPSC-derived motor neuron cultures that overexpressed TNFAIP2-GFP were 1)
significantly less viable as measured using an MTT assay, and 2) had significantly higher
levels of activated caspases 3 and 7.
These proof of concept experiments demonstrated transient overexpression of
TNFAIP2 (an upregulated sALS group-specific DEG) promoted cell death within in vitro
models of sALS disease-vulnerable cell types. This is consistent with previous literature
linking elevated TNFAIP2 expression with increased apoptosis (Park et al. 2003, Rusiniak
et al. 2000, Ma et al. 2003). The observed TNFAIP2-mediated reduction in neural cell
viability relied on activated Caspase 9, a protein necessary for TNF-α superfamily
mitochondrial-mediated apoptosis. Taken together, these results are consistent with our
hypothesis that TNFAIP2 functionally contributed to spinal motor neuron death in our
sALS patients via the TNF superfamily mitochondrial apoptotic pathway.
Modulating TNF signaling activity may be effective in slowing sALS disease
progression. TNF-α is a potent inflammatory cytokine that plays an instrumental role in
cell fate decisions, and elevated TNF-α signaling has been shown to kill motor neurons
in previous literature (He, Wen, Strong 2002, Robertson et al. 2001, Terrado et al. 2000).
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TNF signaling-mediated pro-survival processes are largely effected via upregulation of
the TFs NFKB1 and Jun Proto-Oncogene (JUN) (Micheau, Tschopp 2003, Walczak
2011), whereas its cell death processes are ultimately carried out by initiator and effector
caspases. Bioactive forms of TNF-α commence these processes via two cell surface
receptors, TNFR1 and TNFR2. TNFR1 directs cell survival or death, whereas TNFR2 is
only known to promote pro-survival effects (Probert 2015).
The extracellular domains of TNFR1 and TNFR2 are shed into general circulation
after interacting with bioactive forms of TNF-α, and function in a negative feedback loop
as they retain their ability to bind TNF-α (Mohler et al. 1993). Intriguingly, elevated levels
of TNF-α and extracellular domains of TNFR1 and TNFR2 have been found in the blood
(Poloni et al. 2000) and serum (Babu et al. 2008, Cereda et al. 2008) of human ALS
patients compared to controls.
Novel therapies to reduce TNF-α synthesis in human sALS patients could be of
great therapeutic value. Non-selective TNF-α inhibitors have proven invaluable in the
treatment of chronic diseases with an inflammatory component including rheumatoid
arthritis, psoriasis, and inflammatory bowel disease (Probert 2015). Measurement of
sALS patients’ circulating levels of TNF-α and the extracellular domains of the TNF
receptors (TNFR1, and TNFR2) at various treatment timepoints could help establish
therapeutic efficacy. They would also serve as non-invasive biomarkers of disease
progression.
Two potential therapeutic agents to reduce TNF-α synthesis are Bupropion and
curcumin. Bupropion, a drug commonly used to treat clinical depression, decreased TNF-
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α serum levels in mice likely via increasing intracellular cAMP signaling after binding betaadrenergic and/or D1 receptors (Brustolim et al. 2006). Curcumin, an anti-inflammatory
compound in turmeric, reduced TNF-α transcription in human cancer cells (Han, Keum,
Seo, Surh 2002, Surh et al. 2001) and lipopolysaccharide (LPS)-stimulated murine
microglia (Jin et al. 2007). Curcumin likely reduced TNF-α transcription via inhibition of
NFKB1. NFKB1, a TF that is upregulated by TNF signaling, is known to induce TNF-α
and other inflammatory cytokines under certain biological circumstances (Hoesel, Schmid
2013). Curcumin is also predicted to bind and inhibit caspase-3 (Khan et al. 2015), an
effector caspase used by the TNF superfamily mitochondrial and non-mitochondrial
apoptotic pathways. Curcumin oral bioavailability and brain penetration was substantially
increased by micellular formulation (Hagl et al. 2015), setting the stage for clinical testing
of it and Bupropion.
Our study has several important limitations. First, we measured and compared
gene expression in a small number of postmortem cervical spinal cord section samples.
There are ~35,000 persons with ALS in the US. The cost of RNA-sequencing limited the
numbers of cases we could examine at the sequencing depth employed. As a result, it is
impossible to state to what degree our findings can be generalized to thousands of
patients. Second, we used postmortem tissue. As a result, we examined gene expression
of cells (mainly astrocytes) that were survivors of the neurodegenerative process. To what
extent ALS modifies gene expression over time is not known, and it is not currently
possible to examine human CNS tissues across disease progression. It is unclear
whether the young motor or other neurons we produced using iPSC approaches
approximate changes seen in sALS patients’ spinal motor neurons that are present for
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many years as ALS progresses. Third, we did not explore novel transcripts or smaller
ncRNAs (including miRNAs) in this study.
Although we focused on TNF-α signaling and modulated TNFAIP2 expression in
NSCs and iPSC-derived motor neurons in this study, we do not claim aberrant
inflammatory TNF-α signaling is the sole pathogenic factor in sALS. We identified a
second sALS group-specific gene co-expression network that was associated with cell
proliferation, cell cycle functions, interleukin-4 (IL4) signaling, and various metabolic
compounds’ (methyglyoxal and phenylethylamine) degradation processes. We prioritized
pursuit of candidate genes in the black module, as that gene co-expression network’s
associated cellular processes were more plausibly linked to cell death. As sALS patients
die after the motor neurons that innervate their lungs degenerate, identifying novel
therapeutic targets to prevent motor neuron death is paramount. The black module
appeared to be a better option than the sienna4 module for pursuing that goal.
Aside from TNFAIP2, we identified 8 other hub genes that were also upregulated
DEGs within the black module. These genes could serve as foci for additional mechanistic
studies and therapeutic interventions. Specifically, investigating whether transient
overexpression of each of them (as they were all upregulated in our sALS sample group)
leads to perturbed cellular processes (such as increased apoptosis) in models of sALS
disease-vulnerable cell types would be valuable. Previous literature findings highlight their
potential relationship to perturbed cellular processes important to ALS pathology.
Genetic variants in APOE, a gene encoding a protein important for transporting
cholesterol and other lipids between cells, have been shown to modify ALS age of onset
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and features of disease progression (Verghese, Castellano, Holtzman 2011). This may
be related to aberrant cholesterol transport processes in sALS disease-vulnerable cells,
as accumulation of cholesterol esters has been linked to oxidative stress-induced motor
neuron death in ALS tissues previously (Cutler et al. 2002). Cholesterol was identified as
a significant upstream regulator of genes comprising the black module. It is possible
upregulation of APOE (as observed in our sALS sample group) contributed to aberrant
cholesterol transport processes in our sALS patients spinal cells, leading to oxidative
stress-induced spinal motor neuron death. Transient overexpression of APOE in our in
vitro models of sALS disease-vulnerable cell types followed by measurement of
cholesterol ester and cell viability levels would be valuable.
Bcl2-Modifying Factor (BMF) binds to Bcl2 and related anti-apoptotic proteins and
promotes mitochondrial-mediated apoptosis. Transient overexpression of BMF in our in
vitro models of sALS disease-vulnerable cell types followed by characterization of cell
viability levels could shed light on the potential contributions of mitochondrial-mediated
apoptosis in sALS.
CD37, a gene whose expression is restricted to human leukocytes, is integral to T
cell proliferation (van Spriel et al. 2004). While the majority of immune surveillance in the
CNS (including the spinal cord) is carried out by microglia, T cells do play a role in this
process as well (Ousman, Kubes 2012). CD37’s observed upregulation in our sALS
patients’ spinal cells may reflect recruitment of activated T cells to combat deleterious
cellular processes induced by the disease. Recruited T cells may have excreted large
amounts of TNF-α in this process, as they have been shown to do that in a previous study
(Ofotokun et al. 2015). This may have ultimately led to our sALS patients’ spinal motor
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neuron death. Modeling CD37 overexpression in a rodent model followed by
measurement of TNF- α levels in their spinal tissues could help assess the likelihood of
this connection.
CXCL16, a transmembrane chemokine produced by reactive astroglial cells, plays
an important role in immunosurveillance processes and serves as a chemoattractant for
macrophages. Its expression is increased by TNF-α (Abel et al. 2004), and has been
shown to sensitize cells to TNF-α mediated apoptosis (Kee et al. 2014). It also promotes
CXCR6-positive glial cell invasion that favors astrogliosis (Hattermann et al. 2008), a
feature seen in ALS CNS tissues. Taken together, its observed upregulation in our sALS
patients’ spinal cells may have played a role in sensitizing spinal motor neurons to TNFα mediated apoptosis. This could be tested in our in vitro models of sALS diseasevulnerable cell types.
Glycoprotein NMB (GPNMB) was previously identified as an upregulated DEG in
the spinal cords of fALS rodents. Interestingly, extracellular fragments of GPNMB
released by activated astrocytes lessened the neurotoxicity of mutant SOD1, suggesting
it may play a protective role against neurodegeneration (Tanaka et al. 2012). Its observed
upregulation in our sALS patients’ spinal cells may reflect an attempt to protect motor
neurons against ongoing neurodegenerative processes related to sALS pathology.
Integrin Alpha X (ITGAX), a leukocyte-specific integrin, was found as an
upregulated DEG in leukocytes that invaded the spinal cords of fALS rodents at different
stages of disease progression (Chiu et al. 2008). ITGAX plays a known role in cell-cell
interactions during immune responses, and its observed upregulation in our sALS
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patients’ spinal cells may reflect spinal cells’ recruitment of activated T cells to combat
deleterious effects of sALS pathology.
Leukocyte Immunoglobulin-Like Receptor Subfamily B Member 4 (LILRB4), a cell
surface receptor in immune cells, binds MHC class 1 molecules to inhibit immune
responses. While not directly studied in ALS tissues, LILRB4 expression negatively
correlated with pathologic inflammation in a mouse model of allergic pulmonary
inflammation (Fanning et al. 2013). Its observed upregulation in our sALS patients’ spinal
cells may reflect an attempt to reduce inflammatory processes that may have ultimately
led to motor neuron death.
To our knowledge, no study has investigated the function of WDR91 (WD Repeat
Domain 91), so it is impossible to speculate on its possible connection to ALS pathology.
While more than half (42/74) of our sALS group-specific DEGs were contained in the
black module, 32 DEGs were not. These genes could also play an important role in sALS
disease pathology and may warrant further study. Chemokine C-X-C Motif Ligand 8
(CXCL8), Decorin (DCN), and Neuropilin 1 (NRP1) are particularly good candidates.
CXCL8 was found to be statistically significantly increased in the cerebrospinal
fluid of sALS patients compared to cerebrospinal fluid of patients with other noninflammatory neurological diseases. Further, its level was negatively correlated with these
patients’ scores on the revised ALS functional rating scale (Tateishi 2010). CXCL8 plays
an important role in sending neutrophils to a site of infection, as well as inducing
phagocytosis. DCN’s mRNA and protein expression levels were greatly increased in both
astrocytes and spinal cells of fALS rodents carrying a causal SOD1 mutation. DCN is a
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proteoglycan with a known role in attenuating glial scar formation and inflammation.
(Vargas et al. 2008). Both CXCL8 and DCN downregulation in our sALS patients’ spinal
cells may have contributed to unresolved inflammatory processes that ultimately led to
motor neuron death.
Axon degeneration is often observed in fALS rodent models prior to motor neuron
death. Semaphorin 3A (SEMA3A), an important axon guidance cue involved in neural
patterning during development, binds to NRP1. This leads to axonal retraction by
destabilizing microtubules and microfilament networks. Blocking the interaction between
SEMA3A and NRP1 in fALS rodents led to decreased axon degeneration and motor
neuron death, suggesting NRP1 may play a role in ALS pathology prior to clinical
symptom onset related to motor neuron death (Venkova et al. 2014).
We anticipate future exploratory studies will continue to uncover polygenic
contributions, perturbed cellular processes, and potential therapeutic targets in sALS.
Genome-wide Association Studies (GWAS) comparing sALS cases vs. neurologically
healthy controls were instrumental in the discovery of excess pathogenic non-coding
repeats in C9orf72 found in 7% of Caucasian sALS patients (Renton, Chio, Traynor
2014). Another study identified excess de novo mutations in chromatin regulator genes
after comparing exome sequencing data from sALS offspring and their neurologically
healthy parents (Chesi et al. 2013). This ALS gene expression study joins those
preceding it in identifying perturbed cellular processes and corroborating them using
separate molecular biology assays.
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In this study, we identified sALS group-specific gene expression differences and
associated cellular processes that may be relevant to disease pathology. However, it
lumped all of our sALS patients together to find commonalities across them without
elucidating differences between them.
Emerging findings suggest considerable clinical heterogeneity between patients
with either form of ALS. A recent study (Ganesalingam et al. 2009) applied a latent class
cluster analysis to 1,467 ALS patients’ clinical metrics to assess whether there were
multiple disease sub-groups. These metrics included family history of ALS (fALS vs.
sALS), sex, ethnicity, site of symptom onset, age of onset, and diagnostic delay after
symptom onset. Five different groups emerged, with one group showing no deaths and
another exceeding the average median survival time by 12 years. Heterogeneity in
disease features has also been observed in fALS patients carrying causal mutations in
different genes. Patients carrying causal mutations in the FUS gene show a younger age
of onset and rapid disease progression compared to those with the SOD1 Asp90Ala
variant (Ganesalingam et al. 2009). Even within the same fALS pedigree, some family
members who inherit a fALS-causal mutation do not develop disease features.
Perhaps more striking were study findings where the same fALS causal mutation
was modeled into two genetically distinct transgenic mouse lines (Nardo et al. 2013)
These researchers demonstrated introducing the SOD1 G93A point mutation into 129Sv
and C57 mice led to a rapid and slow disease progression, respectively. They compared
measured gene expression values from each transgenic line’s spinal motor neurons at
multiple disease stages, and identified hundreds of DEGs associated with different
cellular processes at 3 different timepoints. DEGs specific to the 129Sv group (showing
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rapid disease progression) were associated with reduced mitochondrial function and
deficient protein degradation. DEGs specific to the C57 group (showing slow disease
progression) were associated with upregulated immune system processes. These
findings suggest even with a pure monogenic form of ALS and a controlled environment,
genetic differences between animals greatly contributed to clinical disease features.

The above findings imply elucidating genetic differences between ALS patients will
likely be necessary to fully explain for their disease features. As we only had 7 sALS
samples and 8 neurologically healthy controls, we had limited statistical power to identify
these differences. However, as sequencing costs decrease, larger sample sizes
conferring greater statistical detection power will become feasible. These data sets will
likely enable stratification of sALS by its varied molecular phenotypes as has been seen
in other diseases like breast cancer (Cancer Genome Atlas Network 2012). These
approaches may ultimately lead to therapies against pathways that are universally
beneficial to sALS patients, such as TNF signaling, as well as those specifically tailored
to an individual patient’s pathophysiology.
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CHAPTER 3: Mitochondrial gene expression levels were not aberrant in sALS
patients’ postmortem cervical spinal sections

I.

Introduction:
Mitochondrial abnormalities have been identified in ALS tissues in numerous

studies dating back to 1994. Early studies found mitochondria isolated from fALS rodents’
spinal motor neurons had aberrant morphologies (Higgins, Jung 2003, Kong, Xu 1998).
Mitochondria isolated from human sALS and fALS patients’ muscle tissues, spinal cells,
and postmortem motor neurons have also shown morphological abnormalities (Crugnola
et al. 2010, Echaniz-Laguna et al. 2006, Sasaki, Iwata 1996, Hirano, Donnenfeld, Sasaki,
Nakano 1984, Sasaki, Iwata 2007). In addition to aberrant mitochondrial morphology,
defective electron transport chain (ETC) activity and oxidative phosphorylation
(OXPHOS) rates have been observed in various tissues from fALS rodents and human
ALS patients. Mitochondria isolated from fALS rodents’ brain and spinal cord tissues had
significantly decreased rates of OXPHOS compared to mitochondrial isolated from
matched control tissues (Mattiazzi et al. 2002). Postmortem spinal cord tissue from both
sALS and fALS patients have shown decreased activity of ETC complexes I, II, III, IV,
and V (Borthwick et al. 1999, Fujita et al. 1996, Wiedemann et al. 2002), which may reflect
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selective loss of mitochondria in those spinal cells. Further, skeletal muscle from sALS
patients also displayed aberrant ETC activity, specifically in complexes 1 and 4 (Crugnola
et al. 2010, Vielhaber et al. 2000, Wiedermann et al. 1998).
A relatively recent study (Cassina et al. 2008) linked defective OXPHOS activity in
fALS rodents’ spinal cell mitochondria to increased spinal motor neuron apoptosis.
Mitochondria isolated from fALS rodent astrocytes had defective OXPHOS characterized
by decreased oxygen consumption, lack of ADP-dependent respiratory control, and
decreased membrane potential. Interestingly, these fALS rodents’ astrocytes (but not
wildtype rodents’ astrocytes) induced death of spinal motor neurons when both cell types
were co-cultured in vitro. After treating these fALS rodent astrocytes with mitochondrialtargeted antioxidants (ubiquinone and carboxy-proxyl nitroxide), they showed improved
mitochondrial OXPHOS and did not induce motor neuron death when co-cultured with
motor neurons in vitro. Taken together, these findings suggest defective OXPHOS related
to mitochondrial dysfunction in spinal cells may contribute to spinal motor neuron death.
Members of our lab recently published a study (Ladd, Keeney, Govind, Bennett
2014) comparing 76 (72 nuclear-encoded and 4 mitochondrial-encoded) genes’
expression levels in various tissues from ALS patients and neurologically healthy controls.
These 76 genes encode components of the ETC and OXPHOS complexes I-V. Their
expression levels were compared in 16 postmortem cervical spinal section samples (10
ALS and 6 neurologically healthy controls) and 20 peripheral blood mononuclear cell
samples (9 ALS and 11 neurologically healthy controls). Postmortem spinal sections from
select samples in my dissertation project (all 7 sALS patients and 3 neurologically healthy
controls) were analyzed in this referenced study.
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Interestingly, the 4 mitochondrial-encoded OXPHOS genes (12s rRNA, COX3,
ND2, and ND4) had statistically significantly decreased expression levels in both ALS
sample groups (postmortem spinal sections and peripheral mononuclear blood cells)
relative to their respective control sample groups. The majority of the 72 nuclear-encoded
OXPHOS genes had decreased expression levels in the sALS patients’ postmortem
spinal section samples relative to the neurologically healthy controls’ postmortem spinal
section samples. Taken together, reduced expression of these OXPHOS genes may have
led to aberrant OXPHOS activity in these ALS patients’ spinal cells. Further, that may
have promoted spinal motor neuron death.
In this chapter, we used a combination of RNA-sequencing and bioinformatics
tools to elucidate sALS group-specific mitochondrial gene expression level differences.
We assessed whether any of the 37 annotated mitochondrial genes in the hg19 human
reference mitochondrial genome were differentially expressed in our sALS patients’
postmortem cervical spinal section samples relative to our neurologically healthy controls’
postmortem cervical spinal section samples.

II.

Methods:

Input sample datasets: We used the same 7 sALS and 8 neurologically healthy control
samples’ Read 1 and Read 2 FastQ files output by Trimmomatic (as described in Chapter
2) for our downstream Mitochondrial DEG analysis.
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Pre-alignment steps: Prior to attempting alignment of each sample’s paired end reads
to the hg19 human reference mitochondrial transcriptome then hg19 human reference
mitochondrial genome, I needed to generate these files. The hg19 human reference
transcriptome file obtained from the Illumina iGenomes UCSC hg19 directory as
described in Chapter 2 did not include mitochondrial RNA transcripts.
To accomplish this, I downloaded ENCODE’s hg19 human reference
mitochondrial transcriptome file (known mtRNA transcripts) from the UCSC Table
Browser using their website (http://genome.ucsc.edu/cgi-bin/hgTables). I specified Feb.
2009 (GRCh37/hg19) for assembly, GENCODE Genes V19 for track, and chrM in the
position search field under region. All other fields were unchanged from their default
entries.
To generate the hg19 human reference mitochondrial genome file, I simply
extracted the mitochondrial sequence (ChrM) found in the hg19 human reference genome
text file obtained from the Illumina iGenomes UCSC hg19 directory as described in
Chapter 2.
Alignment of paired end reads: We used Tophat2 (Kim et al. 2013) to attempt alignment
of each sample’s paired end reads to the hg19 human reference mitochondrial
transcriptome then hg19 human reference mitochondrial genome. Tophat2 followed the
same alignment procedure detailed in Chapter 2 and shown in Figure 10.
HTSeq-Count: We used HTSeq-Count (Anders, Pyl, Huber 2015) to report the total
number of paired end reads that aligned to each annotated mitochondrial gene’s
transcribed regions. HTSeq-Count used the same counting procedure detailed in Chapter
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2 and shown in Figure 13. For each sample, HTSeq-Count produced a matrix with all
annotated mitochondrial genes and their corresponding paired end read count values.
EdgeR and DEG identification: We used EdgeR (Robinson, McCarthy, Smyth 2010),
to detect sALS group-specific mitochondrial DEGs. EdgeR followed the same
normalization and testing procedures detailed in Chapter 2 to identify sALS group-specific
mitochondrial DEGs. EdgeR reported an associated p-value for each annotated
mitochondrial gene tested. We calculated each annotated mitochondrial gene’s
Benjamini-Hochberg corrected p-value using their corresponding EdgeR reported p-value
via the R function p.adjust. Each annotated mitochondrial gene with a BenjaminiHochberg corrected p-value < 0.10 was identified as a sALS group-specific mitochondrial
DEG.
We used EdgeR’s default workflow for our mitochondrial DEG analysis. We
decided to filter out genes with a cpm (counts per million aligned paired end reads) value
<1 in 7 samples. We chose a cpm value of 1 as smaller values likely reflected noise. We
chose 7 samples as our threshold, as genes that were only expressed in our disease or
control group could play an important role in disease pathology.
DESeq2 and DEG identification: We used DESeq2 (Love, Huber, Anders 2014) to
detect sALS group-specific mitochondrial DEGs. DESeq2 followed the same
normalization and testing procedures detailed in Chapter 2 to identify sALS group-specific
mitochondrial DEGs. DESeq2 reported an associated p-value for each annotated
mitochondrial gene tested. We calculated each annotated mitochondrial gene’s
Benjamini-Hochberg corrected p-value using their corresponding DESeq2 reported p-
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value via the R function p.adjust. Each annotated mitochondrial gene with a BenjaminiHochberg corrected p-value < 0.10 was identified as a sALS group-specific mitochondrial
DEG.
Cufflinks for gene expression estimates: We separately used Cufflinks (Trapnell et al.
2010) to estimate each sample’s mitochondrial gene expression levels for all annotated
mitochondrial genes in the hg19 human reference mitochondrial genome. Cufflinks
followed the same procedure detailed in Chapter 2 to estimate these mitochondrial gene’s
expression levels.
Cuffdiff2 for DEG identification: We used Cuffdiff2 (Trapnell et al. 2013) to detect sALS
group-specific mitochondrial DEGs. Cuffdiff2 followed the same normalization and testing
procedures detailed in Chapter 2 to detect sALS group-specific mitochondrial DEGs.
Cuffdiff2 reported an associated p-value for each annotated mitochondrial gene. We
calculated all annotated mitochondrial genes’ Benjamini-Hochberg corrected p-values
using their corresponding Cuffdiff2 p-values via the R function p.adjust. Each annotated
gene with a Benjamini-Hochberg corrected p-value < 0.10 was identified as a sALS groupspecific mitochondrial DEG.

III.

Results:

Mitochondrial DEG testing: We elected to identify sALS group-specific DEGs using
Cufflinks/Cuffdiff2, DESeq2, and EdgeR. We made this decision based on the findings of
a recent study showing these three analyses have different limitations when they were
directly compared (Zhang et al. 2014), as described in Chapter 2.
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None of the 37 annotated mitochondrial genes were identified as sALS groupspecific DEGs in any of the three analyses. However, 3 of the 4 genes identified as
statistically significantly decreased in ALS samples in our lab’s previous publication
(Ladd, Keeney, Govind, Bennett 2014) had decreased expression levels in our sALS
samples. Further, we found all but three of the 13 mitochondrial protein-coding genes
(whose translated proteins are part of ETC complexes) were expressed at lower levels in
our sALS patients relative to our neurologically healthy controls. These results can be
seen in Figures 26 and 27.
IV.

Discussion:
Evidence for mitochondrial dysfunction has been identified in ALS tissues using a

variety of molecular biology techniques across independent studies. This includes
findings of aberrant mitochondrial morphology and defective OXPHOS in ALS tissues
from human patients (both fALS and sALS) and fALS rodents (Higgins, Jung 2003, Kong,
Xu 1998, Crugnola et al. 2010, Echaniz-Laguna et al. 2006, Sasaki, Iwata 1996, Hirano,
Donnenfeld, Sasaki, Nakano 1984, Sasaki, Iwata 2007, Mattiazzi et al. 2002, Borthwick
et al. 1999, Fujita et al. 1996, Wiedemann et al. 2002, Vielhaber et al. 2000, Wiedermann
et al. 1998, Cassina et al. 2008, Ladd, Keeney, Govind, Bennett 2014).
Defective OXPHOS activity has been shown to increase the production of reactive
oxygen species (ROS), a marker for oxidative stress, in affected cells (Duffy, Chapman,
Shaw, Grierson 2011). Defective OXPHOS activity in ALS patients’ spinal cells may
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Figure 26. Mitochondrial gene expression levels. This figure shows 4 mitochondrial genes’
expression levels (assessed in our lab’s previous study) in our sALS sample group vs. our
neurologically healthy control sample group. None of these genes were identified as statistically
significant DEGs.
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Figure 27. Mitochondrial protein-coding genes’ expression levels. This figure shows all 13
mitochondrial protein-coding genes’ expression levels in our sALS sample group vs. our
neurologically healthy control sample group. None of these genes were identified as statistically
significant DEGs.
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ultimately promote motor neuron death as a result of elevated oxidative stress. A recent
study (Cassina et al. 2008) found mitochondria isolated from fALS rodents’ astrocytes 1)
showed defective OXPHOS activity, and 2) induced motor neuron death when the two
cell types were co-cultured in vitro. After treating these astrocytes with mitochondrialtargeted antioxidants, they showed normal mitochondrial respiratory function and did not
induce motor neuron death when co-cultured with motor neurons in vitro.
Elevated oxidative stress has been observed in ALS tissues from human patients
and fALS rodents. One study revealed cerebrospinal fluid from ALS patients had elevated
levels of 3-nitrotyrosine, a marker of free radical damage related to oxidative stress,
relative to neurologically healthy control samples’ cerebrospinal fluid (Duffy, Chapman,
Shaw, Grierson 2011). Further, fALS rodents’ spinal cord motor neurons have shown
evidence of elevated oxidative stress characterized by increased oxyradical production,
carbonylation of proteins, and peroxidation of lipids in the mitochondrial membrane.
Interestingly, peroxidation of cardiolipin disrupts its interaction with cytochrome C, leading
to cytochrome C release from the mitochondrial membrane. It is widely known that
cytochrome C release can promote mitochondrial-mediated apoptosis (Al-Lamki,
Mayadas 2015, Falschlehner, Emmerich, Gerlach, Walczak 2007, Matthews, Newbold,
Johnstone 2012). Aberrant mitochondrial gene expression could plausibly lead to
OXPHOS defects (and potentially motor neuron death) in sALS patients’ diseasevulnerable tissues.
In this chapter, we combined deep RNA-Sequencing and systems biology
analyses to identify sALS group-specific mitochondrial DEGs in postmortem spinal
tissues. To our knowledge, this study is the only one that uses RNA-Sequencing to
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estimate all 37 annotated mitochondrial genes’ expression levels in sALS patients’
postmortem cervical spinal tissues containing disease-vulnerable motor neurons. We did
not identify any sALS group-specific DEGs in this analysis.
Further, we did not replicate our lab’s previous findings showing 4 mitochondrialencoded OXPHOS genes (12s rRNA, COX3, ND2, and ND4) had statistically significantly
decreased expression levels in postmortem cervical spinal sections from ALS samples
relative to neurologically healthy controls. While there was an overlap in the postmortem
cervical spinal section samples examined in this mitochondrial DEG analysis and our lab’s
previous study, multiple samples were not shared between the two analyses. This likely
explains why we did not replicate the previous study’s findings.
We did not assess whether any of our sALS patients carried known (or novel)
pathogenic variants that lead to defective OXPHOS. Mitochondrial DNA (mtDNA) has an
elevated mutation rate, which results in a high frequency of rare variants across
individuals (Taylor, Turnbull 2009). Further, the pathogenic mtDNA mutations identified
in various mitochondrial diseases invariably lead in defective mitochondrial OXPHOS,
resulting in a reduced ability to produce cellular ATP (Tuppen, Blakely, Turnbull, Taylor
2010).
To determine whether any of our sALS patients harbored known or novel
pathogenic mitochondrial variants that lead to defects in OXPHOS, I would first identify
each patient’s mitochondrial SNVs and indels using the GATK pipeline described in
Chapter 2. I would next assess whether any of these variants match published pathogenic
mitochondrial variants in a database such as MITOMAP (Ruiz-Pesini et al. 2007). For the
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remaining variants, I would 1) assess whether they were found in healthy individuals’
mtDNA sequences catalogued in an online database such as The Human Mitochondrial
Genome Database (Ruiz-Pesini et al. 2007), and 2) input them into a tool such as
PolyPhen-2 (Adzhubei et al. 2010) to assess whether they are likely deleterious.
There is considerable heterogeneity in sALS patients’ clinical features (Al-Chalabi,
Hardiman 2013, Ganesalingam et al. 2009), which likely reflects different genetic
etiologies underlying different instances of sALS. It is also entirely possible the
pathogenesis of sALS in our patients did not involve aberrant mitochondrial gene
expression patterns, or defective mitochondrial OXPHOS.
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CHAPTER 4: Cholesterol biosynthesis defects may contribute to disease
pathology in Postmortem Sporadic ALS patients’ cervical spinal sections

I.

Introduction:
A role for RNA processing defects in ALS pathology was largely confirmed via the

identification of >100 ALS causal mutations in the Fused in Sarcoma/Translocation in
Liposarcoma (FUS/TLS) and TAR DNA-binding protein (TARDBP) genes (Renton, Chio,
Traynor 2014). These genes encode the RNA-binding proteins FUS/TLS and TDP-43,
respectively. FUS/TLS and TDP-43 regulate nuclear RNA processing activities including
pre-mRNA splicing, RNA stability, RNA transport, protein translation, and microRNA
maturation (Xu 2012, Colombrita et al 2012). Each protein binds >5,000 RNA transcripts
(with minimal overlap in which RNA transcripts each binds to), suggesting they are both
major regulators of nuclear RNA processing activities (Donnelly, Grima, Sattler 2014).
However,

it

remains

unclear

how mutations

in

these

two

genes

promote

neurodegenerative processes in ALS patients.
A recent study found iPSC-derived motor neurons carrying a FUS/TLS causal ALS
mutation had cytoplasmic aggregates of FUS/TLS (known as FUS/TLS proteinopathy)
and elevated levels of apoptosis relative to iPSC-derived motor neurons that did not carry
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a FUS/TLS causal ALS mutation (Ichiyanagi et al. 2016). Similarly, overexpression of
mutant TDP-43 proteins (encoded by the TARDBP gene carrying different causal ALS
mutations) led to increased 1) TDP-43 proteinopathy and apoptosis in HEK-293 cells
(Mutihac et al. 2015), and 2) TDP-43 proteinopathy and neurodegeneration in a
Drosophila model (Vanden Broeck et al. 2015).
While <4% of Caucasian sALS patients carry a causal ALS mutation in TARDBP
or FUS/TLS as of 2014 (Renton, Chio, Traynor 2014), ~98% of all ALS patients (both
fALS and sALS) have TDP-43 proteinopathy in their spinal motor neurons, spinal glial
cells, and/or select brain cells (Lagier-Tourenne, Cleveland 2009, Donnelly, Grima,
Sattler 2014, Yang et al. 2014). Interestingly, cells exhibiting FUS/TLS or TDP-43
proteinopathy (with or without accompanying FUS/TLS or TARDBP causal ALS
mutations) have reduced levels of FUS/TLS or TDP-43 protein in their nuclei, respectively
(Kwiatkowski et al. 2009, Yang et al. 2014).
Reduced nuclear levels of FUS/TLS or TDP-43 promote apoptosis in cellular and
animals models. iPSC-derived motor neurons with reduced nuclear FUS/TLS had
elevated rates of apoptosis compared to iPSC-derived motor neurons with basal nuclear
levels of FUS/TLS (Ichiyanagi et al. 2016). Systemic knockdown of TDP-43 in zebrafish
led to muscle degeneration, as well as morphological and functional defects in the CNS
(Schmid et al. 2013). Similarly, systemic knockdown of TDP-43 in a transgenic mouse
line led to an age-dependent neurodegenerative phenotype characterized by motor
weakness, paralysis, death of spinal motor neurons and layer V cortical neurons, and
premature death (Yang et al. 2014). Taken together, 1) the majority of ALS patients’
disease-vulnerable cells likely have reduced nuclear levels of TDP-43 as a result of TDP-
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43 proteinopathy, and 2) reduced nuclear levels of TDP-43 (or FUS/TLS) can promote
neurodegeneration.
Reduced nuclear levels of FUS/TLS or TDP-43 may lead to apoptosis (or
neurodegeneration) via disruption of some or all of their normal RNA processing activities
in the nucleus. Systemic knockdown of TDP-43 in a mouse model induced pre-mRNA
splicing defects alongside neurodegeneration in affected cells (Yang et al. 2014).
Whether those pre-mRNA splicing defects contributed to neurodegenerative processes
or simply coincided with them is unknown. However, disruption of either FUS/TLS or TDP43’s pre-mRNA splicing activities could plausibly lead to neurodegeneration.
Within human primary cortical neurons and mouse brains, FUS/TLS is known to
splice RNA transcripts from genes associated with neurodegenerative disorders
(including Microtubule-Associated Protein Tau [MAPT], Calmodulin-Dependent Protein
Kinase II Alpha [CAMK2A], Fragile X Mental Retardation 1 [FMR1], and NDRG Family
Member 2 [Ndrg2]) (Masuda, Takeda, Ohno 2016). Further, shRNA-mediated knockdown
of TDP-43 in human neuroblastoma cells 1) led to splicing changes for genes with known
roles in neuronal development and survival, and 2) increased expression of BCL-2
Interacting Mediator of Cell Death (BIM)’s most cytotoxic RNA isoform (Tollervey et al.
2011).
None of our sALS patients carried a known causal ALS coding mutation in the
TARDBP or FUS/TLS genes, as reported in Chapter 2. However, it is likely our sALS
patients’ cervical spinal cells had TDP-43 proteinopathy, as this feature is seen in 98% of
ALS patients (Lagier-Tourenne, Cleveland 2009, Donnelly, Grima, Sattler 2014, Yang et
al. 2014). As TDP-43 proteinopathy is often accompanied by reduced nuclear TDP-43
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levels (Yang et al. 2014), corresponding TDP-43 splicing defects may have occurred in
our sALS patients’ cervical spinal cells as a result.
In this chapter, we used a combination of RNA-sequencing, bioinformatics tools,
and systems biology analyses to elucidate sALS group-specific exon usage differences
in nuclear genes and assess their biological significance. Specifically, we set out to 1)
identify cellular processes associated with nuclear genes containing exons that were
statistically significantly differentially used in the sALS sample group, as they may be
relevant to disease pathology.

II.

Methods:

Input sample datasets: We used the same 7 sALS and 8 neurologically healthy control
samples’ Read 1 and Read 2 FastQ files output by Trimmomatic (as described in
Chapter 2) for our downstream DEXSeq (Anders, Reyes, Huber 2012) differential exon
usage analysis.
Pre-alignment steps: The DEXSeq analysis’ script was originally written using several
of Ensembl’s annotated human reference transcriptome and genome files.
Consequently, DEXSeq is known to have compatibility issues with the hg19 human
reference transcriptome and genome files I obtained from the Illumina iGenomes UCSC
hg19 directory as described in Chapter 2.
Prior to attempting alignment of each sample’s paired end reads to the hg19
human reference transcriptome then genome, I downloaded Ensembl’s hg19 human
reference transcriptome and hg19 human reference genome files from
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ftp://ftp.ensembl.org/pub/release-63/gtf/homo_sapiens/ and
ftp://ftp.ensembl.org/pub/release-63/fasta/homo_sapiens/dna/, respectively. I combined
each chromosome’s DNA sequence (contained in individual Fasta files) to create the
hg19 human reference genome file.
Alignment: We used STAR, an open source program specially designed for RNASequencing data, to attempt alignment of each sample’s paired end reads to Ensembl’s
hg19 human reference genome. STAR used each sample’s Read 1 and Read 2 FastQ
files from Trimmomatic as input, and output a file containing their aligned paired end reads
for downstream analysis.
DEXSeq counting process: For each annotated gene, DEXSeq first identified
every unique counting bin within each of its exons via comparing known RNA transcripts’
sequences (in the Ensembl hg19 human reference transcriptome file) to each annotated
gene’s exon sequences (in the Ensembl hg19 human reference genome file). Figure 28
illustrates this process for a fictional gene.
Ensembl’s hg19 human reference transcriptome file listed some exons as
belonging to RNA transcripts from multiple genes (rather than one gene) based on
observations from previous studies. We decided to exclude these exons’ counting bins
from the DEXSeq analysis, as determining which of those gene’s RNA transcripts
contained that exon would be impossible in most instances given the length of our RNASequencing reads. Inputting all of possible genes into the downstream overrepresentation analyses would likely bias our results.
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Figure 28. DEXSeq counting bin identification. This figure shows counting bins identified for
a fictional gene A by DEXSeq. This fictional gene has three annotated RNA transcripts
(transcribed exons are represented by light gray boxes). The majority of the first exon’s
sequence is contained in all three RNA transcripts, but transcript 1 has additional transcribed
sequence on its 5’ end relative to the other two RNA transcripts. DEXSeq thereby splits this
fictional gene A’s first exon into 2 counting bins. The other counting bins’ boundaries correspond
exactly to known boundaries for those exons in fictional gene A. Four total counting bins (dark
shaded boxes) were formed for this gene. Adapted from Anders, Reyes, Huber 2012.

139

For each sample, DEXSeq counted the number of aligned paired end reads that
fell within each eligible counting bin. Reads that overlapped several counting bins were
counted for each of those bins.
DEXSeq analysis: We used DEXSeq to identify sALS group-specific DUEs. The creators
of DESeq2 made DEXSeq, and DEXSeq applied many of the same mathematical
procedures used in DESeq2 (and EdgeR) to appropriately model counting bins’ counts
across samples. These procedures ultimately reduced the number of identified DUEs that
were false positives. DEXSeq relied on generalized linear models to identify sALS groupspecific DUEs.
Prior to testing for sALS group-specific DUEs, DEXSeq omitted 1) any gene that
only contained one counting bin (or had less than two counting bins with counts), and 2)
any counting bin with an extremely low count sum across samples. It would be impossible
to identify whether an annotated gene with only one counting bin (or with less than two
counting bins with counts) was differentially expressed or if its individual counting bin was
differentially expressed. Removing counting bins with a low count sum across samples
served to reduce downstream false positive DUEs, as these counting bins had a low
signal-to-noise ratio.
To further prevent false positive DUEs, DEXSeq mathematically accounted for 1)
differences in the total number of counting bin counts between samples, 2) overdispersion
in each counting bin’s counts across samples, and 3) whether each counting bin’s
corresponding annotated gene was differentially expressed between groups.
For a given counting bin, differences in the number of counts between samples
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could reflect each sample’s total number of RNA-Sequencing reads as opposed to
differences in that counting bin’s expression levels between samples. Assume two of our
samples’ RNA-Sequencing libraries had an equal number of sequenceable dscDNA
molecules corresponding to a given counting bin (suggesting that counting bin had an
equal expression level in both samples’ postmortem cervical spinal sections). If more total
sequencing reads were generated for one of those samples, that sample’s sequencing
data would likely have more total paired end reads corresponding to that counting bin
relative to the other sample. This is because denatured strands from that counting bin’s
corresponding sequenceable dscDNA molecules were appropriated more Illumina
NextSeq500 binding spots (covalently bound oligonucleotides) to potentially hybridize to
for sequencing.
Like paired end read counts, counting bin counts across samples are often
overdispersed. This means the variance of counting bin counts across each group’s
samples often exceeds what is expected using a Poisson distribution. DEXSeq’s DUE
analysis relied on negative binomial distributions to best account for variance in each
counting bin’s counts across each group’s samples. DEXSeq also estimated the level of
dispersion for each individual counting bin (using maximum likelihood modeling) and
counting bins with similar expression levels across samples. DEXSeq then applied an
empirical Bayes’ theorem to moderate overdispersion via shrinking each counting bin’s
level of dispersion towards the level of dispersion estimated for counting bins with a
similar expression level.
DEXSeq assessed whether each counting bin’s corresponding annotated gene
was differentially expressed between our sALS and neurologically healthy control groups.
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If a given annotated gene was differentially expressed between groups, the authors
reasoned each of that annotated gene’s counting bins was likely to be differentially used
between groups by a similar quantitative factor. In cases where a given annotated gene
was differentially expressed, that quantitative factor was accounted for when testing
whether each of that annotated gene’s counting bins was differentially used between
groups.
For each counting bin, two generalized linear models (full and reduced) were
generated. Each of these generalized linear models incorporated the above factors and
a log fold change value calculated via comparing the counting bin’s representative count
values in our sALS and neurologically healthy control groups. The full generalized linear
model included a variable that estimated how much of the difference in each counting
bin’s estimated usage levels between groups was explained by group membership (case
vs. control status), whereas the reduced generalized linear model omitted that variable.
To assess whether a given counting bin was differentially used between groups,
DEXSeq compared the fits of these two generalized linear models using a likelihood ratio
test. For each counting bin, this comparison produced a corresponding p-value. We
calculated all counting bins’ Benjamini-Hochberg corrected p-values using DEXSeq’s
reported p-values via the R function p.adjust. Each counting bin with a BenjaminiHochberg corrected p-value < 0.10 was identified as a sALS group-specific DUE. Prior to
uploading our list of annotated genes containing a DUE to IPA, we converted their
Ensembl ID’s to HGNC ID’s using Biomart’s ID conversion tool.
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Ingenuity Pathway Analysis: We used QIAGEN’s Ingenuity Pathway Analysis to assess
what canonical signaling pathways, diseases/disorders, and cellular functions were
statistically significantly associated with our 46 annotated genes containing one or more
DUEs. IPA used a right-tailed Fisher Exact test to assess the number of these annotated
genes that were separately associated with each canonical signaling pathway,
disease/disorder, and cellular functions in the IPA Knowledge base. Corresponding
association p-values relating these annotated genes carrying one or more DUEs to each
tested canonical signaling pathway, disease/disorder, and cellular function were reported.

III.

Results:

DEXSeq DUE testing and associated cellular processes: At an FDR of .10, DEXSeq
identified 52 sALS group-specific DUEs (from 46 annotated genes). These results are
shown in Table 9. A visual schematic of a sALS group-specific DUE can be seen in Figure
29. Among various findings, QIAGEN’s Ingenuity Pathway Analysis revealed these
DUEs’ annotated genes were associated with cholesterol biosynthesis, the mevalonate
pathway, and lipid metabolism. These results are shown in Table 10.
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Table 9: sALS group-specific DUEs
Annotated
Gene

sALS
groupspecific
DUE

Fold
Change

Annotated
Gene

sALS
groupspecific
DUE

Fold
Change

LINC00476
SEMA4G
SLCO2B1
CTNND2
FCGR2A
SUSD1
CD27-AS1
PCNT
SLC25A36
LRRTM4
GABPA
HAPLN4
MORC3
MORC3
CCDC91
GRAMD3
CDK17
BARD1
CHCHD2
LYPLA1
MKLN1
DDR1

CB007
CB044
CB019
CB048
CB024
CB013
CB011
CB017
CB021
CB006
CB005
CB001
CB018
CB017
CB027
CB020
CB018
CB018
CB001
CB008
CB016
CB129

-2.32
-1.73
-1.69
-1.53
-1.52
-1.26
-1.15
-1.15
-1.12
-1.09
-1.08
-1.08
-1.08
-1.07
-1.06
-1.05
-1.05
-1.05
-1.05
-1.05
-1.05
-1.04

ENTPD4
FAM219B
POLI
RNF170
VEZT
MYLK
HSD17B7
FDFT1
RSRC2
TF
TF
ATRNL1
ATAD5
HMGCS1
RSRC2
CCDC141
RICTOR
KALRN
USH2A
THAP9-AS1
NBEAL2
IDI1

CB003
CB005
CB012
CB004
CB086
CB044
CB016
CB025
CB046
CB004
CB003
CB048
CB021
CB025
CB047
CB004
CB002
CB071
CB001
CB009
CB083
CB013

1.04
1.09
1.17
1.17
1.22
1.24
1.27
1.29
1.30
1.31
1.34
1.34
1.35
1.38
1.50
1.51
1.51
1.52
1.52
1.54
1.55
1.56

144

Figure 29. DEXSeq differentially used exon plot. This figure shows the difference in exon
usage for counting bin #13 of the IDI1 locus. This counting bin was selected as an illustrative
example, as its usage level had the largest positive fold change in our sALS sample group
relative to our neurologically healthy control sample group.
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Table 10: IPA results for sALS group-specific DUEs
Top Canonical Pathways

Overlapping Genes

p-Value

Superpathway of Cholesterol Biosynthesis

4/28

2.40E-07

Cholesterol Biosynthesis I

2/13

2.82E-04

Mevalonate Pathway I

2/13

2.82E-04

Cholesterol Biosynthesis II

2/13

2.82E-04

Cholesterol Biosynthesis III

2/13

2.82E-04

Top Diseases and Disorders

p-Value

Cardiovascular Disease

4.48E-02 - 1.16E-03

Hematological Disease

3.44E-02 - 1.16E-03

Cancer

4.81E-02 - 1.94E-03

Connective Tissue Disorders

4.80E-02 - 1.94E-03

Developmental Disorder

4.74E-02 - 1.94E-03

Top Upstream Regulators

Overlapping Genes

p-Value

FOXO4

4/26

1.23E-06

SREBF2

4/37

8.33E-06

Pitavastatin

3/13

9.10E-06

NPPB

3/20

2.37E-05

SREBF1

5/92

2.38E-05
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IV.

Discussion:
Aberrant RNA processing has been recurrently associated with ALS-group specific

DEGs identified in tissues from both human patients (fALS and sALS) and fALS rodents
(Heath, Kirby, Shaw 2013). This may reflect a disruption of TDP-43’s normal RNA
processing activities as a result of reduced nuclear TDP-43 protein in ALS tissues.
Reduced nuclear TDP-43 has been observed in cells with TDP-43 proteinopathy, a
feature found in ~98% of ALS patients’ (both fALS and sALS) spinal motor neurons, spinal
glial cells, and/or select brain cells (Lagier-Tourenne, Cleveland 2009, Donnelly, Grima,
Sattler 2014, Yang et al. 2014).
Reduced nuclear TDP-43 levels promoted neurodegeneration in various animal
models (Schmid et al. 2003, Yang et al. 2014). Further, one of those studies demonstrated
reduced nuclear TDP-43 caused TDP-43 splicing defects alongside neurodegeneration
(Yang et al. 2014). It is unclear whether TDP-43 splicing defects functionally contribute to
neurodegenerative processes. However, it seems plausible as TDP-43 regulates premRNA splicing for genes that 1) encode synaptic proteins (Polymenidou et al. 2011), 2)
preserve neuronal integrity (Lagier-Tourenne et al. 2012), and 3) promote neuronal
survival (Tollervey et al. 2011).
To date, two ALS studies have used splicing-sensitive microarrays to identify
statistically significant splicing differences in spinal motor neurons from sALS patients and
neurologically healthy controls (Rabin et al. 2010, Highley et al. 2014). In both studies,
researchers confirmed their sALS patients’ spinal motor neurons had TDP-43
proteinopathy. The earlier study identified 411 aberrantly spliced genes, and overrepresentation analyses revealed those genes were associated with cell adhesion,
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transmembrane receptor protein tyrosine kinase activity, and the extracellular matrix
(Rabin et al. 2010). The later study identified 6,449 sALS group-specific DUEs (in 4,311
genes), and over-representation analyses revealed those genes were associated with
ribonucleotide binding, cytoskeletal organization, protein localization, and macromolecule
catabolic processes (Highley et al. 2014).
In this chapter, we combined deep RNA-Sequencing and systems biology
analyses to identify sALS group-specific DUEs in postmortem spinal tissues from sALS
patients and neurologically healthy controls. We discovered 52 DUEs in 46 annotated
genes. 15 of these DUEs’ fold change usage difference between groups was <10%. It is
difficult to envision these differences playing a significant role in disease pathology.
Nonetheless, over-representation analyses revealed the 46 genes containing DUEs were
associated with cholesterol biosynthesis, the mevalonate pathway, and lipid metabolism.
Cholesterol is an essential component of neuronal membranes, and is needed to
form membrane lipid rafts necessary for protein anchorage and trafficking. Cholesterol is
also used for continued axon growth and synapse remodeling in the mature adult brain,
and serves as a precursor of neurosteroids (Anchisi, Dessi, Pani, Mandas 2013).
Cholesterol biosynthesis involves a multi-step process beginning with conversion of
acetyl-CoA to 3-hydroxy-3-methylglutaryl-CoA, followed by the generation of mevalonate
(Martin, Pfrieger, Dotti 2014). After conversion into many other intermediary substrates,
cholesterol is produced.
Defects in cholesterol biosynthesis are known to cause several rare
neurodegenerative

disorders.

These

include
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lathosterolosis,

desmosterolosis,

cerebrotendinous

xanthomatosis,

congenital

hemidysplasia

with

ichthyosiform

erythroderma and limb defects, and Smith-Lemli-Opitz Syndrome (SLOS) (Vance 2012).
Dysregulated cholesterol homeostasis has separately been associated with more
common neurodegenerative disorders (including Alzheimer’s disease, Huntington’s
disease, and Parkinson’s disease). If and how defects in cholesterol biosynthesis or
homeostasis functionally contribute to these disorders’ neurodegenerative processes
remains largely unknown. However, we do know SLOS causal mutations in the 7Dehyrocholesterol reductase (DHCR7) gene lead to abnormally low levels of cholesterol
(and high levels of 7-dehydrocholesterol) in cells, plasma, and the brain (Vance 2012).
Our best understanding of how dysregulated cholesterol metabolism can
functionally contribute to neurodegenerative processes comes from studies of NiemannPick Type C (NPC), a neurodegenerative disorder affecting 1 in 150,000 people. In NPC,
mutant NPC1 and NPC2 proteins fail to transport free cholesterol from lipoproteins into
neuronal cells’ cytosols, leaving the cholesterol sequestered in late endosomes and/or
lysosomes. This results in disproportionately low levels of cholesterol in affected neurons’
plasma membranes and axons (Vance 2012).
Interestingly, subcutaneous injection of a cholesterol binding compound
(cyclodextrin) into NPC -/- mice slowed neurodegeneration and extended their lifespan
by 50% (Liu et al. 2009). A separate analysis showed administrating a low dose of
cyclodextrin to NPC -/- neurons released sequestered cholesterol from their late
endosomes and/or lysosomes into their cytoplasms (Vance 2012). Researchers have
proposed cyclodextrin may stop neurodegeneration in NPC mouse models by redistributing sequestered cholesterol from affected neurons’ late endosomes and/or
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lysosomes into their plasma membranes (where it was low in concentration) (Martin,
Pfreiger, Dotti 2014).
Much less is known about how cholesterol biosynthesis, cholesterol homeostasis,
or the distribution of cholesterol in neuronal cells may contribute to sALS pathology. A
very early study (Cutler et al. 2002) reported elevated levels of sphingomyelin, ceramides,
and cholesterol esters were found in the spinal cords of ALS patients and fALS rodents
carrying

a

SOD1

mutation.

Further,

they

speculated

this

could

promote

neurodegeneration via oxidative stress related apoptotic events. Several recent studies
have shown ALS patients with higher circulating cholesterol levels (characterized by
elevated LDL to HDL ratios) live longer than patients with lower cholesterol levels
(D’Amico, Factor-Litvak, Santella, Mitsumoto 2013). It is tempting to think this protective
effect is the result of higher cholesterol concentrations in those neurons’ plasma
membranes,

especially

considering

low

cholesterol

levels

were

linked

to

neurodegneration in SLOS and NPC. However, the CNS blocks entry of cholesterol-rich
lipoproteins circulating in the blood via the blood brain barrier (BBB). Therefore, it is
unclear how a higher circulating cholesterol level would protect disease-vulnerable cells
in the spinal cord (Martin, Pfreiger, Dotti 2014).
We cannot predict whether cholesterol biosynthesis was increased or decreased
in our sALS samples based on our sALS group-specific DUEs alone. Further, it is unclear
what significance these findings have for motor neurons, as the majority of RNA isolated
from these spinal sections came from astrocytes and microglia. However, the link
between cholesterol biosynthesis and neurodegeneration has been established
previously. Further, lower levels of cholesterol (found systemically or within neuronal
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plasma membranes and axons) have been linked to neurodegeneration in SLOS and
NPC. For these reasons, I propose future experiments that first generate iPSC-derived
astrocytes, iPSC-derived microglia, and iPSC-derived motor neurons using mononuclear
blood cells drawn from sALS patients and neurologically healthy controls. I would coculture these cells using 3-dimensional scaffolding techniques in vitro, as described in
this paper (Schwartz et al. 2015).
I would then directly compare both membrane bound and free cholesterol levels in
iPSC-derived motor neurons from sALS patients and neurologically healthy controls using
immunohistochemistry and a colorimetric assay, respectively. My immunohistochemistry
experiments would involving staining for Filipin, a highly fluorescent compound that
specifically binds to cholesterol. Filipin staining is used to diagnosis NPC in clinical
settings by assessing the level of cholesterol found sequestered in late endosomes and/or
lysosomes and in the plasma membrane (Vanier, Latour 2015). I would also lyse equal
amounts of each 3D culture prior to measuring total cholesterol levels (reflecting
cholesterol biosynthesis) using a commercially available colorimetric assay. I would be
most interested in determining 1) whether iPSC-derived motor neurons from sALS
patients (relative to neurologically healthy controls) had significantly different levels of
cholesterol staining in their late endosomes or cell membranes, and 2) whether 3D
neuronal models from sALS patients (relative to neurologically healthy controls) had
significantly different levels of free cholesterol.
If the sALS group did have significant differences in either measurement, I would
assess whether those differences were seen alongside increased rates of motor neuron
death as measuring using a cell viability MTT assay. If that relationship was established,
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I would then begin testing whether different pharmacological agents 1) normalized these
sALS-group specific differences in cholesterol distribution in the cell and/or cholesterol
biosynthesis, and 2) reduced motor neuron death as measured using the MTT assay.
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CHAPTER 5: Summary, What I learned, and future directions

ALS is a disease characterized by degeneration of upper and lower motor
neurons in the brain stem and spinal cord. Average life expectancy after diagnosis is
between 2-5 years, as the death of motor neurons innervating the lungs ultimately leads
to many sALS patients’ deaths. Unfortunately, current treatments only extend life by
several months. More effective therapies are sorely needed for this devastating illness.
As of 2014, 68% of fALS in Caucasians was accounted for by causal mutations
in 9 different genes. However, only 11% of sALS in Caucasians was accounted by
mutations in these genes (Renton, Chio, Traynor 2014). Despite evidence for varying
genetic etiologies, ALS gene expression studies dating back to 2001 suggest there is a
convergent set of perturbed cellular processes germane to both fALS and sALS. ALS
tissue-specific DEGs identified from human (fALS and sALS) patient and fALS model
rodent samples were associated with oxidative stress, mitochondrial dysfunction,
apoptosis, inflammation, RNA processing defects, and protein aggregation (Heath,
Kirby, Shaw 2013). Researchers using separate molecular biology assays found these
same cellular processes were perturbed in human (fALS and sALS) patient and fALS
rodent tissues, as referenced in the introduction of Chapter 2. Taken together, it is likely
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perturbations in these cellular processes contribute to ALS onset, progression, and
symptoms. These findings also support the use of gene expression studies to identify
cellular processes likely perturbed in ALS pathology moving forward.
Follow-up molecular biology experiments can be used to test how sALS groupspecific differences (identified in gene expression studies) may have functional
relevance to disease pathology. Further, these experiments could unveil novel
therapeutic targets that may slow this devastating disorder. In the course of this
dissertation project, we combined RNA-Sequencing, systems biology analyses, and
molecular biology assays to elucidate sALS group-specific differences in postmortem
spinal tissues that may be relevant to disease pathology.
In chapter 2, we discovered inflammatory processes and TNF-α signaling were
statistically significantly associated with sALS group-specific gene expression
differences identified using independent exploratory DEG analyses and an
unsupervised gene co-expression network analysis. Increased inflammatory processes
and elevated TNF-α signaling have been recurrently reported in ALS tissues, and likely
play a role in sALS pathology. We selected TNFAIP2, an upregulated sALS groupspecific DEG and network hub gene, for downstream molecular assays. Elevated TNF-α
signaling is known to increase TNFAIP2 expression in a variety of cell types (Saito et al.
2013, Zhou, Scoggin, Gaynor, Williams 2003, Tian et al 2005), and elevated TNFAIP2
expression has previously been associated with increased apoptosis (Park et al. 2003,
Rusiniak et al. 2000, Ma et al. 2003). Studies linking elevated TNFAIP2 expression to
increased apoptosis did not assess TNFAIP2’s cellular function or whether TNFAIP2
functionally promoted apoptotic processes directly.
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Within in vitro models of sALS disease-vulnerable cell types, we wished to test
whether 1) elevated TNF-α signaling increased TNFAIP2 expression, and 2) whether
transient overexpression of TNFAIP2 increased cell death, potentially through the TNF
superfamily mitochondrial apoptotic pathway. We discovered exposing neural stem cells
to extracellular TNF-α increased TNFAIP2 gene expression by ~100 fold, along with
elevating several other network hub genes’ expression levels. Transient overexpression
of TNFAIP2 decreased neural stem cell viability, and simultaneous inhibition of
activated caspase 9 (a protein necessary for TNF-α superfamily mitochondrial-mediated
apoptosis) reversed this effect in these cells. Further, transient overexpression of
TNFAIP2 with Green Fluorescent Protein (GFP) fused to its N terminus in iPSC-derived
motor neurons led to increased cell death evidenced by decreased cell viability and
increased caspase 3/7 levels.
These proof of concept experiments within in vitro models of sALS diseasevulnerable cell types demonstrated TNFAIP2 expression increased in response to
elevated TNF-α signaling, and transient overexpression of TNFAIP2 promoted cell
death. TNFAIP2 may mediate cell death via the TNF-α superfamily mitochondrialmediated apoptotic pathway, as inhibition of activated Caspase 9 (a protein necessary
for TNF-α superfamily mitochondrial-mediated apoptosis) prevented TNFAIP2-mediated
cell death in our neural stem cells. Taken together, these findings support our
hypotheses that elevated TNF-α signaling 1) increased TNFAIP2 expression in our
sALS patients’ cervical spinal cells, and 2) TNFAIP2 functionally contributed to spinal
motor neuron death in our sALS patients via the TNF mitochondrial apoptotic pathway.
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Further research into the potential role of elevated TNF-α signaling (and TNFAIP2
expression) in sALS pathology is needed.
In chapter 3, we did not identify any statistically significant differences in
mitochondrial gene expression in our sALS sample group vs. our neurologically healthy
controls. However, there were trend level findings of reduced gene expression for the
majority of mitochondrial protein coding genes (12 out of 13) in our sALS patients vs.
our neurologically healthy controls. These genes encode components of ETC protein
complexes, essential for mitochondrial OXPHOS. Defective mitochondrial OXPHOS has
been linked to elevated oxidative stress, a phenomenon known to mediate
neurodegeneration under certain circumstances. While we did not identify sALS groupspecific mitochondrial DEGs, it is possible our sALS patients carried mitochondrial
SNVs or indels that perturbed mitochondrial OXPHOS in their disease-vulnerable cells.
This may have contributed to their motor neurons dying. Further investigation into the
potential role of pathogenic mitochondrial variants in our samples (and in sALS
pathology) is needed.
In chapter 4, we identified 52 sALS group-specific DUEs in 46 annotated genes,
and over-representation analyses revealed those genes were associated with
cholesterol biosynthesis. Defects in cholesterol biosynthesis and metabolism have been
linked to numerous neurodegenerative disorders. In NPC, cholesterol sequestration in
the late endosomes and/or lysosomes leads to lower levels of cholesterol in neurons’
membranes. While the exact mechanism is unknown, this ultimately promotes
neurodegeneration. While little is known about whether (or how) defects in cholesterol
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biosynthesis and/or metabolism play a role in ALS, cholesterol has been linked to
neurodegeneration repeatedly in previous literature.
It is not difficult to imagine how perturbations in the level or distribution of
cholesterol in neurons could lead to pathological cellular processes. Cholesterol is an
essential component of neuronal membranes, necessary for protein anchorage and
trafficking. Further, cholesterol is used for continued axon growth and synapse
remodeling in the mature adult brain, and serves as a precursor of neurosteroids
(Anchisi, Dessi, Pani, Mandas 2013). Research into the potential role of aberrant
cholesterol biosynthesis and/or metabolism in sALS pathology is needed.
What I learned:
In the course of this dissertation project, I have learned how many factors
inherent to current RNA-Sequencing workflows influence gene expression estimates.
Many of these factors are completely unrelated to gene expression levels in the original
biological tissue. I will discuss the numerous factors in our workflow that likely
influenced our annotated gene expression estimates.
For review, the steps of our Illumina RNA-Sequencing workflow for each sample
involved 1) isolating total RNA, 2) removing rRNAs from total RNA, 3) fragmenting
isolated RNA transcripts into a distribution of smaller fragments, 4) converting RNA
fragments into sequenceable dscDNA molecules, 5) increasing the proportion of
properly ligated sequenceable dscDNA molecules via enrichment PCR, 6) binding
denatured strands of sequenceable dscDNA molecules to an Illumina NextSeq500
flowcell for generation of paired end reads, 7) aligning paired end reads to the hg19
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human reference transcriptome then genome, and 8) using bioinformatics analyses to
generate each annotated gene’s expression level estimates. Nearly every one of these
steps influences the final gene expression level estimates!
The QIAGEN miRNeasy kit used in step 1 did not recover all RNA transcripts, as
some were inevitably retained on its isolation column. Use of the RNeasy Micro kit for
sample purification led to our losing various genes’ RNA transcripts <100 nucleotides in
length, as that kit is designed to recover RNA transcripts >100 nucleotides in length.
Finally, RNA transcripts are known to undergo varying levels of degradation during the
RNA isolation process. For any given annotated gene, losing its RNA transcripts would
lead to less 1) corresponding sequenceable dscDNA molecules and 2) paired end reads
that could have aligned to that gene’s transcribed regions. This would lead to an
underestimated gene expression level estimate for that annotated gene relative to its
actual expression level in the biological sample.
Paired end reads corresponding to RNA transcripts that incurred higher levels of
degradation likely preserved shorter stretches (less nucleotides) of those RNA transcripts
relative to RNA transcripts that incurred lower levels of degradation. Paired end reads
preserving longer stretches of their corresponding RNA transcripts were generally more
likely to accurately align to the hg19 human reference genome relative to paired end reads
preserving shorter stretches of their corresponding RNA molecules. While the majority of
our RNA transcripts were not likely to be significantly degraded (as we used RNA with an
RQI score >7), this effect likely led to underestimated gene expression values for any
annotated gene that had significantly degraded RNA transcripts.
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The RNA fragmentation process used in step 3 broke all RNA transcripts into a
tighter distribution of smaller fragments (between 120-210 nucleotides) prior to dscDNA
generation in the next step. The length of a given isolated RNA transcript was positively
correlated with both 1) the number of fragments generated from it, and 2) the number of
corresponding sequenceable dscDNA molecules generated from its fragments in
downstream steps. Relative to shorter RNA transcripts, longer RNA transcripts were
generally more likely to have a greater number of corresponding paired end reads (and
paired end read counts). This concept is illustrated in Figure 16, and was true even when
a long and short RNA transcript had equal expression levels in the biological sample.
As a result of this technical bias, it is highly probable that our annotated genes had
disproportionately more or less aligned paired end reads relative to their actual
expression levels in each sample’s postmortem tissues. This almost certainly influenced
our annotated genes’ expression level estimates, as both HTSeq-Count and Cufflinks
used the number of aligned paired end read counts to calculate their gene expression
level estimates. While Cufflinks applied a normalize step to correct for this bias, it is
unlikely to have completely resolved its effects as discussed later.
The enrichment PCR process in step 5 was necessary to increase the number of
sequenceable dscDNA molecules relative to dscDNA molecules improperly ligated with
one or zero sequencing adaptors. This ensured a negligible amount of unsequenceable
denatured strands (from improperly ligated dscDNA molecules) bound to the NextSeq
500 flowcell. Unfortunately, this necessary step likely altered the amount of input
sequenceable dscDNA molecules relative to each other. A previous study has shown
DNA fragments ligated with Illumina sequencing adaptors used in Illumina library
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preparation kits do not amplify equally (Kebschull and Zador, 2015). Depending on
whether

a

given

annotated

gene’s

sequenceable

dscDNA

molecules

were

disproportionately increased or decreased by enrichment PCR, that annotated gene
would have more or less corresponding denatured strands able to hybridize the limited
number of Illumina NextSeq 500 binding spots (covalently bound oligonucleotides) for
sequencing. This technical property likely led to overestimated or underestimated gene
expression values for affected annotated genes.
Use of paired end reads that were >100 nucleotides in length likely increased our
total number of aligned sequenced reads relative to if we used single end (or shorter
paired end) reads (Salzman, Jiang, Wong 2011, Cho et al. 2014). This likely prevented
underestimated gene expression values for at least a portion of our annotated genes, as
a greater number of their corresponding paired end reads likely aligned to their
transcribed regions.
Perhaps the biggest influence on our downstream gene expression estimates was
the number of paired end reads generated for each sample. The total number of
sequenced reads obtained for a given sample is positively correlated with 1) the likelihood
genes with lower expression levels are represented in their sequencing data, and 2) how
accurate their gene expression estimates are likely to be. These concepts are illustrated
in Figure 12.
According to a recent study, 45-65 million RNA-sequencing reads generated from
input total RNA (depleted of rRNAs) offers a detection level for lowly expressed protein
coding genes that is comparable to a standard Agilent microarray (Zhao et al. 2014). If
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one uses input polyA+ RNA instead, ~13 million reads allows a detection level for lowly
expressed protein coding genes that is comparable to a standard Agilent microarray.
There is not a consensus number of RNA-sequencing reads one should appropriate to
each sample to achieve highly accurate gene expression estimates for very lowly
expressed genes. An early study proposed 200 million reads per sample was necessary
to detect the full range of expressed human RNA transcripts, including those from very
lowly expressed genes (Tarazona et al. 2011). The ENCODE consortium reported ~36
and ~80 million paired end reads per sample were necessary to accurately estimate
genes with expression levels corresponding to FPKM values of >10 and <10, respectively.
We obtained >55 million paired end reads for each of our samples. Taken together,
we should have a comparable detection level for protein coding genes relative to using
standard microarray technology. According to ENCODE’s estimates, our gene expression
estimates for annotated genes with expression levels that correspond to an FPKM value
of >10 should be highly accurate. Our gene expression estimates for annotated genes
with expression levels that correspond to an FPKM value of <10 are likely less accurate
(with decreasing accuracy tracking with lower gene expression levels).
Use of Tophat2 likely had mixed effects on our downstream gene expression
estimates. A group recently compared alignment results from 26 mapping protocols on 4
common RNA-Sequencing read datasets (Engstrom et al. 2013). Tophat2 reported one
the smaller numbers of total aligned reads due to its low tolerance for mismatching
nucleotides, but one of the higher numbers of identified splice sites when used with a
guide annotation. Overall, use of Tophat2 probably led to more underestimated gene
expression values across annotated genes as a result of fewer paired end reads that
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successfully aligned to those genes’ transcribed regions. However, use of Tophat2
probably prevented underestimated gene expression values for some annotated genes
by using additional identified splice sites to correctly map paired end reads to those genes’
transcribed regions across introns.
Finally, properties inherent to the bioinformatics tools used to calculate each
sample’s annotated gene expression estimates were also likely to affect the accuracy of
our gene expression estimates. For each sample, HTSeq-Count reported each
annotated gene’s total number of paired end reads that aligned to its transcribed
regions without accounting for the influences of transcript length or the sample’s total
number of paired end reads on these counts. This likely led to overestimated and
underestimated gene expression values for many of our annotated genes depending on
how they were influenced by these technical factors. Cufflinks’ annotated gene
expression estimates were likely more accurate for each sample, as their FPKM
normalization accounted for transcript length, that sample’s total number of sequenced
reads, and RNA composition biases. However, this is likely an imperfect solution. It is
probable a portion of each sample’s endogenously smaller RNA transcripts didn’t have
any corresponding paired end reads generated (despite equal expression levels to
larger RNA transcripts) as a result of having less corresponding denatured strands to
bind the flowcell for sequencing. Cufflinks can’t normalize aligned paired end read
counts for a given annotated gene if that gene’s endogenously smaller RNA transcripts
didn’t have any corresponding paired end reads.
Provided a thoughtful experimental design that buffers the influences of these
various technical factors on gene expression estimates, RNA-Sequencing is an
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excellent research tool for estimating gene expression levels and performing
downstream analyses. With technological advances, RNA-Sequencing’s ability to 1)
accurately estimate gene expression levels, 2) detect and estimate lowly expressed
genes’ expression levels, and 3) identify various RNA isoforms will only improve.
Commonly used RNA-Sequencing workflows for DEG analyses rely on
sequenceable dscDNA molecules made from fragmented RNA transcripts. Pacific
Biosystem’s current RNA-sequencing workflow does not fragment RNA transcripts, and
its sequencing technology routinely generates sequencing reads that are (on average)
15,000 nucleotides. Generation of each sample’s RNA-Sequencing reads using this
platform would greatly reduce (if not altogether eliminate) the influence of transcript
length on downstream gene expression estimates, and mitigate Cufflinks’ uncertainty in
assigning a given sequenced read to its corresponding RNA transcript. Further, gene
expression estimates would likely be much more accurate as a result, and widespread
use of this platform would produce more trustworthy differential transcript expression
analyses.
However, Pacific Biosystem’s RNA-Sequencing workflow is rarely used in
preparation for DEG analyses today. The average cost per read is drastically higher
compared to platforms that generate shorter reads. Typically, gene expression studies
with DEG analyses involve generation of >10 million reads per sample (when using
polyA+ enrichment input mRNAs) or >30 million reads per sample (when using rRNAdepleted total RNA). It would be astronomically expensive to generate these numbers of
reads per sample using the Pacific Biosystem RNA-Sequencing workflow. However,
sequencing costs have decreased rapidly in the last decade. It is possible this
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technology will become more affordable and replace the current workflows.
A potentially superior approach to Pacific Biosystem’s RNA-Sequencing workflow
in the future would involve generating long sequencing reads (covering the entirety of
the RNA transcript) directly from every RNA transcript in each tested sample. That
would eliminate influences on gene expression estimates introduced by 1) transcript
length, 2) PCR amplification biases, 3) RNA transcripts lost across the library
preparation workflow, and 4) the effects of a sampling procedure for sequencing.
Numerous companies (including Oxford Nanopore Technologies) are in the process of
creating a technology that can generate long sequencing reads (covering the entirety of
the RNA transcript) from every RNA transcript in each tested sample.
Future Directions:
Clinical trials that aim to inhibit TNF-α synthesis may prove fruitful in sALS as
they have in other chronic diseases with an inflammatory component (Probert 2015).
However, the use of non-selective TNF-α inhibitors has exacerbated symptoms in
human multiple sclerosis patients, and induced new cases of demyelinating disease and
neuropathies in other clinical populations. Side effects have included an elevated risk
for bacterial sepsis and invasive fungal infections as a result of suppressed immune
function (Probert 2015).
Additionally, elevated TNF-α signaling can lead to increased cell survival
processes via NFKB signaling under certain biological conditions, so inhibiting it
altogether may prevent those protective processes from occurring in sALS patients’
disease-vulnerable cells. For these reasons, inhibition of target proteins in the TNF
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superfamily apoptotic pathways may prove to be a superior treatment strategy for sALS
patients if therapeutic efforts to generally inhibit TNF-α synthesis have significant
shortcomings.
In our studies presented in Chapter 2, we found exposing neural stem cells to
extracellular TNF-α increased TNFAIP2 gene expression by ~100 fold. We
demonstrated transient overexpression of TNFAIP2 promoted cell death within in vitro
models of sALS disease-vulnerable cell types. Further, we discovered inhibiting
caspase 9 (a protein necessary for TNF-α superfamily mitochondrial-mediated
apoptosis) decreased TNFAIP2-mediated cell death in our neural stem cells. Taken
together, these findings suggest TNFAIP2 may functionally contribute to TNF
superfamily mitochondrial-mediated apoptosis in disease-vulnerable cell types in sALS
patients.
For follow up experiments, I would like to assess whether TNFAIP2 functionally
contributes to apoptosis within iPSC-derived motor neurons in vitro and within
transgenic mice in vivo. The results of these experiments would have important
implications for TNFAIP2’s potential therapeutic relevance in sALS, as it may represent
a good candidate for therapeutic targeting if it does functionally contribute to apoptosis
in one or both models.
In preparation for the in vitro experiment, I would use CRISPR/Cas9 technology
to establish an iPSC-derived motor neuron line without a functional copy of the
TNFAIP2 gene (TNFAIP2 -/-). I would then empirically determine what amount of
extracellular TNF-α reduces cell viability in iPSC-derived motor neurons. I would then
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expose wildtype and TNFAIP2 -/- iPSC-derived motor neuron groups to that predetermined amount of TNF-α for 6 hours, followed by assessing cell viability in both
groups using the MTT assay. If wildtype iPSC-derived motor neurons showed a
statistically significant reduction in cell viability compared to TNFAIP2 -/- iPSC-derived
motor neurons, this would suggest TNFAIP2 functionally contributes to apoptosis
mediated by elevated TNF-α signaling.
In preparation for the in vivo experiment, I would use CRISPR/Cas9 technology
to insert a doxycycline-inducible human TNFAIP2 transgene (coupled to a motor neuron
specific promoter) into various transgenic mouse lines (to assess against different
genomic backgrounds). I would then raise these mice to adulthood, and administer
varying doses of doxycycline to these mice and their littermates (who would serve as
controls). I would then assess whether varying levels of TNFAIP2 overexpression led to
a neurodegenerative phenotype characterized by muscle weakness, paralysis, muscle
wasting, and early death. If it does, I would confirm TNFAIP2 overexpression occurred
in spinal motor neurons, and that death of upper and lower motor neurons was
observed.
These findings (along with those presented in data chapter 2) could provide the
bases for a future clinical trial assessing whether TNFAIP2 knockdown in the CNS
ameliorates symptoms related to motor neuron death in sALS patients. Clinical metrics
to assess disease progression, such as the revised ALS functional rating scale used in
previous studies (Tateishi 2010), could be a preliminary measure of treatment efficacy.
Provided an unlimited budget, I would execute a massive ALS research project
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involving the enrollment of 20,000 sALS patients and 20,000 healthy controls (without
ALS or any other neurological disorder) that are matched for age, ethnicity, and gender.
To better understand the different molecular etiologies of sALS, I would perform
multiple experiments that require collection of DNA samples from sALS patients and
neurologically healthy controls. To avoid an invasive procedure, I would collect blood
samples from sALS patients and neurologically healthy controls upon entry into our
study. I would also collect blood samples from each sALS patient’s parents and an
unaffected sibling whenever available. For healthy controls, I would contact them every
6 months (for 20 years) to ensure they did not develop a neurological disorder. If they
did, I’d remove them from our study.
A recent publication (Kiezun et al. 2012) suggested 1) most of the rare coding
variants in the human population are deleterious, 2) increased sequencing sample sizes
are positively correlated with the number of rare coding variants identified, and 3)
>10,000 cases and controls are likely necessary for sufficient statistical power to identify
a single gene harboring an excess number of rare coding variants in a gene burden
test. These researchers calculated sample sizes of 10,000 would be needed via
simulations that modeled typical numbers of rare variants identified in disease vs.
control groups.
For my first experiment, I would aim to identify genes carrying a statistically
significant excess of rare (minor allele frequency <1%) protein-coding variants in sALS
patients vs. neurologically healthy controls. Variants in these genes could contribute to
(or cause) sALS. I would first extract DNA from blood mononuclear cells for all 20,000
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sALS patients and 20,000 healthy controls. I would then generate, align, and process
whole exome sequencing data for all 40,000 samples using appropriate kits, computing
resources, and bioinformatics software programs.
I would next perform a gene burden test to identify any gene in the hg38 human
genome that harbors a statistically significant excess of rare coding variants in our sALS
patients vs. our neurologically healthy controls. For each annotated gene, the gene
burden test compares the total number of rare coding variants in our sALS patients vs.
our neurologically healthy controls’ exome sequencing data. A corresponding p-value is
generated, and a Bonferroni correction is applied to account for multiple testing. A
significant p-value for a single gene would be p < 1.04X10^-6. That is a p-value of <
0.05 after applying a Bonferroni correction for 48,000 genes tested, as the hg38 human
genome has ~48,000 annotated genes.
I would be particularly interested in any rare variant (in any gene) that was
observed multiple times in our sALS samples’ exome sequencing data, but not found in
our healthy controls’ exome sequencing data. If any of these rare variants were not
found in publically available exome sequencing datasets generated from individuals that
do not have any neurological disorders, I would validate each of them using Sanger
sequencing. I would then generate separate transgenic mouse lines (using
CRISPR/Cas9 technology) that carry each of these validated rare variants to assess
whether any of them cause an ALS-like neurodegenerative phenotype characterized by
muscle weakness, muscle wasting, spinal motor neuron death, paralysis, and early
death. This could lead to the discovery of novel loci that carry causal ALS mutations,
and may provide more insight into neurodegeneration in sALS.
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For my second experiment, I would aim to identify de novo coding variants that
cause sALS. I would first isolate blood mononuclear cells’ DNA from both parents and
an unaffected sibling for every qualifying sALS patient. I would then generate, align, and
process exome sequencing data using these family members’ DNA via the same
methods proposed in my first experiment. For each trio (2 parents and their sALSaffected offspring), I would identify all coding variants found only in the sALS-affected
offspring’s exome sequencing data. I would apply this same approach to each trio
comprised of each sALS patient’s 2 parents and unaffected sibling, identifying all coding
variants found only in the unaffected sibling’s exome sequencing data compared to their
parents’ exome sequencing data.
I would be particularly interested in all de novo coding variants identified in sALSaffected offspring that were not found in their unaffected siblings. If these de novo
variants were also not found in publically available exome sequencing datasets
generated from individuals that do not have any neurological disorders, I would validate
each variant using Sanger sequencing. I would then generate separate transgenic
mouse lines (using CRISPR/Cas9 technology) that carry each of these validated rare
variants to assess whether it leads to an ALS-like neurodegenerative phenotype
characterized by muscle weakness, muscle wasting, spinal motor neuron death,
paralysis, and early death.
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